WO2006097460A1 - Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them - Google Patents

Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them Download PDF

Info

Publication number
WO2006097460A1
WO2006097460A1 PCT/EP2006/060687 EP2006060687W WO2006097460A1 WO 2006097460 A1 WO2006097460 A1 WO 2006097460A1 EP 2006060687 W EP2006060687 W EP 2006060687W WO 2006097460 A1 WO2006097460 A1 WO 2006097460A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
propyl
piperidine
hydroxycarbamoyl
carboxylic acid
Prior art date
Application number
PCT/EP2006/060687
Other languages
French (fr)
Other versions
WO2006097460A8 (en
Inventor
Cristina Rossi
Marina Porcelloni
Piero D'andrea
Daniela Fattori
Elena Marastoni
Original Assignee
Menarini International Operations Luxembourg S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2008501287A priority Critical patent/JP2008533091A/en
Application filed by Menarini International Operations Luxembourg S.A. filed Critical Menarini International Operations Luxembourg S.A.
Priority to US11/886,160 priority patent/US20080207694A1/en
Priority to EA200701970A priority patent/EA012909B1/en
Priority to CA002600528A priority patent/CA2600528A1/en
Priority to EP06708749A priority patent/EP1868997A1/en
Priority to AU2006224624A priority patent/AU2006224624A1/en
Priority to MX2007011072A priority patent/MX2007011072A/en
Priority to AP2007004188A priority patent/AP2007004188A0/en
Priority to BRPI0606290-3A priority patent/BRPI0606290A2/en
Publication of WO2006097460A1 publication Critical patent/WO2006097460A1/en
Priority to IL185882A priority patent/IL185882A0/en
Priority to NO20075281A priority patent/NO20075281L/en
Publication of WO2006097460A8 publication Critical patent/WO2006097460A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Definitions

  • the present invention relates to histone deacetylase inhibitor compounds characterised by the presence of a hydroxamic group, to preparations for obtaining them and to their use for preparing pharmaceutical formulations to be employed for treating pathologies in which the mechanism of gene regulation plays an essential role.
  • -B is a bond or is chosen from the group: -O-, -NR5-, -CO-, -NR5-CO-, -O-CO-, -SO 2 - , -NR5-SO2-, or represents one of the following structures:
  • n 0,1 ,2 in which R5 is a H or a C1 -3 alkyl
  • -R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl or an acyl derived from one of the following acids: benzoic, phenylacetic, benzothiophene- carboxylic, indole-carboxylic -R2 represents a H or a C1 -3 alkyl group or R1 and R2 represent jointly with the nitrogen atom, a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine
  • -R3 represents H or is chosen from the group: -C1 -6 alkyl, -C1 -6 alkylene-W, where
  • W is chosen from - OR5, - SR5, - CONR7R8, -NR7R8, -OCOR6 -NR5COR6, guanidine, and R7 and R8 independently represent a H or C1 -3 alkyl group or R7 and
  • R8 represent jointly with the nitrogen atom a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and R6 is chosen from the group: hydrogen, C1 -3 alkyl, Ar1 where Ar1 is an aromatic group chosen from phenyl, naphthyl, pyridine, quinoline, indole, benzofuran, benzothiophene and can possibly be substituted with up to three groups independently chosen from:
  • R9 is a group chosen from H, C1 -3 alkyl, -(CH 2 )q-NR10R11 , pyrrolidine, R10 and R1 1 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3
  • -R4 is a group chosen from H and C1 -3 alkyl or R4 and R3 represent jointly with the nitrogen atom a heterocycle chosen from pyrrolidine or piperidine
  • -L1 indicates a group attached to any of the carbon atoms in the heterocyclic ring and is chosen from the group: alkylidene of the type -(CH 2 )m-, possibly substituted on each C with one or two methyl groups, and in which m can assume the values 1 , 2, 3,
  • CH CH-(CH 2 )I- possibly substituted on each C with one or two methyl groups and in which e, f, g, h and I can independently assume the values 0,1 ,2,3 or 4
  • -Ar represents a group derived from the following aromatic systems: phenyl, pyridyl, furyl, pyrimidyl, pyrazyl, piperazyl, triazolyl, tetrazolyl, biphenyl, imidazolyl, naphthyl, quinoline, isoquinoline, diphenyl-methyl, benzofuryl, dihydrobenzofuryl, benzothienyl, indolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, oxazolyl-phenyl, thiodiazolyl- phenyl, pyridyl-phenyl, pyrazolyl-phenyl, thiazolyl-phenyl, furyl-phenyl, thienyl-phenyl, benzyloxy-phenyl, tetrazolyl-phenyl, phenyl-oxazolyl, phenyl-
  • the R12 group represents a H, a C1 -3 alkyl or a C1 -3 acyl -
  • the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
  • the aromatic part can be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO 2 , CN, F, Cl, Br, -CF 3 , - SCF 3 , COOR9, CONR9R10, -(CH 2 )q-NR9R10, N(Rg)SO 2 RI O, CH 2 OR9, SOH, CH 2 SO 3 H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH 2 )q-NR10R1 1 , pyrrolidine, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3.
  • B is chosen from -NR5-CO- or -NRS-SO 2 - and at the same time
  • Rx can be Ac, COEt, CO-nPr, CO-iPr, CO-tBu, benzoyl, pNO 2 benzoyl, CH 3 , Et, nPr, iPr, tBu, Benzyl, tetrahydropyranyl.
  • Ry and Rz independently indicate a H or a C1 -3 alkyl group.
  • optical isomers such as enantiomers and/or diastereoisomers, derived from the possible presence of chiral centres in the compounds of general formula (I), and possible mixtures thereof either as racemes or in various ratios thereof, and their inorganic and organic acid salts.
  • Histone deacetylase is known to have an essential role in the mechanism that regulates gene expression.
  • Inhibitors of histone deacetylase (HDAC) induce hyperacetylation of histones, with consequent alteration of gene expression itself. It follows that said inhibitors are useful as therapeutic or prophylactic agents for pathological states caused by abnormal gene expression, such as inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocyte leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections, tumors and the like.
  • APL acute promyelocyte leukaemia
  • the enzyme histone deacetylase is already well known and, via X-ray and SAR studies of various inhibitor classes, the structural characteristics that a potential inhibitor should possess have been elucidated; in particular a) a domain able to bind a metal (specifically Zn), b) a linker able to occupy a channel of the enzyme, c) a surface recognition domain that interacts with the structures on the rim of the enzyme active site (J. Med . Chem., 2003, 46(24), 5097-5116).
  • linker is represented by phenyl-ethyl or styryl; in
  • the linker is a phenyl or a cyclohexyl; the compounds described in WO2004013130 present a linker consisting of athiophene.
  • WO2004069133 describes compounds in which, based on the aforementioned scheme, the metal binding group is represented by a phenylenediamine amide, and the linker by a heterocycle chosen from indole, benzothiophene or benzofuran.
  • WO2005040101 also claims hydroxamates containing carbamoyl piperidino groups or the like as general meanings.
  • the aim of the present invention is to provide new HDAC inhibitors of general formula
  • (I) useful as drugs, and the pharmaceutical compositions that contain them, as active ingredients for the treatment or prophylaxis of pathologies such as inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocyte leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections, tumors and the like.
  • pathologies such as inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocyte leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections, tumors and the like.
  • the present invention provides compounds of general formula (I) as heretofore described.
  • a group of preferred compounds of the present invention are those of general formula
  • -B is a bond, or is chosen from the group:-CO-, -NR5-CO-, -O-CO-, -SO 2 -, -NR5- SO 2 -, or represents one of the following structures:
  • n 0,1 ,2 in which R5 is a H or a C1 -3 alkyl
  • -R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl or an acyl derived from one of the following acids: benzoic, phenylacetic, benzothiophene- carboxylic, indole-carboxylic -R2 represents a H or a C1 -3 alkyl group or R1 and R2 represent jointly with the nitrogen atom, a five- or six-membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine
  • -R3 represents H or is chosen from the group: -C1 -6 alkyl, -C1 -6 alkylene-W, where
  • W is chosen from -OR5, -SR5, -CONR7R8, -NR7R8, -OCOR6 -NR5COR6, guanidine, and R7 and R8 independently represent a H or a C1 -3 alkyl group or R7 and R8 represent jointly with the nitrogen atom a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and R6 is chosen from the group hydrogen, C1 -3 alkyl, Ar1 where Ar1 is an aromatic group chosen from phenyl, naphthyl, pyridine, quinoline, indole, benzofuran, benzothiophene and can possibly be substituted with up to three groups independently chosen from:
  • R9 is a group chosen from H, C1 -3 alkyl, -(CH 2 )q-NR10R11 , pyrrolidine, R10 and R1 1 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3
  • R4 represents an H or a C1 -3 alkyl group or R4 and R3 represent jointly with the nitrogen atom a heterocycle chosen from pyrrolidine or piperidine
  • -L1 is chosen from the group: alkylidene of the type -(CH 2 )m-, possibly substituted on each C with one or two methyl groups, and in which m can assume the values 1 , 2, 3
  • -Ar represents a group derived from the following aromatic systems: phenyl, pyridyl, furyl, pyrimidyl, pyrazyl, piperazyl, triazolyl, tetrazolyl, biphenyl, imidazolyl, naphthyl, quinoline, isoquinoline, diphenyl-methyl, benzofuryl, dihydrobenzofuryl, benzothienyl, indolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, oxazolyl-phenyl, thiodiazolyl- phenyl, pyridyl-phenyl, pyrazolyl-phenyl, thiazolyl-phenyl, furyl-phenyl, thienyl-phenyl, benzyloxy-phenyl, tetrazolyl-phenyl, phenyl-oxazolyl, phenyl-
  • the R12 group represents a H, a C1 -3 alkyl or a C1 -3 acyl
  • the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
  • the aromatic part can be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO 2 , CN, F, Cl, Br, -CF 3 , - SCF 3 , COOR9, CONR9R10, -(CH 2 )q-NR9R10, N(Rg)SO 2 RI O, CH 2 OR9, SOH, CH 2 SO 3 H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH 2 )q-NR10R1 1 , pyrrolidine, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3.
  • B is chosen from -NR5-CO- or -NR5-SO2- and at the same time
  • Rx can be Ac, COEt, CO-nPr, CO-iPr, CO-tBu, Benzoyl, pNO 2 Benzoyl, CH 3 , Et, nPr, iPr, tBu, Benzyl, tetrahydropyranyl Ry and Rz independently indicate a H or C1 -3 alkyl group.
  • optical isomers such as enantiomers and/or diastereoisomers, derived from the possible presence of chiral centres in the compounds of general formula (I), and possible mixtures thereof either as racemes or in various ratios thereof, and their inorganic and organic acid salts.
  • -B is a bond, or is chosen from the group: -CO-, -NR5-CO-, -O-CO-, or represents one of the following structures:
  • n 0,1 in which R5 is a H or a C1 -3 alkyl
  • -R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl
  • -R2 represents a H or a C1 -3 alkyl group
  • -R3 represents H or is a -C1 -6 alkylene-W, where W is chosen from - OR5, -NR7R8 and R7 and R8 independently represent a H or C1 -3 alkyl group -R4 represents a H or a C1 -3 alkyl group,
  • the R12 group represents a H, a C1 -3 alkyl
  • the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
  • the aromatic part can be substituted with up to three groups independently chosen from: a C1 -3 alkyl, OR9, NR9R10, N(R9)COR10, CN, F, Cl, Br, -CF 3 , -SCF 3 , -(CH 2 )q- NR9R10, in which R9 is a group chosen from H, C1 -4 alkyl, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3.
  • B is chosen from -NR5-CO- and at the same time l_2 is chosen from -(CH 2 )P-CO-.
  • C1 -3 alkyl a group chosen from methyl, ethyl, propyl, isopropyl
  • C1 -4 alkyl a group chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl
  • C1 -6 alkyl a group chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl
  • C1 -6 alkylidene a group chosen from methylene, ethylene, propylene, methylethylene, tetramethylene, methylpropylene, pentamethylene, hexamethylene
  • C1 -3 acyl a group chosen from formyl, acetyl, propionyl.
  • salts are intended as salts obtained with inorganic or organic acids chosen from: hydrochloric, hydrobromic, phosphoric, sulphuric, nitric, acetic, trifluoroacetic, methanesulfonic, toluenesulfonic, oxalic, succinic, malonic, adipic, benzoic acids.
  • HDAC inhibitors of the present invention can be synthesised according to reactions known in the state of the art, but which can vary greatly on the basis of the series of synthesis steps needed to prepare the individual compounds summarized in general formula (I).
  • amide bonds also allows passage along the solid phase synthesis paths developed in peptide chemistry based on the use of resin.
  • DIPEA 0.1 1 ml, 0.66 mmols
  • phenylacetyl chloride 0.043 ml, 0.33 mmols
  • anhydrous CH 2 CI 2 10 ml
  • the resulting mixture is left under agitation for 2 hours at ambient temperature.
  • DIPEA 0.085 ml, 0.48 mmols
  • BSA 0.234 ml, 0.96 mmols
  • 4-piperidine butyric acid hydrochloride 100 ml, 0.48 mmols
  • CH 2 CI 2 10 ml
  • phenylacetyl chloride 0.063 ml, 0.48 mmols
  • acyl chloride thus formed, dissolved in 5 ml of anhydrous CH 2 CI 2 , are slowly added 5 ml of an aqueous solution of NH 2 OH HCI (32 mg, 0.45 mmols) and NaHCO 3 (75 mg, 0.9 mmols). The mixture is allowed to react for 1 hour under vigorous agitation at ambient temperature.
  • Phenylacetic aldehyde (0.046 ml_, 0.40 mmols) and sodium triacetoxyboro hydride
  • the mixture is diluted with CH 2 CI 2 and washed with 5% NaHSO 4 , 5% NaHCO 3 and ssNaCI; the organic phase is dried over
  • the resin is filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2 ml). 100 ⁇ l of trifluoroacetic acid and 100 ⁇ l of triethylsilane are added to the thus obtained resin, re-swollen in 2 ml DCM for 20 minutes. It is maintained under agitation for 15 minutes at ambient temperature. The resin is filtered off and washed twice with DCM and MeOH alternately. The filtrates are pooled and evaporated to dryness. Grinding the crude product thus obtained with ethyl ether provides the desired product (35 mg, 80% yield) with a purity of 95%. MFiCi 8 H 27 N 3 O 3 , MW: 333.43.
  • the resin is filtered off and suspended in 2 ml of a solution of 20% piperidine in dichloromethane. After 30 minutes the resin is filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2ml).
  • Step E To the resin obtained in Step E and re-swollen in 2 ml of DCM for 20 minutes are added the mixture of HOAt (68 mg, 0.5 mmols), benzo[b]thiophene-2-carboxylic acid (90 mg, 0.5 mmols) and 0.08 ml of diisopropylcarbodiimide (63 mg, 0.5 mmols) in 3 ml of DMF/DCM previously held at ambient temperature for 1 hour. The suspension is agitated for 18 hours at ambient temperature. The resin is filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2ml).
  • the relative prodrugs of general formula (IV) and (V) also form part of the present invention, for whose production the preparation of suitable syntones in which the hydroxamic acid function is protected in the hydrolysable group of the prodrug' is generally preferred.
  • Non- limitative examples of synthesis of syntones for prodrugs are: Synthesis of prodrug A:
  • Camphorsulfonic acid (37 mg, 0.16 mmols, 1.0 eq.) is added to a solution of 4-(3- hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid benzylamide (50 mg, 0.16 mmols, 1.0 eq.) and 2,2-diethoxypropane (0.076 ml_, 0.47 mmols, 3.0 eq.) in anhydrous DCM (3 ml) and the resulting mixture is left under agitation at ambient temperature for 4 hours. At the end of the reaction a saturated aqueous solution of
  • Histone deacetylase inhibitors are a class of potential therapeutic or prophylactic agents for pathological states caused by abnormal gene expression, such as inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocyte leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections, tumors and the like. In particular they are emerging as a new class of drugs with anti-tumor activity. The connection between some tumorous pathologies, such as carcinoma of the mammary, colon and lung, and acetylation levels of nuclear chromatin has been described.
  • Drugs able to modulate chromatin remodelling are able to inhibit tumor proliferation and could provide new instruments for treating tumor pathologies in the not too distant future.
  • Much experimental evidence leads to the belief that the main field of application of this class of drugs could be in combined therapies.
  • the considerable tolerability that has emerged from the first clinical trials leads to the belief that this class of molecules lends itself to combined therapy with traditional drugs such as cytotoxic drugs, or with radiotherapy treatments or with the new generation antitumor agents.
  • the present invention also provides combinations of compounds with histone deacetylase inhibitory activity of general formula (I) with one or more chemotherapeutic compounds chosen from the group: conventional cytotoxic agents, demethylating agents, cyclin dependent kinase inhibitors, differentiating agents, signal transduction modulators, HSP-90 antagonists, proteasome inhibitors.
  • chemotherapeutic compounds chosen from the group: conventional cytotoxic agents, demethylating agents, cyclin dependent kinase inhibitors, differentiating agents, signal transduction modulators, HSP-90 antagonists, proteasome inhibitors.
  • Preferred compounds are compounds chosen from the following groups: the conventional cytotoxic agents: fludarabine, gemcitabine, decitabine, paclitaxel, carboplatin and Topo l/ll inhibitors to include Etoposide, Irinotecan, Topotecan, T-128 and Anthracyclines such as Doxorubicin, Sabarubicin, Daunorubicin; the demethylating agents (demethylation of DNA): 5-aza-2'-deoxycytidine (5-aza-dC),
  • 5-azacytidine the cyclin dependent kinase inhibitors: Flavopiridol, olomoucin, roscovitin, purvalanol
  • Staurosporine UCN-01 ; the differentiating agents: retinoic acid and derivatives (All Trans Retinoic Acid,
  • ATRA 13-cis retinoic acid
  • PMA phorbol myristate acetate
  • the signal transduction modulators TRAIL, imatinib mesylate, LY-294002, bortezomib
  • the HSP-90 antagonists geldanamycin and its analogues (17-AAG)
  • the proteasome inhibitors lactacystine, MG132, bortezomib (VelcadeTM).
  • HDAC histone deacetylase
  • the assay (Fluor de LysTM kit, BioMol) is divided into two steps: in the first step the substrate which comprises an acetylated lysine residue is reacted with the nuclear extract (HeLa) containing the enzymatic activity in the presence and absence of inhibitors. In the second step a fluorogenic reagent is added which highlights the deacetylated residues. A reduction in fluorescence is obtained where there has been inhibition of the deacetylase activity. The result is finally expressed as percent inhibition relative to the control without inhibitor at a concentration of 0.1 ⁇ M.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds of structure (I) having histone deacetylase (HDAC) inhibitor activity are described. The compounds are chemically characterised by the presence of hydroxamic acid, with zinc as chelator, and an aromatic nucleus connected by a linker in which either a bicyclic aromatic system or a piperidino ring are present.

Description

HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM Field of the invention
The present invention relates to histone deacetylase inhibitor compounds characterised by the presence of a hydroxamic group, to preparations for obtaining them and to their use for preparing pharmaceutical formulations to be employed for treating pathologies in which the mechanism of gene regulation plays an essential role.
In particular the present invention concerns a compound having a general formula (I):
Figure imgf000002_0001
(I) in which v=0,1 ,2
-B is a bond or is chosen from the group: -O-, -NR5-, -CO-, -NR5-CO-, -O-CO-, -SO2- , -NR5-SO2-, or represents one of the following structures:
Figure imgf000002_0002
in which n=0,1 ,2 in which R5 is a H or a C1 -3 alkyl
-R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl or an acyl derived from one of the following acids: benzoic, phenylacetic, benzothiophene- carboxylic, indole-carboxylic -R2 represents a H or a C1 -3 alkyl group or R1 and R2 represent jointly with the nitrogen atom, a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine
-R3 represents H or is chosen from the group: -C1 -6 alkyl, -C1 -6 alkylene-W, where
W is chosen from - OR5, - SR5, - CONR7R8, -NR7R8, -OCOR6 -NR5COR6, guanidine, and R7 and R8 independently represent a H or C1 -3 alkyl group or R7 and
R8 represent jointly with the nitrogen atom a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and R6 is chosen from the group: hydrogen, C1 -3 alkyl, Ar1 where Ar1 is an aromatic group chosen from phenyl, naphthyl, pyridine, quinoline, indole, benzofuran, benzothiophene and can possibly be substituted with up to three groups independently chosen from:
C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, COOR9,
CONR9R10, CH2NR9R10, N(R9)SO2R10, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -3 alkyl, -(CH2)q-NR10R11 , pyrrolidine, R10 and R1 1 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3
-R4 is a group chosen from H and C1 -3 alkyl or R4 and R3 represent jointly with the nitrogen atom a heterocycle chosen from pyrrolidine or piperidine
-L1 indicates a group attached to any of the carbon atoms in the heterocyclic ring and is chosen from the group: alkylidene of the type -(CH2)m-, possibly substituted on each C with one or two methyl groups, and in which m can assume the values 1 , 2, 3,
4, 5, or an alkene chosen from -(CH2)e-CH=CH-(CH2)f-, -(CH2)g-CH=CH-(CH2)h-
CH=CH-(CH2)I- possibly substituted on each C with one or two methyl groups and in which e, f, g, h and I can independently assume the values 0,1 ,2,3 or 4
-L2 indicates a bond or a group chosen from: : -(CH2)p-, -(CH2)p-CH=CH-, -(CH2)p-
T-(CH2)Z-, -(CH2)P-CO-, -(CH2)P-CH=CH-CO-, -CO-T-(CH2)Z- , -(CH2)p-T-CO-, each group being possibly substituted on the Cs with one or two methyl groups and in which p and z can independently assume the values 0,1 ,2,3 or 4 and T is chosen from
-O-, -S-, -NR5-
-Ar represents a group derived from the following aromatic systems: phenyl, pyridyl, furyl, pyrimidyl, pyrazyl, piperazyl, triazolyl, tetrazolyl, biphenyl, imidazolyl, naphthyl, quinoline, isoquinoline, diphenyl-methyl, benzofuryl, dihydrobenzofuryl, benzothienyl, indolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, oxazolyl-phenyl, thiodiazolyl- phenyl, pyridyl-phenyl, pyrazolyl-phenyl, thiazolyl-phenyl, furyl-phenyl, thienyl-phenyl, benzyloxy-phenyl, tetrazolyl-phenyl, phenyl-oxazolyl, phenyl-pyrazolyl-, phenyl-thiazolyl, phenyl-thiadiazolyl, phenyl-isothiazolyl, phenyl-oxadiazolyl, phenyl-isoxazolyl, phenyl- imidazolyl, phenyl-triazolyl, phenyl-furyl, phenyl-thiophenyl, phenyl-pyrrolyl, phenyl- pyrrolidyl, indanyl, fluorenyl, benzopyranyl, dihydrobenzopyranyl, benzodioxolyl, phenoxy-phenyl, benzoxazinyl, dihydrobenzoxazinyl in which each group can possibly be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, -SCF3, COOR9, CONR9R10, -(CH2)q-NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH2)q-NR10R11 , pyrrolidine, R10 and R11 are independently chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3, - or Ar-L2-B can jointly be chosen from the group consisting of:
Figure imgf000004_0001
in which:
- the R12 group represents a H, a C1 -3 alkyl or a C1 -3 acyl - the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
- the aromatic part can be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, - SCF3, COOR9, CONR9R10, -(CH2)q-NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH2)q-NR10R1 1 , pyrrolidine, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3.
To be considered excluded from the present invention are products in which:
B is chosen from -NR5-CO- or -NRS-SO2- and at the same time
L2 is chosen from -(CH2)p-CO- or -(CH2)p-CH=CH-CO-.
The relative prodrugs of general formula (III) and (IV) also form part of the present invention
Figure imgf000005_0001
(III) (IV)
In which Rx can be Ac, COEt, CO-nPr, CO-iPr, CO-tBu, benzoyl, pNO2benzoyl, CH3, Et, nPr, iPr, tBu, Benzyl, tetrahydropyranyl. Ry and Rz independently indicate a H or a C1 -3 alkyl group.
Also forming part of the present invention are all possible optical isomers, such as enantiomers and/or diastereoisomers, derived from the possible presence of chiral centres in the compounds of general formula (I), and possible mixtures thereof either as racemes or in various ratios thereof, and their inorganic and organic acid salts. State of the art
Histone deacetylase is known to have an essential role in the mechanism that regulates gene expression. Inhibitors of histone deacetylase (HDAC) induce hyperacetylation of histones, with consequent alteration of gene expression itself. It follows that said inhibitors are useful as therapeutic or prophylactic agents for pathological states caused by abnormal gene expression, such as inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocyte leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections, tumors and the like.
The enzyme histone deacetylase is already well known and, via X-ray and SAR studies of various inhibitor classes, the structural characteristics that a potential inhibitor should possess have been elucidated; in particular a) a domain able to bind a metal (specifically Zn), b) a linker able to occupy a channel of the enzyme, c) a surface recognition domain that interacts with the structures on the rim of the enzyme active site (J. Med . Chem., 2003, 46(24), 5097-5116).
In the last few years many examples of HDAC inhibitors with the aforesaid structural characteristics have become apparent.
For example, compounds that present a n-hydroxyamide and a linear linker are described in: Bioorganic & Medicinal Chem Letters (2002 ), 12, 2919-2923 ; J Med
Chem (2002) 45 (13), 2877-2885 ; J Med Chem (2002), 45 (4), 753-757; Bioorganic
& Medicinal Chem Letters (2004), 14, 449-453. Other publications demonstrate hydroxamic acids in which the linker is not linear; in Bioorganic & Medicinal Chem
Letters (2001 ), 11 , 2847-2890 the linker is represented by phenyl-ethyl or styryl; in
Bioorganic & Medicinal Chem Letters (2002), 12, 1347-1349 the linker is a phenyl or a cyclohexyl; the compounds described in WO2004013130 present a linker consisting of athiophene.
Other authors have shown the possibility of substituting hydroxamic acid with other groups able to bind the metal of the enzyme active site, for example with amides
(J.Med Chem (2003), 46, 820-830; or in EP847992) or electrophile ketones.
WO2004069133 describes compounds in which, based on the aforementioned scheme, the metal binding group is represented by a phenylenediamine amide, and the linker by a heterocycle chosen from indole, benzothiophene or benzofuran.
WO2005040101 also claims hydroxamates containing carbamoyl piperidino groups or the like as general meanings.
Notwithstanding all that is already known on the subject, there is still however a great need to identify new HDAC inhibitors which allow us to prepare new drugs for the treatment of the many pathologies that are potentially curable via this mechanism of action. Detailed description of the invention
The aim of the present invention is to provide new HDAC inhibitors of general formula
(I), useful as drugs, and the pharmaceutical compositions that contain them, as active ingredients for the treatment or prophylaxis of pathologies such as inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocyte leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections, tumors and the like.
The present invention provides compounds of general formula (I) as heretofore described.
A group of preferred compounds of the present invention are those of general formula
(II)
Figure imgf000007_0001
(H) in which v=1
-B is a bond, or is chosen from the group:-CO-, -NR5-CO-, -O-CO-, -SO2-, -NR5- SO2-, or represents one of the following structures:
Figure imgf000007_0002
in which n=0,1 ,2 in which R5 is a H or a C1 -3 alkyl
-R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl or an acyl derived from one of the following acids: benzoic, phenylacetic, benzothiophene- carboxylic, indole-carboxylic -R2 represents a H or a C1 -3 alkyl group or R1 and R2 represent jointly with the nitrogen atom, a five- or six-membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine
-R3 represents H or is chosen from the group: -C1 -6 alkyl, -C1 -6 alkylene-W, where
W is chosen from -OR5, -SR5, -CONR7R8, -NR7R8, -OCOR6 -NR5COR6, guanidine, and R7 and R8 independently represent a H or a C1 -3 alkyl group or R7 and R8 represent jointly with the nitrogen atom a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and R6 is chosen from the group hydrogen, C1 -3 alkyl, Ar1 where Ar1 is an aromatic group chosen from phenyl, naphthyl, pyridine, quinoline, indole, benzofuran, benzothiophene and can possibly be substituted with up to three groups independently chosen from:
C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, COOR9,
CONR9R10, CH2NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -3 alkyl, -(CH2)q-NR10R11 , pyrrolidine, R10 and R1 1 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3
-R4 represents an H or a C1 -3 alkyl group or R4 and R3 represent jointly with the nitrogen atom a heterocycle chosen from pyrrolidine or piperidine
-L1 is chosen from the group: alkylidene of the type -(CH2)m-, possibly substituted on each C with one or two methyl groups, and in which m can assume the values 1 , 2, 3
-L2 indicates a bond or a group chosen from: -(CH2)p-, -(CH2)p-CH=CH-, -(CH2)p-T-
(CH2)Z-, -(CH2)P-CO-, -(CH2)P-CH=CH-CO-, -CO-T-(CH2)Z-, -(CH2)p-T-CO-, each group being possibly substituted on the Cs with one or two methyl groups and in which p and z can independently assume the values 0,1 ,2,3 or 4 and T is chosen from
-O-, -S-, -NR5-
-Ar represents a group derived from the following aromatic systems: phenyl, pyridyl, furyl, pyrimidyl, pyrazyl, piperazyl, triazolyl, tetrazolyl, biphenyl, imidazolyl, naphthyl, quinoline, isoquinoline, diphenyl-methyl, benzofuryl, dihydrobenzofuryl, benzothienyl, indolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, oxazolyl-phenyl, thiodiazolyl- phenyl, pyridyl-phenyl, pyrazolyl-phenyl, thiazolyl-phenyl, furyl-phenyl, thienyl-phenyl, benzyloxy-phenyl, tetrazolyl-phenyl, phenyl-oxazolyl, phenyl-pyrazolyl-, phenyl-thiazolyl, phenyl-thiadiazolyl, phenyl-isothiazolyl, phenyl-oxadiazolyl, phenyl-isoxazolyl, phenyl- imidazolyl, phenyl-triazolyl, phenyl-furyl, phenyl-thiophenyl, phenyl-pyrrolyl, phenyl- pyrrolidyl, indanyl, fluorenyl, benzopyranyl, dihydrobenzopyranyl, benzodioxolyl, phenoxy-phenyl, benzoxazinyl, dihydrobenzoxazinyl in which each group can possibly be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, -SCF3, COOR9, CONR9R10, -(CH2)q-NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH2)q-NR10R11 , pyrrolidine, R10 and 11 are independently chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3, - or Ar-L2-B can jointly be chosen from the group consisting of:
Figure imgf000009_0001
in which:
- the R12 group represents a H, a C1 -3 alkyl or a C1 -3 acyl
- the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
- the aromatic part can be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, - SCF3, COOR9, CONR9R10, -(CH2)q-NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH2)q-NR10R1 1 , pyrrolidine, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3. To be considered excluded from the present invention are products in which:
B is chosen from -NR5-CO- or -NR5-SO2- and at the same time
L2 is chosen from -(CH2)p-CO- or -(CH2)P-CH=CH-CO-.
The relative prodrugs of general formula (III) and (IV) also form part of the present invention
Figure imgf000010_0001
(III) (IV) in which Rx can be Ac, COEt, CO-nPr, CO-iPr, CO-tBu, Benzoyl, pNO2Benzoyl, CH3, Et, nPr, iPr, tBu, Benzyl, tetrahydropyranyl Ry and Rz independently indicate a H or C1 -3 alkyl group.
Also forming part of the present invention are all possible optical isomers, such as enantiomers and/or diastereoisomers, derived from the possible presence of chiral centres in the compounds of general formula (I), and possible mixtures thereof either as racemes or in various ratios thereof, and their inorganic and organic acid salts. A group of particularly preferred compounds of the present invention are those of general formula (II) in which v=1
-B is a bond, or is chosen from the group: -CO-, -NR5-CO-, -O-CO-, or represents one of the following structures:
Figure imgf000010_0002
in which n=0,1 in which R5 is a H or a C1 -3 alkyl,
-R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl
-R2 represents a H or a C1 -3 alkyl group
-R3 represents H or is a -C1 -6 alkylene-W, where W is chosen from - OR5, -NR7R8 and R7 and R8 independently represent a H or C1 -3 alkyl group -R4 represents a H or a C1 -3 alkyl group,
-L1 is chosen from the group: alkylidene of the type -(CH2)m-, possibly substituted on each C with one or two methyl groups, and in which m can assume the values 2, 3 -L2 indicates a bond or a group chosen from: -(CH2)p-, -(CH2)P-CH=CH-, -(CH2)p-T- (CH2)Z-, -(CH2)P-CO-, -CO-T-(CH2)Z-, -(CH2)p-T-CO-, each group being possibly substituted on the Cs with one or two methyl groups and in which p and z can independently assume the values 0,1 ,2,3, and T is chosen from: -O-, -S-, -NR5- -Ar represents a group derived from the following aromatic systems: phenyl, pyridyl, furyl, triazolyl, biphenyl, naphthyl, quinoline, isoquinoline, benzofuryl, benzothienyl, indolyl, benzothiazolyl, benzoisoxazolyl, oxazolyl-phenyl, thiodiazolyl-phenyl, pyridyl- phenyl, pyrazolyl-phenyl, thiazolyl-phenyl, furyl-phenyl, thienyl-phenyl, benzyloxy-phenyl, tetrazolyl-phenyl, phenyl-oxazolyl, phenyl-pyrazolyl-, phenyl-thiazolyl, phenyl- thiadiazolyl, phenyl-isothiazolyl, indanyl, fluorenyl, benzodioxolyl, phenoxy-phenyl, in which each group can possibly be substituted with up to two groups independently chosen from C1 -3 alkyl, OR9, NR9R10, N(R9)COR10, CN, F, Cl, Br, -CF3, -SCF3, - (CH2)q-NR9R10, in which R9 is a group chosen from H, C1 -4 alkyl, R10 and 11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3, or Ar-L2-B can jointly be chosen from the group consisting of
in which:
- the R12 group represents a H, a C1 -3 alkyl
- the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
- the aromatic part can be substituted with up to three groups independently chosen from: a C1 -3 alkyl, OR9, NR9R10, N(R9)COR10, CN, F, Cl, Br, -CF3, -SCF3, -(CH2)q- NR9R10, in which R9 is a group chosen from H, C1 -4 alkyl, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3.
To be considered excluded from the present invention are products in which:
B is chosen from -NR5-CO- and at the same time l_2 is chosen from -(CH2)P-CO-.
In the present invention the following meanings are preferred: for C1 -3 alkyl a group chosen from methyl, ethyl, propyl, isopropyl, for C1 -4 alkyl a group chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, for C1 -6 alkyl a group chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, for C1 -6 alkylidene a group chosen from methylene, ethylene, propylene, methylethylene, tetramethylene, methylpropylene, pentamethylene, hexamethylene, for C1 -3 acyl a group chosen from formyl, acetyl, propionyl.
Furthermore, possibly preferred salts are intended as salts obtained with inorganic or organic acids chosen from: hydrochloric, hydrobromic, phosphoric, sulphuric, nitric, acetic, trifluoroacetic, methanesulfonic, toluenesulfonic, oxalic, succinic, malonic, adipic, benzoic acids.
The HDAC inhibitors of the present invention can be synthesised according to reactions known in the state of the art, but which can vary greatly on the basis of the series of synthesis steps needed to prepare the individual compounds summarized in general formula (I).
Some descriptive schemes by way of non-limiting examples are given below.
From said schemes the synthesis of all the compounds represented in general formula (I) can be easily deduced or extrapolated by experts of the art:
Figure imgf000012_0001
1 2
Figure imgf000012_0002
Scheme 1 : Amides
Figure imgf000013_0001
Figure imgf000013_0002
Scheme 2: Amines
Figure imgf000013_0003
Figure imgf000013_0004
Scheme 3: Ureas
Figure imgf000013_0005
Figure imgf000013_0006
Scheme 4: Urethanes
Figure imgf000014_0001
1 0
Figure imgf000014_0002
1 1
Scheme 5: Sulphonamides
In some cases the formation of amide bonds also allows passage along the solid phase synthesis paths developed in peptide chemistry based on the use of resin.
Some representative examples of the present invention and the method for their synthesis are given below.
General procedures
Synthesis of type 2 amides
4-(1-phenylacetyl-piperidin-4-yl)-butyric acid methyl ester
DIPEA (0.1 1 ml, 0.66 mmols) and phenylacetyl chloride (0.043 ml, 0.33 mmols) are added to a suspension of 4-piperidino butyric acid methyl ester hydrochloride (100 mg, 0.33 mmols) in anhydrous CH2CI2 (10 ml), maintained at 0°C under N2. The resulting mixture is left under agitation for 2 hours at ambient temperature.
At the end of the reaction (HPLC monitoring) the mixture is diluted with CH2CI2 and
15 ml of 5% NaHCO3 are added. The two phases are separated and the organic phase is then further washed with 5% NaHCO3 (3 times) and ssNaCI. The organic phase is dried over Na2SO4 and the solvent evaporated under reduced pressure to obtain the desired amide with quantitative yield.
Synthesis of the hydroxaminic acids 3, 5, 7, 9, 11 starting from the corresponding esters (method A) or carboxylic acids (method B).
Method A:
A solution of KOH (210 mg, 3.74 mmols) in MeOH (2 ml_) is added to a solution of hydroxylamine hydrochloride (190 mg, 2.72 mmols) in MeOH (2 ml_) maintaining the temperature at 0°C. The solution is then stirred for 15 minutes while at 0°C. A solution of the methyl ester (0.34 mmols) in MeOH/THF (4 ml_) is added and the resulting mixture maintained at ambient temperature for 12 hours under agitation. At the end of the reaction (HPLC monitoring) the pH is adjusted to about 8 by adding a 6N HCI solution.
At this point extraction in the organic phase can be undertaken if the product is not too water-soluble, or, otherwise, purification by inverse phase chromatography. Method B:
N-Hydroxy-4-(1-phenylacetyl-piperidin-4-yl)-butyramide
DIPEA (0.085 ml, 0.48 mmols) and BSA (0.234 ml, 0.96 mmols) are added to a solution of 4-piperidine butyric acid hydrochloride (100 ml, 0.48 mmols) in anhydrous CH2CI2 (10 ml). The mixture is allowed to react at ambient temperature for 2 hours, then phenylacetyl chloride (0.063 ml, 0.48 mmols) is added. The resulting mixture is stirred at ambient temperature for 12 hours.
At the end of the reaction (HPLC monitoring) 15 ml of 5% NaHCO3 are added and the mixture is left under vigorous agitation for 30 minutes. The two phases are separated and the aqueous phase is acidifed to pH 2.
The aqueous phase is extracted with EtOAc, the organic extracts are washed with ssNaCI, dried over Na2SO4 and the solvent evaporated under reduced pressure to obtain the desired carboxylic acid (130 mg, 95%) with suitable purity. COCI2 (0.045 ml, 0.54 mmols) and a catalytic quantity of DMF are added to a solution of the acid (130 mg, 0.45 mmols) in 5 ml of anhydrous CH2CI2. After two hours the CH2CI2 is evaporated under reduced pressure, twice redissolving and re- evaporating the crude reaction product again using CH2CI2. To the acyl chloride thus formed, dissolved in 5 ml of anhydrous CH2CI2, are slowly added 5 ml of an aqueous solution of NH2OH HCI (32 mg, 0.45 mmols) and NaHCO3 (75 mg, 0.9 mmols). The mixture is allowed to react for 1 hour under vigorous agitation at ambient temperature.
At the end of the reaction (HPLC monitoring) the two phases are separated, the organic phase is washed with ssNaCI, dried over Na2SO4 and concentrated under reduced pressure. The crude product obtained is purified by phase inverse chromatography, to obtain 82 mg of the desired product (60%). Synthesis of the amines 4:
4-(1-Phenethyl-piperidin-4-yl)-butyric acid methyl ester
Phenylacetic aldehyde (0.046 ml_, 0.40 mmols) and sodium triacetoxyboro hydride
(190 mg, 0.90 mmols) are added sequentially to a solution of 4-piperidin-4-yl-butyric acid methyl ester hydrochloride salt (80 mg, 0.36 mmols) in THF (3 ml_). The resulting mixture is stirred at ambient temperature for four hours. 10% NaHCO3 (10 ml_) and EtOAc (10 ml_) are then added and the two phases separated. The organic phase is washed with water, ssNaCI and dried over Na2SO4.
Filtration and removal of solvents by reduced pressure provide the desired product with a quantitative yield, which can be used as such in the following reaction.
Synthesis of the ureas 6:
4-(1-Benzylcarbamoyl-piperidin-4-yl)-butyric acid methyl ester
A solution of 4-piperidin-4-yl-butyric acid methyl ester hydrochloride salt (98 mg,
0.443 mmols), DIPEA (0.091 ml_, 0.532 mmols) and benzylisocyanate (0.051 ml_,
0.499 mmols) in dichloromethane (4 ml_) is stirred at ambient temperature for 3 hours.
At the end of the reaction (HPLC monitoring) a portion of aminomethyl polystyrene resin (50 mg, 1 mmol/g loading) is added to remove excess isocyanate and the resulting mixture is stirred for a further 2 hours. The solution is filtered and concentrated under reduced pressure to obtain the desired product (140 mg, 99%) which can be used as such in the following reaction.
Synthesis of the sulfonamides 10:
4-(1-Benzenesulfonyl-piperidin-4-yl)-butyric acid methyl ester
A portion of benzenesulfonyl chloride (45 mg, 0.26 mmols) and one of DIPEA (70 mg,
0.54 momls) are added to a solution of 4-piperidin-4-yl-butyric acid methyl ester hydrochloride salt (60 mg, 0.27 mmols) in anhydrous CH2CI2 (2 ml_).
At the end of the reaction (HPLC monitoring) the mixture is diluted with CH2CI2 and washed with 5% NaHSO4, 5% NaHCO3 and ssNaCI; the organic phase is dried over
NaSO4 and evaporated. The crude product thus obtained is purified by chromatography (silica, petroleum ether/AcOt 8:2). 75 mg (90%) of the desired product are obtained with suitable purity.
Example of synthesis of hydroxamine acids of type 3, 7, 9, 11 in the solid phase
4-[1 -(2-(R) -Amino-3-phenyl-propionyl) -piperidin-4-yl]-N-hydroxy-butyramide 200 mg of the commercial resin N-Fmoc-hydroxylamine-2-chlorotrityl polystyrene (cone. 0.5 mmols/g) is allowed to pre-swell for 1 hour in 2 ml of dichloromethane (DCM). The resin is filtered off and suspended in 2 ml of a solution of 20% piperidine in dichloromethane. After 30 minutes the resin is filtered off and resuspended in 2 ml of a solution containing 20% piperidine in DMF. After 30 minutes the resin is filtered off and washed with DCM (4 x 2ml). At the end the resin is re-swollen in DCM for 20 minutes.
A solution of HOAt (68 mg, 0.50 mmols) in 1.5 ml of anhydrous DMF is added to a solution of 4-[N-(fluoren-9-ylmethoxycarbonyl)piperidin-4-yl]-butanoic acid (200 mg, 0.50 mmols) in 1.5 ml of DCM. 0.08 ml of diisopropylcarbodiimide (63 mg, 0.50 mmols) are slowly added and the mixture is maintained for 1 hour under agitation at ambient temperature. The solution is poured onto polystyrene resin and the suspension stirred for 18 hours at ambient temperature. The resin is filtered off and suspended in 2ml of a solution of 20% piperidine in dichloromethane. After 30 minutes the resin is filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2ml). At the end the resin is re-swollen in DCM for 20 minutes. The qualitative ninhydrin assay on completion of the acylation reaction (Kaiser et al Anal. Biochem. 1970, 34, 595) proves to be negative.
A solution of HOAt (68 mg, 0.05 mmols) in 1.5 ml anhydrous DMF is added to a solution of Fmoc-D-Phe-OH (194 mg, 0.50 mmols) in 1.5 ml of DCM. Diisopropylcarbodiimide (0.08 ml, 63 mg, 0.50 mmols) is slowly added and the mixture maintained for 1 hour at ambient temperature under agitation. The solution is poured onto the polystyrene resin and the suspension agitated for 18 hours at ambient temperature. The resin is filtered off and suspended in 2 ml of a solution of 20% piperidine in dichloromethane. After 30 minutes the resin is filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2 ml). 100 μl of trifluoroacetic acid and 100 μl of triethylsilane are added to the thus obtained resin, re-swollen in 2 ml DCM for 20 minutes. It is maintained under agitation for 15 minutes at ambient temperature. The resin is filtered off and washed twice with DCM and MeOH alternately. The filtrates are pooled and evaporated to dryness. Grinding the crude product thus obtained with ethyl ether provides the desired product (35 mg, 80% yield) with a purity of 95%. MFiCi8H27N3O3, MW: 333.43.
4-[1-(2-(R)-Acetylamino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide 0.048 ml (51 mg, 0.50 mmols) of Ac2O and 0.085 ml of DIPEA (65 mg, 0.50 mmols) in DCM are added to the resin obtained in step F, re-swollen in 2ml of DCM for 20 minutes. The resin is agitated for 18 hours at ambient temperature then filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2ml). 100 μl of trifluoroacetic acid and 100 μl of triethylsilane are added to the thus obtained resin, re-swollen in 2 ml DCM for 20 minutes. It is maintained under agitation for 15 minutes at ambient temperature. The resin is filtered off and washed twice with DCM and MeOH alternately. The filtrates are pooled and evaporated to dryness. Grinding the crude product thus obtained with ethyl ether provides the desired product (28 mg, 75% yield) with a purity of 95%. MF: C20H29N3O4, MW: 375.47.
Benzo[b]thiophene-2-carboxylic acid 2-[(benzo[b]thiophene-2-carbonyl)-(R)- amino]- 3-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1-yl]-3-oxo-propyl ester
A mixture of HOAt (20 mg, 0.15 mmols), Fmoc-D-Ser-OH (49 mg, 0.15 mmols) and diisopropylcarbodiimide (0.024 ml, 18 mg, 0.15 mmols) in 3 ml of DMF/DCM, previously maintained at ambient temperature for an hour, is added to the resin obtained in Step C, re-swollen in 2 ml of DCM for 20 minutes. The suspension is agitated for 18 hours at ambient temperature then the resin is filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2ml).
The resin is filtered off and suspended in 2 ml of a solution of 20% piperidine in dichloromethane. After 30 minutes the resin is filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2ml).
To the resin obtained in Step E and re-swollen in 2 ml of DCM for 20 minutes are added the mixture of HOAt (68 mg, 0.5 mmols), benzo[b]thiophene-2-carboxylic acid (90 mg, 0.5 mmols) and 0.08 ml of diisopropylcarbodiimide (63 mg, 0.5 mmols) in 3 ml of DMF/DCM previously held at ambient temperature for 1 hour. The suspension is agitated for 18 hours at ambient temperature. The resin is filtered off and washed sequentially with DMF (2 x 2 ml) and DCM (2 x 2ml).
100 μl of trifluoroacetic acid and 100 μl of triethylsilane are added to the thus obtained resin, re-swollen in 2 ml DCM for 20 minutes. It is maintained under agitation for 15 minutes at ambient temperature. The resin is filtered off and washed twice with DCM and MeOH alternately. The filtrates are pooled and evaporated to dryness. Grinding the crude product thus obtained with ethyl ether provides the desired product (41 mg, 75% yield) with a purity of 95% (HPLC, 214 nm). MF: C30H3I N3O6S2, MW: 593.73.
The relative prodrugs of general formula (IV) and (V) also form part of the present invention, for whose production the preparation of suitable syntones in which the hydroxamic acid function is protected in the hydrolysable group of the prodrug' is generally preferred.
These syntones are then used for synthesis of the required compounds by synthetic paths totally similar to those used for compounds not defined as 'prodrugs'.
Non- limitative examples of synthesis of syntones for prodrugs are: Synthesis of prodrug A:
4-(3-Acetoxycarbamoyl-propyl)-piperidine- 1 -carboxylic acid benzylamide Pyridine (0.019 ml, 0.23 mmols, 1.5 eq.) and acetic anhydride (0.022 ml, 0.23 mmols, 1.5 eq.) are added to a solution of 4-(3-hydroxycarbamoyl-propyl)-piperidine-1 - carboxylic acid benzylamide (50 mg, 0.16 mmols, 1.0 eq.) in anhydrous DCM (3 ml) and the resulting mixture allowed to react at ambient temperature for 12 hours. At the end of the reaction, after diluting with DCM and washing with 1 N HCI (5 ml), the phases are separated. The organic phase is washed washing with ssNaCI, dried over Na2SO4 and concentrated under reduced pressure. The crude product obtained is purified by flash chromatography (30% petroleum ether in AcOEt then AcOEt) to obtain 45 mg of the desired monoacetylated product as a white solid (80%).
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.90-1.03 (2H, m), 1.16-1.29 (2H, m), 1.32-
1.48 (1 H, m), 1.48-1.67 (4H, m), 2.11 (2H, t, J = 6.8 Hz, CH2CO), 2.15 (3H, s, OCH3),
2.65 (2H, m, N(CHH)2), 3.98 (2H, m, N(CHH)2), 4.24 (2H, d, J = 5.2 Hz, PhCH2), 6.97
(1 H, m, NCONH), 7.16-7.36 (5H, m, ArH), 11.53 (1 H, s, NHO)
MF: C19H27N3O4, MW: 361.43
Synthesis of prodrug B
[3-(5,5-Dimethyl-[1,4,2]dioxazol-3-yl)-propyl]-piperidine-1-carboxylic acid benzylamide
Camphorsulfonic acid (37 mg, 0.16 mmols, 1.0 eq.) is added to a solution of 4-(3- hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid benzylamide (50 mg, 0.16 mmols, 1.0 eq.) and 2,2-diethoxypropane (0.076 ml_, 0.47 mmols, 3.0 eq.) in anhydrous DCM (3 ml) and the resulting mixture is left under agitation at ambient temperature for 4 hours. At the end of the reaction a saturated aqueous solution of
Na2CO3 (5 ml) is added and the phases separated. The aqueous phase is washed with EI2O (4 x 5 ml). The pooled organic phase is finally dried over Na2SO4 and concentrated under reduced pressure. The crude product is purified by flash chromatography (30% petroleum ether in AcOEt) to obtain 45 mg of the desired product (80%).
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.87-0.96 (2H, m), 1.17-1.30 (2H, m), 1.30-
1.45 (1 H, m), 1.46-1.68 (4H, m), 1.49 (6H, s, 2 x CH3), 2.28 (2H, t, J = 7.2 Hz,
CH2CO), 2.63 (2H, m, N(CHH)2), 3.96 (2H, m, N(CHH)2), 4.22 (2H, d, J = 5.2 Hz,
PhCH2), 7.01 (1 H, m, NCONH), 7.16-7.33 (5H, m, ArH)
MF: C20H29N3O3, MW: 359.46.
Synthesis of prodrug C:
4-[3-(Tetrahydro-pyran-2-yloxycarbamoyl)-propyl]-piperidine- 1 -carboxylic acid benzylamide
EDAC (69 mg, 0.36 mmols, 1.0 eq.) and HOBt (49 mg, 0.36 mmols, 1.0 eq) are added to a solution of 4-(1 -benzylcarbamoyl-piperidin-4-yl)-butyric acid (100 mg,
0.328 mmols, 1.0 eq.) in anhydrous DMF (5 ml_) and the mixture maintained under agitation at ambient temperature for 1 hour. O-(tetrahydro-2H-pyran-2- yl)hydroxylamine (13 mg, 0.33 mmols, 1.0 eq.) and DIPEA (0.042 ml_, 0.49 mmols,
1.5 eq.) are then added and the resulting mixture left under agitation at ambient temperature for 12 hours.
At the end of the reaction (HPLC monitoring) a solution of 5% NaHCO3 (5 ml) and
AcOEt (5 ml) are added and the phases separated. The organic phase is washed with ssNaCI, dried over Na2SO4 and concentrated under reduced pressure. The crude product obtained is purified by flash chromatography (AcOEt) to obtain 92 mg of the desired product (70%).
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.93 (2H, dq, J = 3.6 and 12.0 Hz), 1.11 -1.22
(2H, m), 1.28-1.44 (1 H, m), 1.44-1.74 (1 OH, m), 1.96 (2H, t, J = 7.2 Hz, CH2CO), 2.62
(2H, m, N(CHH)2), 3.49 (1 H, m, OCHH), 3.84-4.05 (3H, m, N(CHH)2 and OCHH),
4.21 (2H, d, J = 5.6 Hz, PhCH2), 4.79 (1 H, s, OCHO), 7.00 (1 H, m, NCONH), 7.16-
7.33 (5H, m, ArH), 10.91 (1 H, s, NHO)
MF: C22H33N3O4, MW: 403.51.
Some non- limitative examples representative of the present invention implemented in accordance with the above described synthesis schemes and variations thereof are given below.
Ex 1 4-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.93-1.25 (4H, m), 1.25-1.41 (1 H, m), 1.47 (2H, m), 1.70 (2H, d, J = 12.6 Hz), 1.91 (2H, t, J = 7.2 Hz, CH2CO), 2.67 (2H, m, N(CHH)2), 3.70 (2H, d, J = 12.6 Hz, N(CHH)2), 7.57 (1 H, m, ArH), 7.65-7.75 (2H, m, ArH), 7.98 (1 H, d, J = 7.5 Hz, ArH), 8.65 (1 H, s, OH), 10.32 (1 H, s, NH). MF C15H21CIN2O4S, MW 360.85 Ex 2 N-Hydroxy-4-[1 -(4-methyl-naphthalene-2-sulf onyl)-piperidin-4-yl]- butyramide
1 H NMR (DMSO-d6, 300 MHz): δ (ppm) 1.17-1.23 (5H, m), 1.38-1.46 (2H, m), 1.63-1.69 (2H m), 1.87 (2H, t, J = 7.3 Hz, CH2CO), 2.43 - 2.48 (2H, m,
(N(CHH)2), 2.76 (3H, s), 3.70 (2H, d, J = 12.0 Hz, (N(CHH)2), 7.56 (1 H, d, J
= 7.5 Hz, ArH), 7.71 -7.75 (2 H, m, ArH), 8.02 (1 H, d, J = 7.5 Hz, ArH), 8.18-
8.21 (1 H, m, ArH), 8.63 (1 H, s OH), 8.68-8.71 (1 H, m, ArH), 10.27 (1 H, s,
NH).
MF C20H26N2O4S, MW 390.49
Ex 3 N-Hydroxy-4-[1 -(naphthalene-2-carbonyl)-piperidin-4-yl]- butyramide 1 H NMR (DMSO-d6, 300 MHz): δ (ppm) 1.09-1.12 (2H, m), 1.14-1.24 (2H, m,), 1.49-1.56 (3H m), 1.60-1.76 (2H, m,), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.88 - 3.14 (2H, m, (N(CHH)2), 3.61 -3.64 (1 H, m, (N(CHH)2), 4.41 -4.60 (1 H, m, (N(CHH)2), 7.47-7.50 (1 H, d, J = 8.3 Hz, ArH), 7.56-7.61 (2H, m, ArH), 7.95-8.02 (4H, m, ArH), 8.66 (1 H, s, OH), 10.34(1 H, s). MF C20H24N2O3, MW 340.41
Ex 4 N-Hydroxy-4-[1 -(naphthalene-1 -carbonyO-piperidin^-yll-butyramide 1 H NMR (DMSO-d6, 300 MHz): δ (ppm) 0.75-1.24 (3H, m), 1.39-1.61 (4H, m), 1.76-1.87 (1 H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.80-3.00 (2H, m), 3.18 - 3.21 (1 H, m, (N(CHH)2), 3.61 -3.64 (1 H, m, (N(CHH)2), 4.63-4.70 (1 H, m, (N(CHH)2), 7.37-8.02 (7H, m, ArH), 8.66 (1 H, s, OH), 10.34 (1 H, s, NH). MF C20H24N2O3, MW 340.41
Ex 5 N-Hydroxy-4-[1 -(2-naphthalen-1 -yl-acetyl)-piperidin-4-yl]-butyramide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.86-1.04 (2H, m), 1.11 -1.20 (2H, m), 1.40-1.70 (5H, m), 1.94 (2H, t, J = 7.5, Hz, CH2CO), 2.57 (1 H, t, J =11.6 Hz, NCHH), 3.04 (1 H, t, J =11.6 Hz, N(CHH),), 4.00 (1 H, d, J =12.9 Hz, NCHH), 4.15 (2H, s, CH2Ar), 4.40 (1 H, d, J =12.9 Hz, NCHH), 7.32-7.99 (7H, m, ArH), 8.66 (1 H, s, OH), 10.33 (1 H, s, NH). MF: C21H26N2O3, MW: 354.44 Ex 6 N-Hydroxy-4-[1 -(1 -naphthalen-1 -yl-acetyl)-piperidin-4-yl]-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.80-1.00 (2H, m), 1.11 -1.20 (2H, m), 1.40-1.70 (5H, m), 1.91 (2H, t, J = 7.1 Hz, CH2CO), 2.53 (1 H, t, J =11.6 Hz, NCHH), 2.97 (1 H, t, J =11.6 Hz, NCHH), 3.88 (2H, s,CH2Ar), 4.00 (1 H, d, J=12.9 Hz, NCHH), 4.40 (1 H, d, J=12.9 Hz, NCHH), 7.39 (1 H, d, J=8.5 Hz, ArH), 7.44-7.55 (2H, m, ArH), 7.74 (1 H, s), 7.83-7.93 (3H, m), 8.64 (1 H, s, OH), 10.31 (1 H, s, NH). MF C21 H26N2O3 , MW 354.44
Ex 7 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid benzylamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.95 (2H, dq, J = 3.4 and 12.0 Hz), 1.12-1.23 (2H, m), 1.30-1.45 (1 H, m), 1.51 (2H, m), 1.56-1.66 (2H, m), 1.94 (2H, t, J = 7.0 Hz, CH2CO), 2.64 (2H, m, N(CHH)2), 3.93-4.03 (2H, m, N(CHH)2), 4.23 (2H, d, J = 5.8 Hz, PhCH2), 6.99 (1 H, t, J = 7.0 Hz, NCONH), 7.17-7.34 (5H, m, ArH), 8.65 (1 H, s, OH), 10.34 (1 H, s, NH). MF C17H25N3O3, MW 319.39
Ex 8 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid phenylamide
1 H NMR (DMSO-d6, 300 MHz): δ (ppm) 0.86-0.93 (2H, m), 1.13-1.17 (3H, m), 1.47-1.49 (2H, m), 1.61 -1.65 (2H, m), 1.92 (2H, t, J = 6.9 Hz, CH2CO), 2.96 (2H, m, N(CHH)2), 3.93 (1 H, d, J = 12.9 Hz, NCHH), 4.36 (1 H, d, J = 12.9 Hz, NCHH), 7.19 (1 H, d, J = 6.9 Hz, NCONH), 7.30-7.40 (5H, m, ArH), 8.66 (1 H, s, OH), 10.34 (1 H, s, NH). MF C16H23N3O3, MW 305.37
Ex 9 N-Hydroxy-4-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-butyramide 1 H NMR (DMSO-d6, 300 MHz): δ ?(ppm) 1.04-1.28 (5H, m), 1.42 (2H, m), 1.66 (2H, d, J = 12.3 Hz), 1.86 (2H, t, J = 6.9 Hz, CH2CO), 2.46 (2H, m, N(CHH)2), 3.73 (2H, d, J= 12.3 Hz, N(CHH)2), 7.68-7.72 (3H, m, ArH), 8.12 (2H, t, J = 6.5 Hz, ArH), 8.29 (1 H, d, J = 8.1 Hz, ArH), 8.64 (1 H, d, J = 6.5 Hz, ArH), 8.68 (1 H, s, OH), 10.28 (1 H, s, NH). MF, C19H24N2O4S, MW 376.47
Ex 10 N-Hydroxy-4-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-butyramide
1 H NMR (DMSO-Cl6, 300 MHz): δ (ppm) 1.12 (5H, m), 1.42 (2H, m), 1.67- 1.70 (2H, m), 1.86 (2H, t, J = 6.9 Hz, CH2CO), 2.22 (2H, m, N(CHH)2), 3.70 (2H, d, J = 10.8 Hz, N(CHH)2), 7.70-7.77 (3H, m, ArH), 8.09 (1 H, d, J = 8.1 Hz, ArH), 8.16-8.23 (2H, m, ArH), 8.64 (1 H, s, ArH), 8.63 (1 H, s, OH), 10.27 (1 H, s, NH). MF C19H24N2O4S, MW 376.47
Ex 1 1 N-{3-[4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carbonyl]-phenyl}- benzamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.96-1.16 (2H, m), 1.16-1.32 (2H, m), 1.41 -1.58 (3H, m), 1.58-1.83 (2H, m), 1.94 (2H, t, J = 7.2 Hz, CH2CO), 2.62-2.83 (1 H, m, NCHH), 2.92-3.12 (1 H, m, NCHH), 3.57-3.70 (1 H, m, NCHH), 4.40-4.54 (1 H, m, NCHH), 7.09 (1 H, d, J = 7.6 Hz, ArH), 7.42 (1 H, d, J = 7.6 Hz, ArH), 7.51 -7.59 (2H, m, ArH), 7.59-7.66 (1 H, m, ArH), 7.81 - 7.88 (2H, m, ArH), 7.97 (2H, d, J = 6.8 Hz, ArH), 8.69 (1 H, s, OH), 10.39 (1 H, s, NH). MF C23H27N3O4, MW 409.48
Ex 12 4_[i -(Benzof uran-2-carbonyl)-piperidin-4-yl]-N-hydroxy-butyramide 1 H NMR (DMSO-d6, 300 MHz): δ (ppm) 1.03-1.34 (4H, m), 1.50-1.59 (3H m), 1.76 (2H, d, J= 12.6 Hz), 1.94 (2H, t, J = 7.3 Hz), 2.83 (1 H, brs), 4.17- 4.29 (1 H, brs), 4.29-4.50 (1 H, brs), 7.32-7.36 (2H, m, ArH), 7.44 (1 H, m, ArH), 7.67 (1 H, d, ArH, J = 8.4 Hz), 8.66 (1 H, s, OH), 10.34 (1 H, s, NH). MF C18H22N2O4, MW 330.39 Ex 13 N-Hydroxy-4-[1 -(6-methoxy-naphthalene-2-carbonyl)-piperidin-4-yl]- butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.18-1.26 (4H, m), 1.48-1.82 (5H, m), 1.94 (2H, t, J = 7.2 Hz, CH2CO), 2.70-3.20 (2H, m), 3.60-3.75 (1 H, m, N(CHH)2), 3.90( 3H, s, OCH3), 4.40-4.60 (1 H, m, N(CHH)2), 7.24 (1 H, d, J = 7.2 Hz, ArH), 7.38 (1 H, s, ArH), 7.45 (1 H, d, J = 7.2 Hz, ArH), 7.85-7.95 (3H, m, ArH), 8.65 (1 H, s, OH), 10.32 (1 H, s, NH). MF C21 H26N2O4, MW: 370.44
Ex 14 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- fluoro-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.95-1.25 (4H, m), 1.40-1.60 (4H, m), 1.68 (1 H, d, J = 12.3 Hz), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.75 (2H, t, J = 12.3 Hz, N(CHH)2), 4.10 (2H, d, J = 13.1 Hz ,N(CHH)2), 6.72 (1 H, m, ArH), 7.25 (2H, m, ArH), 7.45 (1 H, d, J = 12.2 Hz, ArH), 8.61 (2H, s, OH, NHAr), 10.31 (1 H, s, NH). MF Ci6H22 FN3O3, MW: 322.36
Ex 15 N-Hydroxy-4-[1-(2-methyl-naphthalene-1-carbonyl)-piperidin-4-yl]- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.40-1.30 (4H, m), 1.22-1.60 (4H, m), 1.85 (1 H, d, J = 13.4 Hz), 1.92 (2H, t, J = 7.2 Hz, CH2CO), 2.30 (3H, s, CH3), 2.70-3.40 (3H, m, N(CHH)2), 4.70 (1 H, t, J= 13.4 Hz, N(CHH)2), 7.40- 7.58 (3H, m, ArH), 7.65 (1 H, d, J = 8.4 Hz, ArH), 7.68 (1 H, d, J = 8.4 Hz, ArH), 7.84 ( 1 H, d, J= 8.4 Hz, ArH), 8.61 (1 H, s, OH), 10.29 (1 H, s, NH). MF: C2IH26N2O3, MW: 354.44
Ex 16 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- bromo-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.95-1.22 (4H, m), 1.40-1.60 (4H, m), 1.68 (1 H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.75 (2H, t, J = 12.1 Hz, N(CHH)2), 4.10 (2H, d, J = 13.2 Hz , N(CHH)2), 7.35 (2H, d, J = 8.9 Hz, ArH), 7.42 (2H, d, J = 8.9 Hz, ArH), 8.60 (1 H, m, NHAr), 8.54 (1 H, s, OH), 10.31 (1 H, s, NH).
MF: Ci6H22 BrN3O3, MW: 384.27
Ex 17 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (4- chloro-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.2 and 12.4 Hz), 1.14-1.29 (2H, m), 1.37-1.48 (1 H, m) 1.53 (2H, quin, J = 7.4 Hz), 1.62-1.72 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.75 (2H, m, N(CHH)2), 4.10 (2H, m, N(CHH)2), 7.26 (2H, d, J = 8.8 Hz, ArH), 7.50 (2H, d, J = 8.8 Hz, ArH), 8.54 (1 H, m, NCONH), 8.63 (1 H, bs, OH), 10.31 (1 H, bs, NHOH). MF C16H22CIN3O3, MW 339.82
Ex 18 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- chloro-phenyl)-amide MF C16H22CIN3O3, MW 339.82
Ex 19 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- chloro-phenyl)-amide MF C16H22FN3O3, MW 323.36
Ex 20 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- methoxy-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.6 and 12.0 Hz), 1.12-1.28 (2H, m), 1.34-1.47 (1 H, m) 1.53 (2H, quin, J = 7.4 Hz), 1.60-1.71 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.72 (2H, m, N(CHH)2), 3.71 (3H, s, OCH3), 4.08 (2H, m, N(CHH)2), 6.81 (2H, d, J= 9.2 Hz, ArH), 7.33 (2H, d, J = 9.2 Hz, ArH), 8.24 (1 H, m, NCONH), 8.63 (1 H, bs, OH), 10.31 (1 H, bs, NHOH). MF C17H25N3O4, MW 335.40 Ex 21 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- methoxy-phenyl)-amide
MF C17H25N3O4, MW 335.40
Ex 22 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid p- tolylamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.2 and 12.0 Hz),
1.12-1.28 (2H, m), 1.33-1.47 (1 H, m) 1.53 (2H, quin, J = 7.6 Hz), 1.61 -1.71
(2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.23 (3H, s, CH3), 2.73 (2H, m,
N(CHH)2), 4.09 (2H, m, N(CHH)2), 7.02 (2H, d, J = 8.0 Hz, ArH), 7.33 (2H, d, J = 8.0 Hz, ArH), 8.30 (1 H, m, NCONH), 8.63 (1 H, bs, OH), 10.31 (1 H, bs,
NHOH).
MF C17H25N3O3, MW 319.40
Ex 23 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid o- tolylamide MF C17H25N3O3, MW 319.40
Ex 24 4-[1-(Benzo[b]thiophene-2-carbonyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 300 MHz): δ (ppm) 0.86-0.91 (2H, m), 1.08-1.40 (3H m), 1.50-1.59 (2H, m), 1.75 (1 H, d, J = 12.1 Hz), 1.96 (2H, t, J = 7.3 Hz), 2.91 (3H, brs, N(CHH)2), 4.27 (2H, brs), 7.41 -7.46 (1 H, m, ArH), 7.68 (1 H, s, ArH), 7.91 -8.04 (2H, m, ArH), 8.63 (1 H, s, OH), 10.34 (1 H, s, NH). MF C18H22N2O3S, MW 346.44
Ex 25 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- fluoro-phenyl)-amide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) 0.95-1.25 (4H, m), 1.40-1.60 (4H, m), 1.68 (1 H, d, J = 12.3 Hz), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.75 (2H, t, J = 12.3 Hz, N(CHH)2), 4.10 (2H, d, J= 13.1 Hz ,N(CHH)2), 6.72 (1 H, m, ArH), 7.25 (2H, m, ArH), 7.45 (1 H, d, J = 12.2 Hz, ArH), 8.61 (2H, s, OH, NHAr), 10.31 (1 H, s, NH). MF: C16H22 FN3O3, MW: 322.363
Ex 26 4-[1-(Benzyloxycarbonyl)-piperidin-4-yl]-N-hydroxy-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.93-1.03 (2H, m), 1.15-1.51 (5H, m), 1.66 (2H, d, J =13.2 Hz), 1.93 (2H, t, J = 7.2 Hz), 2.78 (2H, brs), 3.99 (2H, d, J = 13.1 Hz), 5.07 (2H, s, CH2Ph), 7.36 (5H, s, ArH), 8.62 (1 H, s, OH), 10.31 (1 H, s, NH). MF: Ci7H24N2O4, MW: 320.38
Ex 27 N-Hydroxy-4-[1 -(3-phenyl-acryloyl)-piperidin-4-yl]-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.95-1.25 (4H, m), 1.49-1.57 (3H, m), 1.66-1.75 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.62 (1 H, t, J = 13.3 Hz, N(CHH)2), 3.06 (1 H, t, J = 12.8 Hz ,N(CHH)2), 4.47 (1 H, d, J = 12.7 Hz, N(CHH)2), 4.26 (1 H, d, J = 11.7 Hz, N(CHH)2), 7.23-7.27 (2H, m, ArH), 7.37-7.48 (4H, m, ArH), 7.70-7.72 (2H, m, ArH), 8.63 (1 H, s, OH), 10.31 (1 H, s, NH). MF: Ci8H24 N2O3, MW: 316.39
Ex 28 N-Hydroxy-4-[1-(1-methyl-1 H-indole-3-carbonyl)-piperidin-4-yl]- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.10 (2H, q), 1.19-1.28 (2H, m), 1.49-1.57 (3H, m), 1.70 (2H, d, J = 12.5 Hz), 1.95 (2H, t, J= 7.2 Hz), 2.62 (2H, t, J = 13.3 Hz, N(CH2J2), 4.26 (2H, d, J = 11.7 Hz, N(CH2J2), 7.14 (1 H, t, ArH, J= 7.4 Hz), 7.22 (1 H, t, ArH, J= 7.22 Hz), 7.49 (1 H, d, ArH, J= 8.1 Hz), 7.67 (2H, m, ArH), 8.63 (1 H, s, OH), 10.31 (1 H, s, NH). MF Ci9H25 N3O3, MW: 343.42 Ex 29 N-Hydroxy-4-[1 -(4-phenyl-butyryl)-piperidin-4-yl]-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.70-1.25 (4H, m), 1.40-1.70 (7H, m), 1.79 (2H, q, J = 7.6 Hz, CH2CH2CH2), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.3 (2H, t, J = 7.3 Hz, CH2CO), 2.6 (2H, t, J = 7.3Hz,CH2Ar), 2.91 (1 H, t, J = 13.0 Hz, N(CHH)2), 3.75 (1 H, d, J = 13.0 Hz ,N(CHH)2), 4.40 (1 H, d, J = 13.0 Hz, N(CHH)2), 7.15-7.22 (5H, m, ArH), 10.31 (1 H, s, NH). MF: Ci9H28 N2O3, MW: 332.43
Ex 30 N-Hydroxy-4-[1-(2-1 H-indol-3-yl-acetyl)-piperidin-4-yl]-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.23 (4H, m), 1.30-1.70 (6H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.90 (1 H, t, J = 12.4 Hz, N(CHH)2), 3.75 (2H, s, CH2lnd), 4.01 (1 H, d, J = 12.4 Hz, N(CHH)2), 4.40 (1 H, d, J = 12.4 Hz ,COCH2lnd), 6.95 (1 H, t, J = 7.6 Hz, ArH), 7.08 (1 H, t, J = 7.6 Hz, ArH), 7.18 (1 H, s, ArH), 7.32 (1 H, d, J = 7.6 Hz, ArH), 7.58 (1 H, d, J = 7.6 Hz, ArH), 10.31 (1 H, s, NH), 10.70 (1 H, s, NHInd). MF: Ci9H25 N3O3, MW: 332.43
Ex 31 N-Hydroxy-4-{1 -[2-(5-methyl-2-phenyl-oxazol-4-yl)-acetyl]-piperidin-4- yl}-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.23 (4H, m), 1.30-1.70 (5H, m), 1.95 (2H, t, J = 7.3 Hz, CH2CO), 2.3 (3H, s, CH3), 2.55 (1 H, t, J = 12.2 Hz, N(CHH)2), 3.05 (1 H, t, J = 12.2 Hz, N(CHH)2), 3.6 (2H, s, CH2Ar), 4.00 (1 H, d, J = 12.2 Hz, N(CHH)2), 4.35 (1 H, d, J = 12.2 Hz, N(CHH)2), 7.40- 7.55 (3H, m, ArH), 7.75-7.85 (2H, m, ArH), 10.31 (1 H, s, NH). MF: C2IH27 N3O4 ,MW: 385.45
Ex 32 N-Hydroxy-4-{1-[2-(2-phenyl-thiazol-4-yl)-acetyl]-piperidin-4-yl}- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.23 (4H, m), 1.30-1.70 (5H, m), 1.95 (2H, t, J = 7.3 Hz, CH2CO), 2.55 (1 H, t, J = 12.2 Hz ,N(CHH)2), 3.05 (1 H, t, J= 12.2 Hz, N(CHH)2), 3.9 (2H, s, CH2Ar), 4.05 (1 H, d, J = 12.2 Hz, N(CHH)2), 4.35 (1 H, d, J = 12.2 Hz, N(CHH)2), 7.40-7.55 (4H, m, ArH), 7.75-7.85 (2H, m, ArH), 8.4(1 H1S1OH), 10.31 (1 H, s, NH). MF: C20H25 N3O3 S, MW: 387.50
Ex 33 4-[1 ^-BenzoEdlisoxazol-S-yl-acetyO-piperidin-^yll-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.23 (4H, m), 1.30-1.70 (5H, m), 1.95 (2H, t, J = 7.3 Hz, CH2CO), 2.55 (1 H, t, J = 12.2 Hz, N(CHH)2), 3.05 (1 H, t, J = 12.2 Hz ,N(CHH)2), 4.05 (1 H, d, J = 12.2 Hz, N(CHH)2), 4.15 (2H, s, CH2Ar), 4.35 (1 H, d, J = 12.2 Hz, N(CHH)2), 7.38 (1 H, t, J = 7.32 Hz, ArH), 7.65 (1 H, t, J = 7.32 Hz, ArH), 7.42 (1 H, d, J = 7.32 Hz, ArH), 7.58 (1 H, d, J = 7.32 Hz, ArH), 8.45(1 H, bs, OH), 10.31 (1 H, s, NH). MF: Ci8H23 N3O4 , MW: 387.50
Ex 34 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid 4- chloro-benzylamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.82-1.00 (2H, m), 1.09-1.21 (2H, m), 1.28-1.43 (1 H, m),1.49 (2H, quin, J = 7.6 Hz), 1.54-1.64 (2H, m), 1.91 (2H, t, J= 7.2 Hz, CH2CO), 2.62 (2H, m, N(CHH)2), 3.94 (2H, m, N(CHH)2), 4.18 (2H, s, PhCH2), 7.05 (1 H, m, NCONH), 7.24 (2H, d, J = 8.0 Hz, ArH), 7.35 (2H, d, J = 8.0 Hz, ArH), 8.62 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C17H24CIN3O3, MW 353.84
Ex 35 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid 1- naphthylamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02-1.18 (2H, m), 1.18-1.33 (2H, m), 1.40-1.52 (1 H, m) 1.57 (2H, m), 1.66-1.77 (2H, m), 1.97 (2H, t, J = 7.2 Hz, CH2CO), 2.84 (2H, m, N(CHH)2), 4.18 (2H, m, N(CHH)2), 7.38-7.56 (4H, m), 7.72 (1 H, t, J = 8.0 Hz, ArH), 7.88-7.96 (2H, m, ArH), 8.51 (1 H, s, NCONH), 8.64 (1 H, bs, OH), 10.33 (1 H, s, NHOH). MF C20H25N3O3, MW 355.43
Ex 36 ^(S-Hydroxycarbamoyl-propyO-piperidine-i-carboxylic acid 2- naphthylamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.97-1.12 (2H, m), 1.16-1.30 (2H, m), 1.38-1.50 (1 H, m) 1.55 (2H, m), 1.63-1.75 (2H, m), 1.96 (2H, t, J = 7.2 Hz, CH2CO), 2.80 (2H, m, N(CHH)2), 4.17 (2H, m, N(CHH)2), 7.34 (1 H, t, J = 7.4 Hz, ArH), 7.42 (1 H, t, J = 7.4 Hz, ArH), 7.62 (1 H, d, J = 8.8 Hz, ArH), 7.70-7.83 (3H, m, ArH), 8.02 (1 H, s, ArH), 8.64 (2H, s, NCONH and OH), 10.32 (1 H, s, NHOH). MF C20H25N3O3, MW 355.43
Ex 37 ^(S-Hydroxycarbamoyl-propyO-piperidine-i-carboxylic acid (2- methoxy-phenyl)-amide MF C17H25N3O4, MW 335.39
Ex 38 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (2- chloro-phenyl)-amide MF C16H22CIN3O3, MW 339.82
Ex 39 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid 3- chloro-benzylamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.23 (4H, m), 1.30-1.70 (5H, m), 1.95 (2H, t, J = 7.3 Hz, CH2CO), 2.75 (2H, t, J = 12.2 Hz, N(CHH)2), 3.95 (2H, d, J = 12.2 Hz ,N(CHH)2), 4.15 (2H, s, CH2Ar), 7.00-7.38 (5H, m, ArH+NH amide), 8.35 (1 H, bs, OH), 10.31 (1 H, s, NH). MF: Ci7H24 CIN3O3 , MW: 387.49 Ex 40 4-[1-(2-(S)-Amino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) -0.23-0.11 , 0.61 -0.76 (1 H, q, J = 1 1.7 Hz), 0.89-1.67 (8H, m), 1.95 (2H, dd J = 7.3 and 15.7 Hz), 2.82-3.08 (2H, m, CH2Ph), 3.64 (1 H, d, J= 13.4 Hz, N(CHH)2), 4.35 (1 H, d, J = 13.1 Hz, N(CHH)2), 4.65 (1 H, dd, J =7.0 and 14.7 Hz), 7.20-7.37 (5H, m, ArH), 8.15 (3H, brs, NH3 +), 8.63 (1 H, bs, OH), 10.31 (1 H, s, NH). MF Ci8H27N3O3, MW: 333.42
Ex 41 4-[1-(2-(R)-Amino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy- butyramide MF: Ci8H27N3O3 , MW: 333.42
Ex 42 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid 2- methoxy-benzylamide MF: C18H27N3O4, MW: 349.42
Ex 43 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid 3- methoxy-benzylamide MF: C18H27N3O4, MW: 349.42
Ex 44 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid 4- methoxy-benzylamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.87-1.02 (2H, m), 1.12-1.25 (2H, m), 1.30-1.45 (1 H, m), 1.51 (2H, m), 1.56-1.65 (2H, m), 1.94 (2H, t, J = 7.0 Hz, CH2CO), 2.63 (2H, m, N(CHH)2), 3.73 (3H, s, OCH3), 3.96 (2H, m, N(CHH)2), 4.15 (2H, d, J = 5.2 Hz, PhCH2), 6.86 (2H, d, J = 8.0 Hz, ArH), 6.87 (1 H, m, NCONH), 7.17 (2H, d, J = 8.0 Hz, ArH), 8.62 (1 H, s, OH), 10.30 (1 H, s, NH). MF C18H27N3O4, MW 349.42 Ex 45 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2-f luoro- benzylamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.89-1.05 (2H, m), 1.13-1.26 (2H, m), 1.32-1.46 (1 H, m), 1.52 (2H, quin, J = 7.4 Hz), 1.56-1.70 (2H, m), 1.94 (2H, t, J= 7.0 Hz, CH2CO), 2.66 (2H, m, N(CHH)2), 3.97 (2H, m, N(CHH)2), 4.28 (2H, d, J = 5.2 Hz, PhCH2), 6.95 (1 H, m, NCONH), 7.09-7.20 (2H, m, ArH), 7.23-7.34 (2H, m, ArH), 8.65 (1 H, s, OH), 10.31 (1 H, s, NH). MF C17H24FN3O3, MW 337.39
Ex 46 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 3-f luoro- benzylamide MF C17H24FN3O3, MW 337.39
Ex 47 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2- chloro-benzylamide MF C17H24CIN3O3, MW 353.84
Ex 48 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4- dimethylamino-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.93-1.08 (2H, m), 1.13-1.34 (2H, m), 1.34-1.47 (1 H, m), 1.53 (2H, m), 1.60-1.71 (2H, m), 1.95 (2H, t, J = 7.0 Hz, CH2CO), 2.71 (2H, m, N(CHH)2), 2.84 (6H, s, 2 x CH3), 4.08 (2H, m, N(CHH)2), 6.50-6.87 (2H, m, ArH), 7.18-7.42 (2H, m, ArH), 8.15 (1 H, m, NCONH), 8.63 (1 H, bs, OH), 10.35 (1 H, s, NH). MF, C18H28N4O3, MW 348.44
Ex 49 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4- amino-phenyl)-amide MF C16H24N4O3, MW 320.38
Ex 50 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2- methyl-benzylamide MF C18H27N3O3, MW 333.42 Ex 51 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid 3- methyl-benzylamide
MF C18H27N3O3, MW 333.42
Ex 52 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid 4- methyl-benzylamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.95 (2H, dq, J = 3.2 and 12.0 Hz),
1.12-1.26 (2H, m), 1.30-1.44 (1 H, m), 1.51 (2H, quin, J = 7.4 Hz), 1.55-1.66
(2H, m), 1.94 (2H, t, J = 7.0 Hz, CH2CO), 2.27 (3H, s, CH3), 2.63 (2H, m,
N(CHH)2), 3.96 (2H, m, N(CHH)2), 4.18 (2H, d, J = 4.8 Hz, PhCH2), 6.91
(1 H, m, NCONH), 7.03-7.17 (4H, m, ArH), 8.60 (1 H, bs, OH), 10.30 (1 H, s,
NH).
MF C18H27N3O3, MW 333.42
Ex 53 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (pyridin- 4-ylmethyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.90-1.05 (2H, m), 1.11 -1.27 (2H, m), 1.32-1.46 (1 H, m), 1.53 (2H, m), 1.58-1.69 (2H, m), 1.95 (2H, t, J = 7.0 Hz, CH2CO), 2.70 (2H, m, N(CHH)2), 3.97 (2H, m, N(CHH)2), 4.41 (2H, d, J = 5.2 Hz, PhCH2), 7.26 (1 H, t, J = 7.0 Hz, NCONH), 7.72 (2H, d, J = 5.4 Hz, ArH), 8.74 (2H, d, J= 5.4 Hz, ArH), 10.31 (1 H, s, NH). MF C16H24N4O3, MW 320.39
Ex 54 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid
(naphthalen-i-ylmethyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.95-1.23 (4H, m), 1.30-1.70 (5H, m), 1.95 (2H, t, J = 7.3 Hz, CH2CO), 2.65 (2H, t, J = 12.4 Hz, N(CHH)2), 4.0 (2H, d, J = 12.4 Hz ,N(CHH)2), 4.70 (2H, s, CH2Ar), 6.98 (1 H, s, NHCH), 7.40-7.60 (4H, m, ArH),7.80 (1 H, d, J = 7.88 Hz, ArH), 7.92 (1 H, d, J = 7.8 Hz, ArH), 8.18 (1 H, d, J = 7.8 Hz, ArH), 8.60 (1 H,bs,OH), 10.32 (1 H, s, NH). MF C2i H27 N3O3, MW: 369.46 Ex 55 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid
(naphthalen-2-ylmethyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.95-1.23 (4H, m), 1.30-1.70 (5H, m), 1.95 (2H, t, J = 7.30 Hz, CH2CO), 2.65 (2H, t, J = 12.4 Hz, N(CHH)2), 4.0 (2H, d, J = 12.4 Hz, N(CHH)2), 4.30 (2H, s, CH2Ar), 7.20(1 H, s, NHCH), 7.45-7.55 (3H, m, ArH), 7.70 (1 H, s, ArH) 7.88-7.85 (3H, m, ArH), 8.30 (1 H, bs, OH), 10.28 (1 H, s, NH). MF C21 H27 N3O3, MW: 369.457
Ex 56 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid
(biphenyl-4-ylmethyl)-amide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) 0.95-1.23 (4H, m), 1.30-1.65 (5H, m), 1.95 (2H, t, J = 7.25 Hz, CH2CO), 2.64 (2H, t, J = 12.3 Hz, N(CHH)2), 4.0 (2H, d, J = 12.3 Hz, N(CHH)2), 4.30 (2H, s, CH2Ar), 7.00(1 H,s, NHCH), 7.32 (3H, t, J = 8.92 Hz, ArH), 7.45 (2H, t, J = 8.92 Hz, ArH), 7.60 (2H, J = 7.56 Hz, ArH), 7.65 (2H, J = 7.56 Hz, ArH), 8.60 (1 H, bs, OH), 10.30 (1 H, s, NH). MF C23H29 N3O3, MW: 395.50
Ex 57 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid 4- phenoxy-benzylamide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) 0.95-1.23 (4H, m), 1.30-1.75 (5H, m), 1.95 (2H, t, J= 7.2 Hz, CH2CO), 2.62 (2H, t, J = 12.4 Hz, N(CHH)2), 4.0 (2H, d, J= 12.4 Hz ,N(CHH)2), 4.22 (2H, s, CH2Ar), 6.94-7.00 (5H, m, ArH), 7.12 (1 H, t, J = 7.5 Hz, NHCH), 7.26 (2H,m, ArH), 7.38 (2H, d, J = 7.4 Hz, ArH), 8.50 (1 H, bs, OH), 10.32 (1 H, s, NH). MF C23H29 N3O4, MW: 41 1.50
Ex 58 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid phenethyl-amide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) 0.75-1.23 (4H, m), 1.30-1.65 (5H, m), 1.95 (2H, t, J = 7.30 Hz, CH2CO), 2.60 (2H, t, J = 12.5 Hz, N(CHH)2), 2.72 (2H, t, J = 7.25 Hz, CH2Ph), 3.40 (2H, m, CH2NH), 3.80 (2H, d, J = 12.5 Hz ,N(CHH)2), 6.50 (1 H, s, CH2NH ), 7.25-7.60 (5H, m, ArH), 8.50 (1 H, bs, OH), 10.32 (1 H, s, NH). MF Ci8H27 N3O3, MW, 333.42
Ex 59 6-{[Benzyl-(2-hydroxy-ethyl)-amino]-methyl}-7-fluoro- benzo[b]thiophene-2-carboxylic acid hydroxyamide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) 0.75-1.23 (4H, m), 1.30-1.85 (7H, m), 1.95 (2H, t, J = 7.3 Hz, CH2CO), 2.50-2.70 (4H, m, CH2Ph and CH2N), 3.20 (2H, m, CH2NH), 3.95 (2H, d, J = 12.6 Hz, N(CHH)2), 6.35 (1 H, s, CH2NH), 7.25-7.60 (5H, m, ArH), 8.50 (1 H, bs, OH), 10.32 (1 H, s, NH). MF Ci9H29 N3O3, MW: 347.45
Ex 60 4_{i -^-Amino-S^-chloro-phenyO-propionylJ-piperidin^-ylJ-N- hydroxy-butyramide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) -0.13-0.02, 0.63-0.75 (1 H, dd, 1 H, J =13.0 Hz, J =24.9Hz), 0.99-1.01 (3H, m), 1.33-1.71 (5H, m), 1.95 (2H, dd J = 7.3 and 15.7 Hz), 2.55 (1 H, m), 2.86-3.05 (2H, m, CH2Ph), 3.64-3.76 (1 H, m, N(CHH)2), 4.35 (1 H, d, J = 13.8 Hz ,N(CHH)2), 4.61 -4.68 (1 H, m, N(CHH)2), 7.23-7.27 (2H, t, ArH, J= 7.7 Hz), 7.40-7.44 (2H, dd, J = 6.1 Hz, J =8.2 Hz, ArH), 8.14 (3H, bs, NH3 +), 8.62 (1 H, bs, OH), 10.31 (1 H, s, NH). MF: Ci8H26CIN3O3 , MW: 367.87
Ex 61 4_{i -^-Amino-S^S-chloro-phenyO-propionylJ-piperidin^-ylJ-N- hydroxy-butyramide MF Ci8H26CIN3O3, MW: 367.87
Ex 62 4-{1-[2-(R)-Amino-3-(3,4-dichloro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide.
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) -0.002-0.09, 0.64-0.73 (1 H, dd, 1 H, J =11.3 Hz, J =24.7 Hz), 1.16-1.24 (2H,m), 1.35-1.55 (4H, m), 1.62-1.72 (2H, m), 1.95 (2H, dd, J =7.8Hz, J =16.5Hz), 2.55 (1 H, m), 2.77-2.84 (1 H, t, J =12.3Hz), 2.90-3.04 (2H, m, CH2Ph), 3.72-3.78, 3.82-3.89 (1 H, d, J = 13 Hz, N(CHH)2), 4.35 (1 H, d, J = 13.3 Hz ,N(CHH)2), 4.63-4.71 (1 H, m, N(CHH)2), 7.24 (1 H, dt, ArH), 7.52-7.65 (2H, m, ArH), 8.14 (3H, brs, NH3 +), 8.62 (1 H, bs, OH), 10.31 (1 H, s, NH). MF C18H25CI2N3O3, MW: 402.31
Ex 63 4-{1-[2-(R)-Amino-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) -0.16-0.05, 0.64-0.75 (1 H, dd, J =12.2Hz, J =23.2Hz), 0.85-1.04 (2H,m), 1.28-1.69 (6H, m), 1.88-1.94 (2H, m), 2.83-3.03 (3H, m, CH2Ph, N(CHH)2),3.61 (1 H, t, J = 11.7 Hz, N(CHH)2), 3.74 (3H, s, OCH3), 4.36 (1 H, d, J = 12.4 Hz ,N(CHH)2), 4.58 (1 H, brs, N(CHH)2), 6.89-6.92 (2H,m, ArH), 7.11 -7.17 (2H, t, ArH, J = 8.9 Hz), 8.13 (3H, brs, NH3 +), 8.62 (1 H, bs, OH), 10.31 (1 H, s, NH). MF Ci9H29N3O4, MW: 363.45
Ex 64 4-[1-(2-(R)-Amino-2-methyl-3-phenyl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide.
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) 1.00-1.23 (4H, m), 1.50-1.60 (2H, m, CH2NH),1.63 (3H, s, CH3), 1.80 (2H, m, CH2NH),1.95 (2H, t, J= 7.35 Hz, CH2CO) , 2.95(2H, m, CH2NH), 3.10 (1 H, d, J = 7.00 Hz, CH2Ph), 3.30 (1 H, d, J = 7.00 Hz, CH2Ph), 4.30 (2H, m, CH2NH), 7.20-7.40 (5H, m, ArH), 8.00 (3H, s, NH3 +), 8.60 (1 H, bs, OH), 10.32 (1 H, s, NH). MF Ci9H29 N3O3, MW: 347.45
Ex 65 4_{i -[2-(R)-Amino-3-(1 H-indol-3-yl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) -0.50-0.30 (1 H, dq, J=12.2 Hz), 0.8-1.7 (6H, m), 1.95 (2H, t, J = 7.35 Hz, CH2CO), 2.7 (1 H, t, J = 12.4 Hz, N(CHH)2), 3.15 (2H, m, CH2In), 3.50 (1 H, t, J = 13.2 Hz, N(CHH)2), 3.65 (1 H, t, J = 13.2 Hz, N(CHH)2), 4.30 (1 H, t, J = 1 1.9 Hz, N(CHH)2), 4.60 (1 H, m, CHNH), 7.00-7.15 (2H, dt, J = 7.60 Hz, ArH), 7.25 (1 H, m, ArH), 7.38 (1 H, d, J = 7.60 Hz, ArH) ArH), 7.45-7.55 (1 H, d, J = 7.60 Hz, ArH), 8.2 (3H, bs, NH3 + ), 8.60 (1 H, s, OH), 10.32 (1 H, s, NH), 11.0 (1 H, s, NHInd). MF C20H28 N4O3, MW: 372.46
Ex 66 4-{1-[2-(S)-Amino-3-(1 H-indol-3-yl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) -0.50-0.30(1 H, dq, J=12.25 Hz), 0.8-1.7 (6H, m), 1.95 (2H, t, J = 7.35 Hz, CH2CO), 2.7 (1 H, t, J = 12.4 Hz, N(CHH)2), 3.15 (2H, m, CH2In), 3.50 (1 H, t, J = 13.2 Hz, N(CHH)2), 3.65 (1 H, t, J = 13.2 Hz, N(CHH)2), 4.30 (1 H, t, J = 11.92 Hz, N(CHH)2), 4.60 (1 H,m, CHNH), 7.00-7.15 (2H, dt, J = 7.60 Hz, ArH), 7.25 (1 H, m, ArH), 7.38 (1 H, d, J = 7.60 Hz, ArH), 7.45-7.55 (1 H, d, J = 7.60 Hz, ArH), 8.2 (3H, bs, NH3 + ), 8.60 (1 H,s,OH), 10.32 (1 H, s, NH), 11.0 (1 H,s, NH-lnd). MF C20H28 N4O3, MW: 372.46
Ex 67 4_[i -(2-(R)-Amino-3-benzyloxy-propionyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) 0.60-1.23 (4H, m), 1.40-1.80 (5H, m), 1.95 (2H, t, J = 7.27 Hz, CH2CO) , 2.65(1 H, m, CH2NH), 2.95(1 H, m, CH2NH), 3.60-3.70 (2H, m, OCH2Ph), 4.50-4.70 (3H, m, CHCH2O, CHNH2), 3.80 (1 H, m, CH2NH), 4.35 (1 H, m, CH2NH), 7.20-7.40 (5H, m, ArH), 8.20 (3H, s, NH3 +), 8.60 (1 H, bs, OH), 10.36 (1 H, s, NH). MF Ci9H29 N3O4, MW: 347.45
Ex 68 4_{i -[2-(R)-Amino-3-(4-tert-butoxy-phenyl)-propionyl]-piperidin-4-yl}- N-hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.0-0.80(1 H, dq, J=12.23 Hz), 0.7- 1.2 (2H, m), 1.30 (9H, s, O(CH3)3), 1.30-1.70 (5H,m), 1.95 (2H, q, J = 7.80 Hz, CH2CO), 2.2 (1 H, t, J = 11.0 Hz, N(CHH)2), 2.45 (1 H, t, J = 11.0 Hz, N(CHH)2), 2.80-3.00 (2H, m, CH2Ph), 3.60 (1 H, m, N(CHH)2), 4.35 (1 H, d, J = 12.6 Hz, N(CHH)2), 4.65 (1 H,m, CHNH), 6.90-6.96 (2H, d, J = 7.08 Hz, ArH), 7.10-7.18 (2H, d, J = 7.08 Hz, ArH), 8.2 (3H, bs, NH3 +), 8.00 (1 H, s, OH), 10.32 (1 H, s, NH). MF C22H35 N3O4, MW: 372.46
Ex 69 4_[i -(2-(R)-Amino-3-benzylsulfanyl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO- d6, 400 MHz): δ (ppm) 0.70-1.23 (4H, m), 1.40-1.80 (5H, m), 1.95 (2H, t, J = 7.27 Hz, CH2CO) , 2.65-3.10 (4H, m, CH2NH, CH2Ph), 3.75 (1 H, t, J=12.39Hz,CH2NH), 3.85 (2H,d, J=8.74Hz ,SCH2Ph), 4.35 (1 H,d, J=13.36Hz, CH2NH), 4.55 (1 H, m, CH2NH), 7.20-7.40 (5H, m, ArH), 8.20 (3H, s, NH3 + ), 8.60 (1 H,bs,OH), 10.36 (1 H, s, NH). MF Ci9H29 N3O3S, MW 379.517
Ex 70 ^(S-Hydroxycarbamoyl-propyO-piperidine-i-carboxylic acid pyridin- 3-ylamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.98-1.11 (2H, m), 1.15-1.31 (2H, m), 1.39-1.62 (3H, m), 1.62-1.76 (2H, m), 1.95 (2H, t, J = 7.0 Hz, CH2CO), 2.82 (2H, m, N(CHH)2, 4.13 (2H, m, N(CHH)2), 7.66 (1 H, m, ArH), 8.23 (1 H, d, J = 8.4 Hz, ArH), 8.34 (1 H, d, J = 4.4 Hz, ArH), 8.91 (1 H, m, ArH), 9.08 (1 H, s, NCONH), 10.32 (1 H, s, NH). MF C15H22N4O3, MW 306.36
Ex 71 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (pyridin- 3-ylmethyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.95 (2H, dq, J = 3.2 and 12.0 Hz), 1.11 -1.23 (2H, m), 1.32-1.46 (1 H, m), 1.51 (2H, quin, J = 7.5 Hz), 1.56-1.71 (2H, m), 1.94 (2H, t, J = 7.0 Hz, CH2CO), 2.67 (2H, m, N(CHH)2, 3.95 (2H, m, N(CHH)2), 4.34 (2H, d, J = 3.9 Hz, PhCH2), 7.18 (1 H, s, NCONH), 7.73- 7.84 (1 H, m, ArH), 8.12-8.22 (1 H, m, ArH), 8.65-8.72 (2H, m, ArH), 8.46 (1 H, bs, OH), 10.32 (1 H, s, NH). MF C16H24N4O3, MW 320.39
Ex 72 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- amino-phenyl)-amide
MF C16H24N4O3, MW 320.39
Ex 73 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (2- amino-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.08 (2H, dq, J = 3.2 and 12.0 Hz), 1.18-1.30 (2H, m), 1.40-1.50 (1 H, m), 1.55 (2H, m), 1.64-1.74 (2H, m), 1.96 (2H, t, J = 7.0 Hz, CH2CO), 2.82 (2H, m, N(CHH)2, 4.12 (2H, m, N(CHH)2), 7.09-7.25 (4H, m, ArH), 8.44 (1 H, s, OH), 10.31 (1 H, s, NH). MF C16H24N4O3, MW 320.39
Ex 74 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid 4- dimethylamino-benzylamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.94 (2H, dq, J = 3.2 and 12.0 Hz), 1.12-1.23 (2H, m), 1.30-1.45 (1 H, m), 1.51 (2H, quin, J = 7.6 Hz), 1.56-1.65 (2H, m), 1.94 (2H, t, J = 7.0 Hz, CH2CO), 2.62 (2H, m, N(CHH)2), 2.95 (6H, s, 2 x CH3), 3.96 (2H, m, N(CHH)2), 4.15 (2H, d, J = 5.8 Hz, PhCH2), 6.90 (1 H, s, NCONH), 7.19 (4H, m, ArH), 10.31 (1 H, s, NH). MF C19H30N4O3, MW 362.47
Ex 75 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- fluoro-phenyl)-amide MF ' C1 I 6oH2222FN33O, 3' MW 323.36
Ex 76 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid m- tolylamide MF C17H25N3O3, MW 319.40
Ex 77 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid benzyl- methyl-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.95 (2H, dq, J = 3.2 and 12.4 Hz), 1.14-1.24 (2H, m), 1.31 -1.45 (1 H, m), 1.51 (2H, quin, J = 7.4 Hz), 1.58-1.69 (2H, m), 1.94 (2H, t, J = 7.0 Hz, CH2CO), 2.63-2.74 (2H, m, N(CHH)2), 2.67 (3H, s, CH3), 3.57 (2H, m, N(CHH)2), 4.31 (2H, s, PhCH2), 7.22-7.30 (3H, m, ArH), 7.32-7.39 (2H, m, ArH), 8.63 (1 H, s, OH), 10.31 (1 H, s, NH). MF C18H27N3O3, MW 333.42
Ex 78 N-Hydroxy-4-{1-[2-(2-1 H-indol-3-yl- acetylamino)-acetyl]-piperidin-4- yl}-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.20 (4H, m), 1.40-1.70 (5H, m), 1.95 (2H, t, J = 7.27 Hz, CH2CO) , 2.55 (1 H, t, J=12.3 Hz,CH2NH), 2.95 (1 H, t, J=12.3 Hz,CH2NH), 3.58 (2H, s, CH2lnd), 3.70 (1 H, d, J=12.3 Hz,CH2NH), 3.80-3.95 ( 2H, m, CH2NH), 4.30 (1 H, d, J=12.3 Hz, CH2NH), 6.95-7.10(2H, dt, J= 7.36 Hz, ArH), 7.25 (1 H, s, ArH), 7.35 (1 H, d, J=7.4 Hz, ArH), 7.55 (1 H, d, J=7.4 Hz, ArH), 7.80 (1 H, m, CH2NH), 8.60 (1 H, bs, OH), 10.36 (1 H, s, NH), 10.85 (1 H, s, NHInd). MF: C2iH28 N4O4, MW: 400.47
Ex 79 Benzo[b]thiophene-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl- propyl)- piperidin-1-yl]-2-oxo-ethyl}- amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.20 (4H, m), 1.40-1.80 (5H, m), 1.95 (2H, t, J = 7.30 Hz, CH2CO), 2.55 (1 H, t, J=10.9 Hz, CH2NH), 3.00 (1 H, t, J=10.9 Hz,C H2NH), 3.90 (1 H, d, J=10.9 Hz, CH2NH), 4.15 (2H, s, CH2GIy), 4.40 (1 H, d, J=10.9 Hz, CH2NH), 7.40-7.50 (2H, m, ArH), 7.95- 8.15 (2H, d, J= 7.4 Hz ,ArH), 8.65 (1 H, s ,OH), 8.65 (1 H, s, NHCH), 10.36 (1 H, s, NH). MF: C20H25 N3O4S, MW: 403.49 Ex 80 Naphthalene-1-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1-yl]-2-oxo-ethyl}-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.75-1.25 (4H, m), 1.40-1.80 (5H, m), 1.95 (2H, t, J = 7.3 Hz, CH2CO) , 2.60 (1 H, t, J= 10.9 Hz,CH2NH), 3.05 (1 H, t, J=10.9 Hz,CH2NH), 3.90 (1 H, d, J= 10.9 Hz, CH2NH), 4.15 (2H,d , J=5.8 Hz, CH2GIy), 4.40 (1 H, d, J= 10.9 Hz,CH2NH), 7.55-7.65 (4H, m, ArH), 7.95-8.05 (2H, m, ArH), 8.50 (1 H, t, J= 5.6 Hz, NHCH2), 8.65 (1 H, s, OH), 10.36 (1 H, s, NH). MF: C22H27 N3O4, MW: 397.47
Ex 81 2-Methyl-naphthalene-1-carboxylic acid {2-[4-(3-hydroxycarbamoyl- propy l)-pipendin-1-yl]-2-oxo-ethyl}-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.75-1.25 (4H, m), 1.40-1.80 (5H, m), 1.95 (2H, t, J = 7.3 Hz, CH2CO), 2.45 (3H, s, CH3), 2.60 (1 H, t, J= 10.9 Hz, CH2NH), 3.05 (1 H, t, J=10.9 Hz,CH2NH), 3.90 (1 H, d, J= 10.9 Hz, CH2NH), 4.15 (2H,d, J=5.8 Hz, CH2GIy), 4.40 (1 H, d, J= 10.90 Hz, CH2NH), 7.55-7.65 (3H, m, ArH), 7.95-8.05 (2H, m, ArH), 8.50 (1 H, s, NHCH2), 8.65 (1 H, bs, OH), 10.36 (1 H, s, NH). MF C23H29 N3O4, MW: 41 1.49
Ex 82 4_[i -(2-(S)-Amino-4-phenyl-butyryl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.86-1.02 (2H, m), 1.17 (2H, m), 1.51 (3H, m), 1.69 (2H, m), 1.94 (4H, m), 2.57-2.74 (3H, m, CH2Ph), 2.92- 3.07 (1 H, q, J= 13.6 Hz), 3.61 -3.75 (1 H, m), 4.29-4.42 (2H, m), 7.21 -7.32 (5H, m, ArH), 8.12 (2H, s, NH3 +), 8.63 (1 H, s), 10.32 (1 H, s, NH). MF: Ci7H24N2O4, MW: 320.38 Ex 83 4-(3-Hydroxycarbamoyl-piOpyl)-pipeπdine-1-carboxylic acid (3- chloro-2-fluoro-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.04 (2H, dq, J = 3.2 and 12.0 Hz), 1.13-1.29 (2H, m), 1.37-1.48 (1 H, m) 1.54 (2H, quin, J = 7.4 Hz), 1.61 -1.73 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.78 (2H, m, N(CHH)2), 4.06 (2H, m, N(CHH)2), 7.12 (1 H, m, ArH), 7.27 (1 H, m, ArH)), 7.37 (1 H, m, ArH), 8.39 (1 H, s, NCONH), 8.64 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C16H21CIFN3O3, MW 357.81
Ex 84 4-(3-Hydroxycarbamoyl-piOpyl)-pipeπdine-1-carboxylic acid (2,4- difluoro-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.03 (2H, dq, J = 3.2 and 12.0 Hz), 1.14-1.29 (2H, m), 1.35-1.48 (1 H, m) 1.53 (2H, m), 1.60-1.72 (2H, m), 1.95 (2H, t, J= 7.2 Hz, CH2CO), 2.76 (2H, m, N(CHH)2), 4.05 (2H, m, N(CHH)2), 7.00 (1 H, m, ArH), 7.21 (1 H, m, ArH), 7.38 (1 H, m, ArH), 8.18 (1 H, s, NCONH), 8.61 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C16H21 F2N3O3, MW 341.35
Ex 85 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- chloro-4-methyl-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.7 and 12.6 Hz), 1.13-1.26 (2H, m), 1.35-1.47 (1 H, m) 1.53 (2H, m), 1.60-1.73 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.24 (3H, s, CH3), 2.74 (2H, m, N(CHH)2), 4.09 (2H, m, N(CHH)2), 7.15-7.21 (1 H, m, ArH), 7.31 (1 H, dd, J= 2.1 and 8.3 Hz, ArH), 7.61 -7.66 (1 H, m, ArH), 8.50 (1 H, s, OH), 10.32 (1 H, s, NHOH). MF C17H24CIN3O3, MW 353.84
Ex 86 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3,4- difluoro-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.7 and 12.5 Hz), 1.14-1.27 (2H, m), 1.37-1.48 (1 H, m) 1.53 (2H, m), 1.61 -1.74 (2H, m), 1.95 (2H, t, J= 7.2 Hz, CH2CO), 2.76 (2H, m, N(CHH)2), 4.09 (2H, m, N(CHH)2), 7.17-7.34 (2H, m, ArH), 7.62 (1 H, ddd, J = 2.3 and 7.5 and 13.7 Hz), 8.61 (2H, bs, NCONH and OH), 10.31 (1 H, s, NHOH). MF C16H21 F2N3O3, MW 341.35
Ex 87 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (3,4- dimethyl-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.01 (2H, dq, J = 3.5 and 12.6 Hz), 1.14-1.25 (2H, m), 1.32-1.47 (1 H, m) 1.53 (2H, m), 1.61 -1.71 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.14 (3H, s, CH3), 2.16 (3H, s, CH3), 2.72 (2H, m, N(CHH)2), 4.09 (2H, m, N(CHH)2), 6.93-6.99 (1 H, m, ArH), 7.13-7.19 (1 H, m, ArH), 7.21 -7.25 (1 H, m, ArH), 8.23 (1 H, s, NCONH), 8.63 (1 H, bs, OH), 10.31 (1 H, s, NHOH). MF C18H27N3O3, MW 333.42
Ex 88 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- chloro-4-fluoro-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.8 and 12.6 Hz), 1.13-1.25 (2H, m), 1.36-1.48 (1 H, m) 1.53 (2H, m), 1.62-1.73 (2H, m), 1.94 (2H, t, J= 7.2 Hz, CH2CO), 2.76 (2H, m, N(CHH)2), 4.09 (2H, m, N(CHH)2), 7.27 (1 H, d, J = 9.1 Hz, ArH), 7.38-7.45 (1 H, m, ArH), 7.76 (1 H, dd, J = 2.6 and 6.9 Hz, ArH), 8.61 (2H, bs, NCONH and OH), 10.31 (1 H, s, NHOH). MF C16H21CIFN3O3, MW 357.81
Ex 89 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (2,5- difluoro-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.04 (2H, dq, J = 3.7 and 12.6 Hz), 1.14-1.27 (2H, m), 1.35-1.48 (1 H, m) 1.53 (2H, m), 1.60-1.74 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.78 (2H, m, N(CHH)2), 4.03-4.11 (2H, m, N(CHH)2), 6.84-6.93 (1 H, m, ArH), 7.17-7.26 (1 H, m, ArH), 7.37-7.46 (1 H, m, ArH), 8.30 (1 H, s, NCONH), 8.63 (1 H, s, OH), 10.33 (1 H, s, NHOH). MFC1nH91F9NLO, MW 341.35
Ex 90 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- chloro-2-fluoro-phenyl)-amide
1HNMR(DMSO-Cl6, 400 MHz): δ (ppm) 1.03(2H,dq, J =3.8 and 12.6 Hz), 1.15-1.27 (2H, m), 1.37-1.48 (1 H, m) 1.53 (2H, quin, J = 7.4 Hz), 1.61 -1.74 (2H, m), 1.95 (2H,t, J = 7.2 Hz, CH2CO), 2.77 (2H, m, N(CHH)2), 4.06 (2H, m, N(CHH)2), 7.16-7.22 (1H, m, ArH), 7.38 (1H, dd, J = 2.3 and 10.5 Hz, ArH), 7.42-7.49 (1H, m, ArH), 8.27 (1H, s, NCONH), 8.62 (1H, bs, OH), 10.31 (1 H, s, NHOH). MFC16H21CIFN3O3, MW 357.81
Ex 91 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (2,4- dimethoxy-phenyl)-amide
1HNMR(DMSO-d6, 400 MHz): δ (ppm) 1.03(2H,dq, J =3.8 and 12.6 Hz), 1.14-1.28 (2H, m), 1.33-1.48 (1H, m) 1.53 (2H, m), 1.63-1.71 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.74 (2H, m, N(CHH)2), 3.74 (3H, s, OCH3), 3.78 (3H, s, OCH3), 4.01 (2H, m, N(CHH)2), 6.45 (1H, dd, J = 2.6 and 8.7 Hz, ArH), 6.57 (1 H, d, J = 2.6 Hz, ArH), 7.35-7.39 (1 H, m, ArH), 7.42 (1 H, s, NCONH), 8.63 (1 H, bs, OH), 10.31 (1 H, s, NHOH). MFC18H27N3O5, MW 365.42
Ex 92 N-Hydroxy-4-[1-(2-(R)-methylamino-3-phenyl-propionyl)-piperidin-4- yl]-butyramide
1H NMR (DMSO-d6, 400 MHz): δ (ppm) -0.5-0.60 (1H, dq, J= 12.20 Hz), 0.8-1.7 (8H, m), 1.95 (2H, q, J = 7.80 Hz, CH2CO), 2.05-2.45 (1H, d7, J=13.4 Hz, N(CHH)2 ), 2.5 (3H, m, CH3), 2.70-2.85 (2H, m, CH2Ph), 3.10 (1H, m, N(CHH)2), 3.25 (1H, m, N(CHH)2), 4.35 (1H, m, N(CHH)2), 4.45 (1 H, m, CHNHCH3), 7.10-7.40 (5H, m, ArH), 8.8-9.2 (3H, bs, NH2 +, OH),
10.32 (1 H, s, NH).
MF: Ci9H29 N3O3, MW: 347.452
Ex 93 4-[1-(2-(R)-Amino-3-naphthalen-1-yl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) -0.5-0.65(2H, dq, J=12.1 Hz), 0.7- 1.7 (7H, m), 1.95 (2H, q, J = 7.80 Hz, CH2CO), 2.15-2.45 (1 H, dt, J=13.3 Hz, N(CHH)2), 2.75-2.85 (2H, m, CH2Ph), 3.10 (1 H, m, N(CHH)2), 3.45 (1 H, m, N(CHH)2), 4.35 (1 H, m, N(CHH)2), 4.50( 1 H,m, CHNH2), 7.40-8.00 (7H, m, ArH), 8.2-8.5 (4H, bs, NH3 + ,OH), 10.28 (1 H, d, J = 13.00 Hz, NH). MF: C22H29 N3O3, MW: 383.48
Ex 94 4-[1-(2-(R)-Amino-3-benzo[b]thiophen-3-yl-propionyl)-piperidin-4-yl]- N-hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) -0.57-0.12 (1 H, dq), 0.73-1.79 (8H, m), 1.86 (2H, m), 2.15-2.28 (1 H, m), 2.37 (1 H, t, J=12.5 Hz), 2.73 (2H, m), 3.18-3.36 (2H, m), 4.26 (1 H, t, J= 13.7 Hz, N(CHH)2), 4.73(1 H, s, CHNH2), 7.43 (2H, m, ArH), 7.61 (1 H, s, ArH), 7.75-7.81 (1 H, 2d, J= 7.4 Hz, ArH), 8.02 (1 H, d, J= 7.7 Hz, ArH), 8.2-8.5 (3H, bs, NH3 +), 8.69 (1 H, brs, OH), 10.28 (1 H, s, NH). MF: C20H27 N3O3S, MW: 389.51
Ex 95 4_[i -(2-(R)-Amino-3-m-tolyl-propionyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) -0.2-0.75 (1 H, dq, J=12.10 Hz), 0.85-1.85 (8H, m), 1.95 (2H, q, J = 7.9 Hz, CH2CO), 2.3 (3H, s, CH3), 2.25- 2.45 (1 H, m, N(CHH)2), 2.70-2.75 (1 H, m, , N(CHH)2 ), 2.75-2.85 (2H, m, CH2Ph), 3.40-3.50 (1 H, m, N(CHH)2), 4.10-4.20 (1 H, m, N(CHH)2 ), 4.50 (1 H, m, CHNH2), 7.00-7.40 (4H, m, ArH), 8.1 -8.4 (4H, bs, NH3 +, OH), 10.25 (1 H, d, J= 13.0 Hz, NH).
MF Ci9H29 N3O3, MW: 347.45
Ex 96 4-{1-[2-(S)-Amino-3-(4-benzoyl-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) -0.20-0.75 (1 H, 2q, J=12.1 Hz ), 0.87-1.06 (2H, m), 1.12-1.22 (1 H, m), 1.28-1.72 (5H, m), 1.95 (2H, 2t, J = 7.3 Hz), 2.45 (1 H, m, N(CHH)2 ), 2.90 (1 H, t, J= 13.5 Hz, N(CHH)2), 3.00- 3.20 (2H, m, CH2Ph), 3.65-3.77 (1 H, m, N(CHH)2), 4.37 (1 H, d, N(CHH)2 J= 12.8 Hz), 4.74 (1 H, m, CHNH2), 7.41 -7.48 (2H, m, ArH), 7.57-7.61 (2H, m, ArH), 7.68-7.77 (5H, m, ArH), 8.20 (3H, d, NH3 +), 8.61 (1 H, brs, OH), 10.29 (1 H, d, J= 9.9 Hz, NH). MF C25H31 N3O4, MW: 437.53
Ex 97 4-{1-[2-(R)-Amino-3-(2-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.0-0.80 (1 H, dq, J=12.1 Hz), 0.85- 1.85 (8H, m), 1.95 (2H, q, J = 7.9 Hz, CH2CO), 2.35-2.45 (1 H, m, N(CHH)2 ), 2.60-2.65 (1 H, m, N(CHH)2 ), 2.75-2.85 (2H, m, CH2Ph), 3.40-3.50 (1 H, m, N(CHH)2), 4.15 (1 H, d, J = 11.9 Hz, N(CHH)2), 4.55 (1 H,m, CHNH2), 7.10-7.50 (4H, m, ArH), 8.10-8.35 (4H, bs, NH3 +, OH), 10.20 (1 H, d, J = 13.0 Hz, NH). MF C18H26 FN3O3, MW: 351.42
Ex 98 4-{1-[2-(R)-Amino-3-(3-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide MF C18H26 FN3O3, MW: 351.42
Ex 99 4-{1-[2-(R)-Amino-3-(4-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide MF C18H26 FN3O3, MW: 351 .42 Ex 100 N-Hydroxy-4-[1-(2-(R)-hydroxy-3-phenyl-propionyl)-piperidin-4-yl]- butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.75-1.20 (4H, m), 1.40-1.80 (5H, m), 1.95 (2H, t, J = 7.30 Hz, CH2CO), 2.50 (1 H,m, CH2NH), 2.70 (1 H,m, CH2NH), 2.85 (2H,m, CH2Ph), 3.90 (1 H, t, J = 12.3 Hz, CH2NH), 4.35 (1 H, m, CH2NH), 4.40 (1 H, d, J = 10.9 Hz,CH2NH), 4.50 (1 H, m, CHOH), 7.15- 7.30 (5H, m, ArH), 8.65 (1 H, bs, OH), 10.35 (1 H, s, NH). MF C18H26 N2O4, MW: 334.41
Ex 101 Benzo[b]thiophene-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl- propyl)- piperidin-1-yl]-1-(S)-hydroxymethyl-2-oxo-ethyl}-amide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.20 (4H, m), 1.40-1.80 (5H, m), 1.95 (2H, m, CH2CO), 2.55 (1 H, t, J = 12.5Hz, CH2NH), 3.05 (1 H, t, J=12.5Hz, CH2NH), 3.60 (1 H, m, CH2OH), 3.75 (1 H, m, CH2OH), 4.05 (1 H, d, J=12.3 Hz, CH2NH), 4.40 (1 H,d, J=12.3 Hz,CH2NH), 4.90 (1 H, m, CH2OH), 5.00 (1 H, m, CHCH2OH), 7.40-7.50 (1 H, m, ArH), 7.95 (1 H, d, J=7.2 Hz, ArH), 8.05 (1 H, d, J=7.2 Hz, ArH), 8.20-8.25 (1 H, m, ArH), 8.65(1 H, bs, OH), 8.80 (1 H, m, NHCH), 10.35 (1 H, s, NH). MF C2i H27 N3O5S, MW: 433.52
Ex 102 Benzo[b]thiophene-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl- propyl)- piperidin-1-yl]-1-(R)-hydroxymethyl-2-oxo-ethyl}-amide MF C2i H27 N3O5S, MW: 433.52
Ex 103 4-[1-(2-(S)-Dimethylamino-4-phenyl-butyryl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.20 (4H, m), 1.40-1.80 (7H, m, CH2NH and CH2CO), 2.50-2.60 (4H, m, CH2CH2NH), 2.65 (1 H,m, CH2NH), 2.75 (3H, s, CH3), 2.85 (3H, s, CH3), 3.10 (1 H,m, CH2NH), 3.90 (1 H, m, CH2NH), 4.45 (1 H, m, CH2NH), 4.60 (1 H, m, CHN), 7.20-7.40 (5H, m, ArH), 9.80 (1 H, m, +NH(CH3)2). MF C2i H33 N3O3, MW: 375.50 Ex 104 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid 2,4- dichloro-benzylamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.87-1.03 (2H, m), 1.10-1.21 (2H, m), 1.30-1.45 (1 H, m) 1.45-1.56 (2H, quin, J = 7.5 Hz), 1.56-1.67 (2H, m),
1.92 (2H, m, CH2CO), 2.66 (2H, m, N(CHH)2), 3.97 (2H, m, N(CHH)2), 4.23
(2H, s, PhCH2), 7.08 (1 H, s, NCONH), 7.27 (1 H, d, J = 8.0 Hz, ArH), 7.42
(1 H, d, J= 8.0 Hz, ArH), 7.56 (1 H, s, ArH), 8.69 (1 H, bs, OH), 10.35 (1 H, bs,
NHOH).
MF C17H23CIN3O3, MW 388.29
Ex 105 4-[1-(2-(S)-Amino-4-phenyl-butyryl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.80-1.20 (4H, m), 1.40-1.80 (5H, m), 1.90-2.00 (4H, m, CH2CO and CH2Ph) , 2.55-2.60 (2H, m, CH2CH2), 2.65 (1 H, m, CH2NH), 2.95 (1 H, q, J = 14.8 Hz, CH2NH), 3.60 (1 H, m, CH2NH), 4.20-4.30 (2H, m, CH2NH and CHNH), 7.10-7.40 (5H, m, ArH), 8.20-8.45 (2H, bs, OH and NHCH), 10.36 (1 H, s, NH). MF Ci9H29 N3O3, MW: 347.45
Ex 106 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (f uran-2- ylmethyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.92 (2H, m), 1.07-1.22 (2H, m), 1.27-1.42 (1 H, m) 1.49 (2H, m), 1.54-1.64 (2H, m), 1.91 (2H, t, J = 7.2 Hz, CH2CO), 2.60 (2H, m, N(CHH)2), 3.93 (2H, m, N(CHH)2), 4.18 (2H, s, NHCH2), 6.09-6.16 (1 H, m, FurH), 6.35 (1 H, m, FurH), 6.90 (1 H, m, NCONH), 7.52 (1 H, m, FurH), 8.68 (1 H, s, OH), 10.33 (1 H, s, NHOH). MF C15H23N3O4, MW 309.36 Ex 107 Benzo[b]thiophene-2-carboxylic acid{4-amino-1-(R)[4-(3- hydroxycarbamoyl-propyl)-piperidine-1-carbonyl]-butyl}-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.70-1.20 (4H, m), 1.40-1.95 (11 H, m, CH2CH2 and CH2CO and CH2 N), 2.55 (1 H, q, J=12.8 Hz, CH2NH), 2.80 (2H, m, CH2NH2), 3.00 (1 H, t, J = 12.8 Hz,CH2NH), 3.95 (1 H, d, J = 12.5 Hz, CH2NH), 4.40 (1 H, t, J = 12.5 Hz, CH2NH), 4.90 (1 H, m, CHNH), 7.20-7.25 (2H, m, ArH), 7.65 (1 H, m, NH+), 7.90-8.00 (2H, m, ArH), 8.20 (1 H, s, ArH), 8.60(1 H, d, J = 10.7 Hz, OH), 8.90-9.10 (1 H, d, J = 10.7 Hz, NHCH), 10.36 (1 H, d, J= 10.7 Hz, NH). MF C23H32 N4O4S, MW: 460.59
Ex 108 4-[1-(3-(R)-Amino-4-naphthalen-2-yl-butyryl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.78-1.18 (4H, m), 1.37-1.53 (3H, brs), 1.54-1.66 (2H, m), 1.91 (2H, dd, J=7.0 and 12.6 Hz), 2.52-2.68 (3H, m, N(CHH)2, and CHHCHN), 2.89 (1 H,m, N(CHH)2), 3.02 (1 H, m, CHHCHN), 3.09-3.15 (1 H, m, CHHCHN ), 3.64-3.70 (1 H, m, N(CHH)2), 3.79 (1 H,brs, CH2CHN ), 4.34 (1 H, d, J = 12.7 Hz, N(CHH)2), 7.42-7.54 (3H, m, ArH), 7.76-7.92 (7H, m, +NH3, ArH), 8.68(1 H,brs, OH), 10.36 (1 H, d, J = 10.7 Hz, NH). MF C23H31 N3O3, MW 379.50
Ex 1 19 4-[1-(3-(S)-Amino-3-naphthalen-2-yl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.67-0.90 (2H, m), 0.97-1.12 (2H, m), 1.35-1.65 (5H,m), 1.85-1.92 (2H, m), 2.54 (1 H,m), 2.92 (1 H, q), 2.99- 3.10 (2H,m, COCH2CH), 3.77 (1 H, d, J= 13.9 Hz, N(CHH)2), 4.37 (1 H, d, J= 12.6 Hz, N(CHH)2), 4.78 (1 H, s, CHNH2), 7.56-7.58 (2H, m, ArH), 7.62 (1 H, d, ArH), 7.90-7.98 (3H, m, ArH), 8.00 (1 H,s, ArH), 8.35 (3H, s, NH3 +), 8.67 (1 H, d, OH), 10.34 (1 H, d, NH). MF C22H29N3O3 , MW 383.48 Ex 1 10 Benzo[b]thiophene-2-carboxylic acid{3-hydroxy-1-(R)-[4-(3- hydroxycarbamoyl-propyl)-piperidine-1-carbonyl]-propyl}-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.70-1.20 (4H, m), 1.40-1.95 (9H, m, CH2NH and CHCH2CH2 and CH2CO), 2.55 (1 H, m, CH2NH), 3.00 (1 H, t, J = 12.8 Hz, CH2NH), 3.40-3.50 (2H, m, CH2OH), 4.00 (1 H, t, J = 12.5 Hz, CH2NH), 4.35 (1 H, d, J = 12.5 Hz, CH2NH), 5.00 (1 H, m, CHNH), 7.30-7.45 (2H, m, ArH), 7.85-8.00 (2H, m, ArH), 8.20 (1 H, s, ArH), 8.60-8.65 (1 H, m, OH), 8.90-9.10 (1 H, m, NHCH), 10.36(1 H, m, NHOH). MF C22H29 N3O5S, MW: 460.59
Ex 1 1 1 4-[1-(3-(R)-Amino-3-naphthalen-2-yl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ?(ppm) 0.65-0.93 (2H, m), 0.97-1.07 (2H, m), 1.35-1.61 (5H,m), 1.84-1.92 (2H, m), 2.54 (1 H,s, N(CHH)2), 2.91 (1 H, q, N(CHH)2), 2.96-3.15 (2H,m, CH2CH2CO), 3.77 (1 H, d, J= 13.2 Hz, N(CHH)2), 4.37 (1 H, d, J= 12.8 Hz, N(CHH)2), 4.78 (1 H, s, CHNH2), 7.56- 7.58 (2H, m, ArH), 7.90-7.98 (3H, m, ArH), 8.00 (1 H,s), 8.38-8.45 (1 H,d, OH), 10.34 (1 H, s, NH). MF C22H29N3O3 , MW 383.48
Ex 1 12 4-[1-(3-(S)-Amino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.76-0.95 (2H, m), 1.10-1.17 (2H, m), 1.39-1.52 (3H, m), 1.56-1.69 (2H, m), 1.90 (2H, q, J= 7.1 Hz), 2.52 (1 H, m, N(CHH)2), 2.88-2.99 (3H, m, CH2CO and N(CHH)2), 3.75 (1 H, d, J= 13.6 Hz, N(CHH)2), 4.37 (1 H, d, J = 12.8 Hz, N(CHH)2), 4.60 (1 H, brs, CHNH2), 7.32-7.50 (5H, m, ArH), 8.28 (1 H, d, OH), 10.33 (1 H, s, NH). MF C18H27N3O3, MW 333.42
Ex 1 13 Benzo[b]thiophene-2-carboxylic acid{3-hydroxy-1-(S)-[4-(3- hydroxycarbamoyl-propyl)-piperidine-1-carbonyl]-propyl}-amide MF C22H29 N3O5S, MW 460.59 Ex 1 14 Benzo[b]thiophene-5-carboxylic acid{2-[4-(3-hydroxycarbamoyl- propyl)-piperidin-1-yl]-1-(S)-hydroxymethyl-2-oxo-ethyl}-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.70-1.20 (4H, m), 1.40-1.80 (5H, m), 1.95 (2H, q, J = 7.4 Hz, CH2CO), 2.55 (1 H, t, J = 11.9 Hz, CH2NH), 3.05 (1 H, t, J = 12.5 Hz, CH2NH), 3.55 (1 H, m, CH2OH), 3.75 (1 H, m, CH2OH), 4.10 (1 H, d, J = 1 1.9 Hz, CH2NH), 4.40 (1 H,d, J=1 1.9 Hz, CH2NH), 5.00 (1 H, m, CHCH2OH), 7.55 (1 H, d, J = 5.4Hz, ArH), 7.65 (2H, m, ArH), 8.10 (1 H, d, J = 7.2 Hz, ArH), 8.45 (1 H, d, J = 5.4 Hz, ArH), 8.50-8.60 (1 H, m, NHCH), 8.80 (1 H, m, NHCH), 10.35 (1 H, s, NH). MF C2i H27 N3O5S, MW: 433.52
Ex 1 15 2-oxo-ethyl}-amideBenzo[b]thiophene-2-carboxylic acid{1-(R)- aminomethyl-2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1-yl]- 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.75-1.25 (4H, m), 1.40-1.80 (5H, m), 1.85-1.95 (2H, dt, J = 7.2 Hz, CH2CO), 2.55 (1 H, m, CH2NH), 3.05 (1 H, m, CH2NH), 3.06-3.20 (2H, m, CH2NH2), 3.80 (1 H, m, CH2NH), 4.40 (1 H, m, CH2NH), 5.15 (1 H, m, CHCH2NH2), 7.20-7.30 (2H, m, ArH), 7.80-8.05 (3H, m, ArH and NH+), 7.65 (2H, m, ArH), 8.20 (1 H, s, ArH), 8.50-8.60 (1 H, m, NHCH), 9.25-9.40 (1 H, d, J= 8.8 Hz, NHCH), 10.35 (1 H, m, NH). MF C2i H28 N4O4S, MW: 432.54
Ex 1 16 4_{i -[2-(S)-(2-Benzo[b]thiophen-3-yl-acetylamino)-3-hydroxy- propionyl]-piperidin-4-yl}-N-hydroxy-butyramide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.70-1.25 (4H, m), 1.40-1.80 (5H, m), 1.85-1.95 (2H, q, J= 7.4 Hz, CH2CO), 2.55 (1 H,t ,J = 11.6 Hz, CH2NH), 3.05 (1 H, t, J= 11.6 Hz, CH2NH), 3.30-3.40 (2H, m, CH2OH), 4.00 (1 H, t , J = 11.6 Hz,CH2NH), 4.35 (1 H, d, J = 11.6 Hz, CH2NH), 4.60 (1 H, m, OH), 5.00 (1 H, m, CHCH2OH), 7.00-7.20 (2H, m, ArH), 7.85-8.05 (2H, m, ArH), 8.22 (1 H, m, ArH), 8.65(1 H, s, OH), 8.85-8.95 (1 H, m, NHCH), 10.35 (1 H, m, NH). MF C22H29 N3O5S, MW: 447.55 Ex 1 17 Benzo[b]thiophene-3-carboxylic acid{2-[4-(3-hydroxycarbamoyl- propyl)-piperidin-1-yl]-1-(S)-hydroxymethyl-2-oxo-ethyl}-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.70-1.30 (4H, m), 1.40-1.80 (5H, m), 1.85-1.95 (2H, m, CH2CO), 2.55 (1 H, t, J = 11.8 Hz, CH2NH), 3.05 (1 H, t, J = 11.8 Hz, CH2NH), 3.50-3.75 (2H, m, CH2OH), 4.10 (1 H, d, J = 11.6 Hz,CH2NH), 4.40 (1 H, d, J = 11.8 Hz, CH2NH), 4.85-5.00 (1 H, dt, J = 5.9 Hz, CHNH), 5.10 (1 H, m, OH), 7.40-7.50 (2H, m, ArH), 8.04-8.10 (1 H, d, J = 7.9 Hz, ArH), 8.45-8.55 (2H, m, ArH), 8.60(1 H, d, J = 7.9 Hz, NHCH), 8.75.8-80 (1 H, d, J = 7.9 Hz ,OH), 10.36 (1 H, d, J= 9.6 Hz, NH). MF C2i H27 N3O5S, MW: 433.52
Ex 1 18 Benzofuran-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1-yl]-1-(S)-hydroxymethyl-2-oxo-ethyl}-amide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.65-1.30 (4H, m), 1.40-1.80 (5H, m), 1.85-1.95 (2H, m, CH2CO), 2.55 (1 H, t, J = 11.8 Hz, CH2NH), 3.05 (1 H, t, J = 11.8 Hz, CH2NH), 3.50-3.75 (2H, m, CH2OH), 4.10 (1 H, d, J = 11.6 Hz, CH2NH), 4.40 (1 H, d, J = 1 1.8 Hz, CH2NH), 5.10 (2H, m, OH and CHNH), 7.25-7.35 (2H, m, ArH), 7.60 (1 H, d, J= 8.40 Hz, ArH), 7.70 (1 H, d, J= 8.40Hz, ArH), 7.80 (1 H, d, J = 8.40 Hz, ArH), 8.40-8.55 (2H, d, J = 7.90 Hz, NHCH), 8.75.8-80 (1 H, m, OH), 10.36 (1 H, s, NH). MF C2i H27 N3O6, MW: 417.46
Ex 1 19 N-Hydroxy-4-{1-[3-hydroxy-2-(S)-(2-naphthalen-1-yl-acetylamino)- propionyl]-piperidin-4-yl}-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.54-0.83 (1 H, 2q), 0.84-1.17 (4H, m), 1.28-1.66 (5H, m), 1.85-1.95 (2H, m), 2.45 (1 H, m, N(CHH)2), 2.85 (1 H, m, N(CHH)2), 3.40 (1 H, m, CHHO), 3.59 (1 H, m, CHHO ), 3.81 -3.91 (1 H, m, N(CHH)2), 3.94 (2H, s, CH2Naf), 4.35 (1 H, m, N(CHH)2), 4.79 (1 H, m, CHNH3 +), 4.89 (1 H, t, J = 6.0 Hz, OH), 7.38-7.54 (4H, m, ArH), 7.76-7.93 (2H, m, ArH), 8.02-8.13 (1 H, m, ArH), 8.36-8.49 (1 H, 2d, J= 8.22 Hz, NHCH), 8.68 (1 H, brs, OH), 10.36 (1 H, brs, NH). MF C24H3I N3O5, MW 441 .52
Ex 120 i H-lndole-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1-yl]-1-(S)-hydroxymethyl-2-oxo-ethyl}-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.75-1.30 (4H, m), 1.40-1.80 (5H, m), 1.85-1.95 (2H, m, CH2CO), 2.55 (1 H, t, J=11.9 Hz, CH2NH), 3.05 (1 H, t, J= 11.9 Hz ,CH2NH), 3.50-3.75 (2H, m, CH2OH), 4.10 (1 H, d, J = 11.9 Hz, CH2NH), 4.40 (1 H, d , J = 11.9 Hz, CH2NH), 4.95 (1 H, m, OH), 5.10 (1 H, m, CHNH), 7.00 (1 H, t, J = 7.9 Hz, ArH), 7.15(1 H, t, J = 7.90 Hz, ArH), 7.25 (1 H, d, J = 7.90 Hz, ArH), 7.40(1 H, d, J = 7.9 Hz, ArH), 7.6 (1 H, d, J = 7.9 Hz, ArH), 8.04-8.10 (1 H, d, J = 7.9 Hz, ArH), 8.40-8.55 (1 H, d, J = 8.2 Hz, NHCH), 8.65 (1 H, d, J= 6.8 Hz ,OH), 10.36 (1 H, d, J= 10.25 Hz, NH), 11.60(1 H, m, NHInd). MF C2i H28 N3O5, MW: 416.47
Ex 121 Quinoline-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1-yl]-1-(S)-hydroxymethyl-2-oxo-ethyl}-amide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.80-1.30 (4H, m), 1.45-1.80 (5H, m), 1.85-1.95 (2H, m, CH2CO), 2.60 (1 H, q, J = 11.7Hz, CH2NH), 3.05 (1 H, m, CH2NH), 3.40 (2H, s, CH2OH), 4.10 (1 H, d, J = 11.7 Hz, CH2NH), 4.40 (1 H, d, J= 11.7 Hz, CH2NH), 5.05 (1 H, q, J= 5.54Hz, CHNH), 7.70 (1 H, t, J= 7.8Hz, ArH), 7.90(1 H, t, J = 7.8 Hz, ArH), 8.10-8.40 (3H, m, ArH), 8.60 (1 H, d, J = 8.6 Hz, ArH), 8.80-8.90 (1 H, m, NHCH), 10.36 (1 H, d, J = 7.8 Hz, NHOH). MF C22H28 N4O5, MW: 428.48 Ex 122 lsoquinoline-1-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1-yl]-1-(S)-hydroxymethyl-2-oxo-ethyl}-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.75-1.30 (4H, m), 1.45-1.80 (5H, m), 1.85-1.95 (2H, q, J = 7.6 Hz CH2CO), 2.65 (1 H, m, CH2NH), 3.05 (1 H, t, J = 12.0 Hz, CH2NH), 3.55-3.65 (2H, m, CH2OH), 4.10 (1 H, d, J = 12.0 Hz, CH2NH), 4.40 (1 H, d, J = 12.0 Hz, CH2NH), 5.05-5.10 (1 H, m, CHNH), 7.40(1 H, t, J= 7.8 Hz, ArH), 7.75(1 H, t, J= 7.8 Hz, ArH), 8.05 (2H, d, J = 6.6 Hz, ArH), 8.58 (1 H, d, J = 5.6 Hz, ArH), 9.15 (1 H, d, J = 8.4 Hz, ArH), 8.85- 8.95 (1 H, m, NHCH), 10.35 (1 H, m, NHOH). MF C22H28 N4O5, MW 428.48
Ex 123 lsoquinoline-3-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1-yl]-1-(S)-hydroxymethyl-2-oxo-ethyl}-amide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.75-1.30 (4H, m), 1.45-1.80 (5H, m), 1.80-1.95 (2H, q, J= 7.8 Hz CH2CO), 2.65 (1 H, q, J= 11.9 Hz, CH2NH), 3.05 (1 H, m, CH2NH), 3.55-3.65 (2H, m, CH2OH), 4.10 (1 H, d, ,J = 12.6 Hz, CH2NH), 4.40 (1 H, d, J = 12.6 Hz, CH2NH), 5.05-5.10 (1 H, m, CHNH), 7.80-7-92 (2H, dt, J= 7.9 Hz, ArH), 8.22 (1 H, d, J = 8.2 Hz, ArH), 8.28 (1 H, d, J= 8.2 Hz, ArH), 8.58 (1 H, d, J= 4.6 Hz, ArH), 8.85-8.95 (1 H, m, NHCH), 9.40 (1 H, s, ArH), 10.35 (1 H, m, NHOH). MF C22H28 N4O5, MW 428.48
Ex 124 Benzo[b]thiophene-2-carboxylic acid{1-aminomethyl-2-[4-(3- hydroxycarbamoyl-propyl)-piperidin-1-yl]-2-oxo-ethyl}-amide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.80-1.30 (4H, m), 1.45-1.80 (5H, m), 1.80-1.95 (2H, dt, J = 7.2 Hz, CH2CO), 2.65 (1 H, m, CH2NH), 3.05 (1 H, m, CH2NH), 3.00-3.20 (2H, m, CH2NH2), 4.10 (1 H, m, CH2NH), 4.40 (1 H, m, CH2NH), 5.05-5.10 (1 H, m, CHNH), 7.40-7.50 (2H, m, ArH), 7.80-8.10 (3H, m, NH3 +, ArH), 8.20 (1 H, s, ArH), 8.60 (1 H, bs, OH), 9.30-9.40 (1 H, m, NHCH), 10.35 (1 H, m, NHOH). MF C22H28 N4O5, MW: 432.54 Ex 125 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid 4- chloro-2-fluoro-benzylamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.84-1.02 (2H, m), 1.10-1.26 (2H, m), 1.29-1.43 (1 H, m) 1.43-1.70 (4H, m), 1.92 (2H, t, J = 7.2 Hz, CH2CO),
2.63 (2H, m, N(CHH)2), 3.94 (2H, m, N(CHH)2), 4.21 (2H, s, PhCH2), 7.02
(1 H, s, NCONH), 7.18-7.42 (3H, m, ArH), 8.67 (1 H, bs, OH), 10.33 (1 H, s,
NHOH).
MF C17H23CIFN3O3, MW 371.83
Ex 126 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid (2- amino-4-methyl-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.05 (2H, dq, J = 3.5 and 12.6 Hz), 1.14-1.28 (2H, m), 1.38-1.48 (1 H, m) 1.53 (2H, quin, J = 7.4 Hz), 1.62-1.73 (2H, m), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 2.25 (3H, s, CH3), 2.77 (2H, m, N(CHH)2), 4.10 (2H, m, N(CHH)2), 6.76-6.93 (2H, m, ArH), 7.23 (1 H, m, ArH), 8.29 (3H, bs, NH2+)8.71 (1 H, bs, OH), 10.36 (1 H, s, NHOH). MF C17H26N4O3, MW 334.41
Ex 127 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (2- fluoro-6-methoxy-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.5 and 12.6 Hz), 1.14-1.27 (2H, m), 1.33-1.48 (1 H, m) 1.53 (2H, m), 1.59-1.70 (2H, m), 1.95 (2H, t, J= 7.2 Hz, CH2CO), 2.72 (2H, m, N(CHH)2), 3.78 (3H, s, OCH3), 4.06 (2H, m, N(CHH)2), 6.79 (1 H, m, ArH), 6.82-6.88 (1 H, m, ArH), 7.14.7.23 (1 H, m, ArH), 7.68 (1 H, s, NCONH), 8.70 (1 H, bs, OH), 10.36 (1 H, s, NHOH). MF C17H24FN3O4, MW 353.39 Ex 128 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (2- fluoro-5-methyl-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.8 and 12.6 Hz),
1.13-1.28 (2H, m), 1.34-1.47 (1 H, m) 1.53 (2H, m), 1.60-1.72 (2H, m), 1.94
(2H, t, J= 7.2 Hz, CH2CO), 2.25 (3H, s, CH3), 2.74 (2H, m, N(CHH)2), 4.06
(2H, m, N(CHH)2), 6.85-6.92 (1 H, m, ArH), 6.98-7.08 (1 H, m, ArH), 7.18-
7.25 (1 H, m, ArH), 8.14 (1 H, s, NCONH), 8.69 (1 H, s, OH), 10.36 (1 H, s,
NHOH).
MF C17H24FN3O3, MW 337.39
Ex 129 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (2- chloro-6-fluoro-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.93-1.14 (2H, m), 1.14-1.32 (2H, m), 1.38-1.60 (3H, m) 1.60-1.75 (2H, m), 1.95 (2H, t, J = 1.2 Hz, CH2CO), 2.78 (2H, m, N(CHH)2), 4.07 (2H, m, N(CHH)2), 7.13-7.42 (3H, m, ArH), 8.21 (1 H, s, NCONH), 8.70 (1 H, bs, OH), 10.36 (1 H, s, NHOH). MF C16H21CIFN3O3, MW 357.81
Ex 130 4-[1-(3-(R)-Amino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ ?(ppm) 0.76-0.92 (2H, m), 1.07-1.28 (2H, m), 1.39-1.64 (5H, m), 1.92 (2H, q, J = 7.1 Hz), 2.52 (1 H,s, N(CHH)2), 2.86- 3.01 (3H, m, CH2CO, N(CHH)2), 3.75 (1 H, d, J= 13.1 Hz, N(CHH)2), 4.37 (1 H, d, J = 12.6 Hz, N(CHH)2), 4.60 (1 H, s, CHNH2), 7.36-7.49 (5H, m, ArH), 8.23 (3H,bs, NH3+), 8.67 (1 H, s, OH), 10.34 (1 H, s, NH). MF C18H27N3O3, MW 333.42
Ex 131 4-[1-(3-(S)-Amino-5-phenyl-pentanoyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.89-1.03 (2H, m), 1.16 (2H, m), 1.45-1.53 (2H, m), 1.66-1.95 (5H, m), 2.59 (2H, m, N(CHH)2), 2.68 (2H, t, J = 8.0 Hz), 2.83 (1 H, dd), 2.97 (1 H, t, J = 12.3 Hz, CH2CO), 3.82 (1 H, d, J = 13.6 Hz, N(CHH)2), 4.41 (1 H, bs, CHNH2), 7.21 -7.32 (5H, m, ArH), 7.79 (3H, bs, NH3+), 8.70 (1 H, s, OH), 10.36 (1 H, s, NH). MF C20H31 N3O3 , MW 361.48
Ex 132 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (4-butyl- phenyl)-amide
1 H NMR (CDCI3-di , 400 MHz): δ (ppm) 1.37-1.58 (4H, m), 1.65-1.81 (1 H, m), 1.81 -2.09 (4H, m), 2.39 (2H, m, CH2CO), 3.18 (2H, m, N(CHH)2), 4.41 - 4.58 (2H, m, N(CHH)2), 7.60-7.72 (2H, m, ArH), 7.72-7.82 (1 H, m, ArH), 8.42 (1 H, d, J= 8.0 Hz, ArH), 8.74 (1 H, d, J= 8.0 Hz, ArH), 9.02 (1 H, s, ArH), 9.62 (1 H, s, NCONH). MF C19H24N4O3, MW 356.42
Ex 133 N-Hydroxy-4-(1 -phenylsulfamoyl-piperidin-4-yl)-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ?(ppm) 0.85-0.95 (2H, m), 1.04-1.11 (2H, m), 1.17-1.25 (1 H, brs), 1.37-1.47 (2H, m), 1.57-1.65 (2H, d, J= 12.4 Hz), 1.88 (2H, t, J= 7.2 Hz), 2.61 (2H, t, J= 11.8 Hz), 3.57 (2H, d, 12.1 Hz), 7.01 - 7.04 (1 H, t, ArH, J=7.3 Hz), 7.16-7.18 (2H, d, ArH, J=8.3 Hz), 7.26-7.30 (2H, t, ArH, J= 7.7 Hz), 8.70 (1 H, s, OH), 9.85 (1 H, s, NHPh), 10.30 (1 H, s, NH). MF Ci5H23N3O4S , MW 341.43
Ex 134 4-[1-(3-(R)-Amino-5-phenyl-pentanoyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-d6, 400 MHz): δ?(ppm) 1.05-1.21 (2H, m), 1.37 (2H, m), 1.69 (3H, m), 1.87 (2H, brs), 2.13 (2H, s), 2.45 (2H, m, CH2CO, N(CHH)2), 3.00-3.20 (3H, m, CH2Ph, CH2CO), 3.86 (2H, s, NCH), 4.59 (1 H, d, J=12.7 Hz, N(CHH)2), 7.47-7.58 (5H, m, ArH), 8.04-8.06 (3H, bs, NH3 +), 8.86 (1 H, s, OH), 10.56 (1 H, s, NH). MF C19H29N3O3 , MW 347.45 Ex 135 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid biphenyl-4-ylamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.93-1.13 (2H, m), 1.13-1.28 (2H, m), 1.33-1.47 (1 H, m), 1.52 (2H, m), 1.61 -1.75 (2H, m), 1.94 (2H, t, J = 7.2 Hz, CH2CO), 2.75 (2H, m, N(CHH)2), 4.12 (2H, m, N(CHH)2), 7.30 (1 H, m, ArH), 7.38-7.46 (2H, m, ArH), 7.50-7.59 (4H, m, ArH), 7.62 (2H, d, J = 7.6 Hz, ArH), 8.55 (1 H, s, NCONH), 8.70 (1 H, bs, OH), 10.34 (1 H, s, NHOH). MF C22H27N3O3, MW 381.47
Ex 136 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid
(benzo[1 ,3]dioxol-5-ylmethyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.83-1.00 (2H, m), 1.08-1.22 (2H, m), 1.27-1.41 (1 H, m), 1.49 (2H, m), 1.54-1.65 (2H, m), 1.92 (2H, t, J = 7.2 Hz, CH2CO), 2.61 (2H, m, N(CHH)2), 3.94 (2H, m, N(CHH)2), 4.10 (2H, s, OCH2O), 5.96 (2H, s, CH2Ph), 6.66-6.73 (1 H, m, ArH), 6.77-6.85 (2H, m, ArH), 6.93 (1 H, m, NCONH), 10.33 (1 H, s, NHOH). MF C18H25N3O5, MW 363.41
Ex 137 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- propoxy-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.93-1.07 (2H, m), 1.13-1.24 (2H, m), 1.32-1.46 (1 H, m), 1.52 (2H, m), 1.59-1.72 (2H, m), 1.93 (2H, t, J = 7.2 Hz, CH2CO), 2.73 (2H, m, N(CHH)2), 4.09 (2H, m, N(CHH)2), 6.92 (4H, m, ArH), 7.07 (1 H, m), 7.34 (2H, m, ArH), 7.46 (2H, d, J = 8.4 Hz, ArH), 8.46 (1 H, s, NCONH), 8.68 (1 H, s, OH), 10.34 (1 H, s, NHOH). MF C22H27N3O4, MW 397.47
Ex 138 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- propoxy-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.90-1.04 (2H, m), 0.95 (3H, t, J= 7.2 Hz, CH3), 1.13-1.26 (2H, m), 1.33-1.45 (1 H, m), 1.51 (2H, quin, J = 7.4 Hz), 1.59-1.75 (4H, m), 1.93 (2H, t, J= 7.2 Hz, CH2CO), 2.70 (2H, m, N(CHH)2), 3.84 (2H, t, J = 6.4 Hz, PhOCH2), 4.07 (2H, m, N(CHH)2), 6.78 (2H, d, J= 8.8 Hz, ArH), 7.30 (2H, d, J= 8.8 Hz, ArH), 8.25 (1 H, s, NCONH), 8.68 (1 H, bs, OH), 10.34 (1 H, s, NHOH). MF C19H29N3O4, MW 397.47
Ex 139 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- isopropoxy-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.90-1.06 (2H, m), 1.12-1.20 (2H, m), 1.22 (6H, d, J= 6.0 Hz, CH(CH3)2), 1.32-1.45 (1 H, m), 1.51 (2H, m), 1.59-1.69 (2H, m), 1.93 (2H, t, J= 7.2 Hz, CH2CO), 2.70 (2H, m, N(CHH)2), 4.07 (2H, m, N(CHH)2), 4.48 (1 H, hept, J= 6.0 Hz, CH(CH3)2), 6.77 (2H, d, J = 8.4 Hz, ArH), 7.29 (2H, d, J= 8.4 Hz, ArH), 8.25 (1 H, s, NCONH), 8.39- 8.93 (1 H, bs, OH), 10.34 (1 H, s, NHOH). MF C20H29N3O4, MW 363.45
Ex 140 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (1-(R)- phenyl-ethyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.83-0.99 (2H, m), 1.09-1.20 (2H, m), 1.26-1.40 (1 H, m), 1.33 (3H, d, J= 6.8 Hz, CH3), 1.43-1.53 (2H, m), 1.54-1.64 (2H, m), 1.92 (2H, t, J= 7.2 Hz, CH2CO), 2.59 (2H, m, N(CHH)2), 3.98 (2H, m, N(CHH)2), 4.81 (1 H, m, CHNH), 6.69 (1 H, d, J= 8.0 Hz, ArH), 7.14-7.21 (1 H, m, CHNH), 7.26-7.32 (4H, m, ArH), 8.68 (1 H, s, OH), 10.33 (1 H, s, NHOH). MF C18H27N3O3, MW 333.42
Ex 141 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (1-(S)- phenyl-ethyl)-amide MF C18H27N3O3, MW 333.42
Ex 142 4-[1-(3-(R)-Amino-3-naphthalen-2-yl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide MF C22H29N3O3, MW 383.48 Ex 143 ^(S-Hydroxycarbamoyl-propyO-piperidine-i-carboxylic acid quinolin-2-ylamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.01 -1.15 (2H, m), 1.16-1.25 (2H, m), 1.40-1.60 (3H, m), 1.66-1.78 (2H, m), 1.94 (2H, t, J= 7.2 Hz, CH2CO), 2.88 (2H, m, N(CHH)2), 4.20 (2H, m, N(CHH)2), 7.56 (1 H, m, ArH), 7.75- 7.87 (2H, m, ArH), 7.75-7.87 (2H, m, ArH), 7.98 (2H, d, J= 7.6 Hz, ArH), 8.48 (1 H, m, ArH), 10.34 (1 H, s, NHOH). MF C19H24N4O3, MW 356.42
Ex 144 ^[i-CS-CRJ-Amino^-naphthalen^-yl-butyryO-piperidin^-yll-N- hydroxy-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.70-1.30 (4H, m), 1.45-1.80 (5H, m), 1.80-1.95 (2H, m, CH2CO), 2.65 (2H, t, J = 6.6 Hz, COCH2CH), 2.70- 2.85 (1 H, q, J = 6.6 Hz, CH2NH), 3.00-3.20 (2H, m, CH2Ph), 3.30-3.80 (3H, m, CH2NH, and CHNH), 4.35 (1 H, m, CHNH), 7.40-7.55 (3H, m, ArH), 7.80 (1 H, s, ArH), 7.85-7.95 (3H, m, ArH), 8.00-8.20 (1 H, m, NH3 +), 8.36 (1 H, s, OH), 10.35 (1 H, s, NHOH). MF C23H3I N3O5, MW 397.51
Ex 145 4-(3-HydiOxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid [4-(2- diethylamino-ethyl)-phenyl]-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.99 (2H, m), 1.13-1.24 (2H, m), 1.21 (6H, t, J= 7.3, N(CH2CHs)2), 1.35-1.46 (1 H, m), 1.48-1.57 (2H, m), 1.61 -1.70 (2H, m), 1.93 (2H, t, J= 7.3 Hz, CH2CO), 2.72 (2H, m, N(CHH)2), 2.82-2.91 (2H, m, PhCH2), 3.16-3.27 (6H, m, CH2N(CH2 CH3J2), 4.08 (2H, m, N(CHH)2), 7.15 (2H, d, J= 8.6 Hz, ArH), 7.41 (2H, d, J= 8.6 Hz, ArH), 8.41 (1 H, m, NHCON), 9.11 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C22H36N4O3, MW 404.55 Ex 146 4-[1 -(3-(S)-Amino-4-benzo[b]thiophen-3-yl-butyryl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.82-0.94 (2H, m), 1.12-1.17 (2H, m), 1.39-1.69 (5H, m), 1.92 (2H, m), 2.54-2.75 (3H, m, COCH2CH, N(CHH)2), 2.87-2.95 (1 H, m, N(CHH)2), 3.16 (2H, m, NCHCHH), 3.66-3.77 (2H, m, NCHCH2, N(CHH)2), 4.38 (1 H, d, J = 13.6 Hz, N(CHH)2), 7.40-7.47 (2H, m, ArH), 7.61 (1 H, s, ArH), 7.91 -8.04 (3H, m, ArH and NH+), 8.66 (1 H, brs, OH), 10.31 (1 H, s, NHOH). MF C2I H29N3O5S, MW: 403.54
Ex 147 4_[i -(3-(R)-Amino-4-benzo[b]thiophen-3-yl-butyryl)-piperidin-4-yl]-N- hydroxy-butyramide MF C21 H29N3O5S, MW: 403.54
Ex 148 Benzo[b]thiophene-2-carboxylic acid{1-dimethylaminomethyl-2-[4- (3-hydroxycarbamoyl-propyl)-piperidin-1-yl]-2-oxo-ethyl}-amide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.80-1.30 (4H, m), 1.45-1.80 (5H, m), 1.85-1.95 (2H, dt, J = 7.23 Hz, CH2CO), 2.50-2.70 (1 H, m, CH2NH), 2.90-3.10 (1 H, q, J = 12.0 Hz, CH2NH), 3.00-3.20 (2H, m, CH2Ph), 3.80 (1 H, t, J = 12.0 Hz, CH2NH), 4.35 (1 H, d, J =11.7 Hz, CH2NH), 5.30 (1 H, m, CH2CHNH), 7.40-7.50 (2H, m, ArH), 7.95 (1 H, t, J = 8.1 Hz, ArH), 8.05 (1 H, t, J =7.6 Hz, ArH), 8.20 (1 H, s, ArH), 8.60 (1 H, bs, OH), 9.35-9.45 (1 H, d, J = 8.8 Hz, NHCH), 10.35 (1 H, m, NHOH). MF C23H32 N4O4 S, MW: 460.59
Ex 149 4-[1-(3-(S)-Amino-3-naphthalen-2-yl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.63-1.12 (4H, m), 1.44 (3H, m), 1.60 (2H, m), 1.89-1.91 (2H, td, J=7.3 and 14.6 Hz), 2.64 (3H, s, CH3), 2.79 (3H, s, CH3), 2.98 (1 H, q, J= 10.7 Hz), 3.41 (3H, m, NCHCH2 and N(CHH)2), 3.96 (1 H, d, J=12.8 Hz, N(CHH)2), 4.28 (1 H, d, J= 11.6 Hz, N(CHH)2), 5.01 (1 H, s, NCHCH2), 7.59-8.12 (7H, m, ArH), 9.72 (1 H, s, OH), 10.29 (1 H, s, NH). MF C24H33N3O3, MW 41 1 .54
Ex 150 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid biphenyl-3-ylamide
MF C22H27N3O3, MW 381.46
Ex 151 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (4- pyridin-2-yl-phenyl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.03 (2H, dq, J = 3.2 and 12.0 Hz), 1.11 -1.28 (2H, m), 1.36-1.48 (1 H, m), 1.53 (2H, quin, J = 7.4 Hz), 1.62-1.72 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.77 (2H, m, N(CHH)2), 4.13 (2H, m, N(CHH)2), 7.41 -7.53 (2H, m, ArH), 7.65 (2H, d, J = 8.0 Hz, ArH), 7.95 (2H, d, J = 8.0 Hz, ArH), 8.00-8.13 (2H, m, ArH), 8.67 (1 H, m, NHCON), 8.72 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C21 H26N4O3, MW 382.46
Ex 152 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- oxazol-5-yl-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.0 and 12.4 Hz), 1.13-1.24 (2H, m), 1.34-1.46 (1 H, m), 1.52 (2H, quin, J = 7.4 Hz), 1.62-1.73 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.75 (2H, m, N(CHH)2), 4.11 (2H, m, N(CHH)2), 7.51 (1 H, s, OxazH), 7.56-7.60 (4H, m, ArH), 8.35 (1 H, s, OxazH), 8.62 (1 H, m, NHCON), 8.65 (1 H, s, OH), 10.32 (1 H, s, NHOH). MF C19H24N4O4, MW 372.42
Ex 153 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- pyridin-3-yl-phenyl)-amide MF C21 H26N4O3, MW 382.45 Ex 154 4-[1-(3-(S)-Amino-4-naphthalen-1-yl-butyryl)-piperidin-4-yl]-N- hydroxy-butyramide
MF C23H31 N3O3, MW 397.51
Ex 155 4-[1-(3-(R)-Amino-4-naphthalen-1-yl-butyryl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.80-0.95 (2H, m), 1.09-1.20 (2H, m), 1.39-1.70 (5H, m), 1.92 (2H, q, J = 7.4 Hz), 2.62-2.67 (2H, m, CH2CHNH2CH2), 2.89 (1 H, q, J = 12.1 Hz), 3.37 (2H, m, CH2CHNH2CH2), 3.67(1 H, d, J = 13.9 Hz, N(CHH)2), 3.77 (1 H, s, CH2CHNH2CH2), 4.35 (1 H, d, J =14.2 Hz, N(CHH)2, 7.42-7.63 (4H, m, ArH), 7.87-7.98 (3H, m, ArH and NH+), 8.21 (1 H, d, J = 8.3 Hz, ArH), 8.60 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C23H31 N3O3, MW 397.51
Ex 156 4-(4-(hydroxyamino)-4-oxobutyl)-N-((2-phenylthiazol-4- yl)methyl)piperidine-1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.96 (2H, m), 1.11 -1.21 (2H, m), 1.31 -1.45 (1 H, m) 1.50 (2H, quint, J= 7.6 Hz), 1.56-1.65 (2H, m), 1.92 (2H, t, J= 7.6 Hz, CH2CO), 2.65 (2H, m, N(CHH)2), 3.98 (2H, m, N(CHH)2), 4.36 (2H, m, PhCH2), 7.04 (1 H, bs, NCONH), 7.29 (1 H, s, ThiazH), 7.33-7.53 (3H, m, ArH), 7.87-7.95 (2H, m, ArH), 10.30 (1 H, s, NHOH). MF C20H26N4O3S, MW 402.51
Ex 157 N-(benzo[b]thiophen-3-ylmethyl)-4-(4-(hydroxyamino)-4- oxobutyl)piperidine-1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.93 (2H, dq, J = 3.6 and 12.4 Hz), 1.10-1.20 (2H, m), 1.30-1.43 (1 H, m) 1.50 (2H, quint, J = 7.6 Hz), 1.54-1.63 (2H, m), 1.92 (2H, t, J = 7.6 Hz, CH2CO), 2.63 (2H, m, N(CHH)2), 3.97 (2H, m, N(CHH)2), 4.46 (2H, m, PhCH2), 6.96 (1 H, bs, NCONH), 7.33-7.43 (3H, m, ArH), 7.93 (2H, dd, J= 1.6 and 12.0 Hz, ArH), 10.31 (1 H, s, NHOH). MF C19H25N3O3S, MW 375.49 Ex 158 4-[1-(3-(S)-Amino-3-naphthalen-1-yl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide
MF C22H29N3O3, MW 383.48
Ex 159 4-[1-(3-(R)-Amino-3-naphthalen-1-yl-propionyl)-piperidin-4-yl]-N- hydroxy-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.61 -0.91 (2H, m), 1.12 (1 H, m), 1.34-1.65 (6H, m), 1.92 (2H, q, J= 7.4 Hz), 2.51 (1 H, m, N(CHH)2), 2.86 (1 H, q, J=12.2 Hz, N(CHH)2), 2.99-3.16 (2H, m, CH2CH2CO), 3.70( 1 H, brs, N(CHH)2), 4.36 (1 H, brs, N(CHH)2), 5.48 (1 H, s,CHNH2), 7.54-7.74 (4H, m, ArH), 8.00 (2H, t, J = 9.4 Hz, ArH), 8.13 (1 H, d, J =8.4 Hz, ArH), 8.45-8.50 (2H, bs, OH, NH+), 10.32 (1 H, s, NHOH). MF C22H29N3O3, MW 383.48
Ex 160 4-(4-hydroxyamino)-4-oxobutyl)-N-(1-methoxynaphthalen-2- yl)piperidine-1 -carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.97-1.14 (2H, m), 1.14-1.27 (2H, m), 1.38-1.50 (1 H, m) 1.53 (2H, quin, J = 7.4 Hz), 1.63-1.73 (2H, m), 1.94 (2H, t, J= 7.6 Hz, CH2CO), 2.82 (2H, m, N(CHH)2), 3.82 (3H, s, OCH3), 4.13 (2H, m, N(CHH)2), 7.42 (1 H, t, J= 7.2 Hz, ArH), 7.51 (1 H, t, J= 7.2 Hz, ArH), 7.61 (1 H, d, J= 8.8 Hz, ArH), 7.75 (1 H, d, J= 8.8 Hz, ArH), 7.87 (1 H, d, J= 8.0 Hz, ArH), 7.99 (1 H, d, J= 8.0 Hz, ArH), 8.05 (1 H, s, NCONH), 8.66 (1 H, s, OH), 10.32 (1 H, s, NHOH). MF C21 H27N3O4, MW 385.46
Ex 161 4-(4-hydroxyamino)-4-oxobutyl)-N-(3-methoxynaphthalen-2- yl)piperidine-1 -carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.99-1.12 (2H, m), 1.14-1.25 (2H, m), 1.37-1.48 (1 H, m) 1.53 (2H, quin, J = 7.6 Hz), 1.65-1.74 (2H, m), 1.94 (2H, t, J = 7.6 Hz, CH2CO), 2.81 (2H, m, N(CHH)2), 3.96 (3H, s, OCH3), 4.05 (2H, m, N(CHH)2), 7.25-7.36 (3H, m, ArH), 7.66-7.79 (2H, m, ArH), 8.25-8.29 (1 H, m, ArH), 8.66 (1 H, s, OH), 10.32 (1 H, s, NHOH). MF C21 H27N3O4, MW 385.46
Ex 162 4-(4-hydroxyamino)-4-oxobutyl)-N-((5-methyl-2-phenyloxazol-4- yl)methyl)piperidine-1-carboxamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.91 (2H, dq, J = 3.6 and 11.6 Hz), 1.08-1.20 (2H, m), 1.27-1.41 (1 H, m) 1.49 (2H, quin, J = 7.6 Hz), 1.53-1.62 (2H, m), 1.91 (2H, t, J = 7.2 Hz, CH2CO), 2.37 (3H, s, CH3), 2.60 (2H, m, N(CHH)2), 3.94 (2H, m, N(CHH)2), 4.09 (2H, m, PhCH2), 6.87 (1 H, t, J = 5.6 Hz, NCONH), 7.43-7.55 (3H, m, ArH), 7.85-7.95 (2H, m, ArH), 8.65 (1 H, bs, OH), 10.30 (1 H, s, NHOH). MF C21 H28N4O4, MW 400.47
Ex 163 N-(2-(1 H-indol-3-yl)ethyl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine- 1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.84-0.99 (2H, m), 1.11 -1.21 (2H, m), 1.28-1.41 (1 H, m) 1.50 (2H, quin, J= 7.6 Hz), 1.54-1.62 (2H, m), 1.92 (2H, t, J= 7.6 Hz, CH2CO), 2.60 (2H, m, N(CHH)2), 2.80 (2H, J= 7.6 Hz, NHCH2CH2), 3.26 (2H, J= 7.6 Hz, NHCH2CH2), 3.92 (2H, m, N(CHH)2), 6.96 (1 H, t, J= 7.4 Hz, ArH), 7.05 (1 H, t, J= 7.4 Hz, ArH), 7.11 (1 H, s, IndH), 7.32 (1 H, d, J= 8.0 Hz, ArH), 7.54 (1 H, d, J= 8.0 Hz, ArH), 10.31 (1 H, s, NHOH), 10.75 (1 H, s, IndNH). MF C20H28N4O3, MW 372.46
Ex 164 4-[1-(3-Benzylamino-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.75-1.30 (4H, m), 1.45-1.80 (5H, m), 1.95 (2H, t, J = 7.0 Hz, CH2CO), 2.55 (1 H, t, J = 11.5 Hz, CH2NH), 2.70 (2H, t, J = 6.7 Hz, CH2CO), 2.95 (1 H, t, J = 11.5 Hz, CH2NH), 3.10 (2H, t, J = 6.7 Hz, CH2NH), 3.70 (1 H, d, J = 1 1.5 Hz, CH2NH), 4.18 (2H, s, CH2Ph), 4.35(1 H, d, J = 11.5 Hz, CH2NH), 7.40-7.55 (5H, m, ArH), 8.60 (1 H, s, NH+), 8.65 (1 H, bs, OH), 10.35 (1 H, s, NHOH). MF Ci9H29 N3O3, MW: 347.452
Ex 165 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (31- fluoro-biphenyl-4-yl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.4 and 12.3 Hz), 1.11 -1.29 (2H, m), 1.36-1.48 (1 H, m), 1.48-1.59 (2H, m), 1.62-1.73 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.75 (2H, m, N(CHH)2), 4.12 (2H, m, N(CHH)2), 7.07-7015 (1 H, m, ArH), 7.41 -7051 (4H, m, ArH), 7.54-7.62 (3H, m, ArH), 8.57 (1 H, m, NHCON), 8.67 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C22H26FN3O3, MW 399.46
Ex 166 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (41- fluoro-biphenyl-4-yl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, m), 1.13-1.29 (2H, m), 1.37-1.47 (1 H, m), 1.47-1.60 (2H, m), 1.63-1.73 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.75 (2H, m, N(CHH)2), 4.11 (2H, m, N(CHH)2), 7.24 (2H, m, ArH), 7.53 (4H, m, ArH), 7.65 (2H, m, ArH), 8.53 (1 H, m, NHCON), 8.65 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C22H26RN3O3, MW 399.46
Ex 167 4-{1-[3-(S)-Amino-3-(2-chloro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide MF C1 nH9nCINLO,, MW 367.87
Ex 168 4-{1-[3-(S)-Amino-3-(3-chloro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.84-0.96 (2H, m), 1.13 (2H, m), 1.47 (3H, brs), 1.64 (2H, m), 1.92 (2H, brs), 2.54 (1 H, m, N(CHH)2), 2.84- 3.07 (3H, m, CH2CO, N(CHH)2), 3.76 (1 H, d, J =13.1 Hz, N(CHH)2), 4.37 (1 H, d, J=12.8 Hz, N(CHH)2), 4.62 (1 H, s, CHNH2), 7.45 (3H, s, ArH), 7.61 (1 H, s, ArH), 8.33 (1 H, s, OH), 10.30 (1 H, s, NH). MF C18H26CIN3O3, MW 367.87
Ex 169 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (31- methoxy-biphenyl-4-yl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.6 and 12.5 Hz), 1.15-1.26 (2H, m), 1.36-1.47 (1 H, m), 1.47-1.58 (2H, m), 1.61 -1.72 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.74 (2H, m, N(CHH)2), 3.77 (3H, s, OCH3), 4.11 (2H, m, N(CHH)2), 6.98 (2H, d, J=8.8 Hz, ArH), 7.44-7.59 (6H, m, ArH), 8.48 (1 H, m, NHCON), 8.54 (1 H, bs, OH), 10.32 (1 H, s, NHOH). MF C23H29N3O4, MW 41 1.49
Ex 170 N-(3-(1 H-indol-3-yl)propyl)-4-(4-(hydroxyamino)-4- oxobutyl)piperidine-1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.91 (2H, dq, J = 3.2 and 12.4 Hz), 1.09-1.19 (2H, m), 1.27-1.40 (1 H, m) 1.49 (2H, quint, J = 7.2 Hz), 1.53-1.62 (2H, m), 1.76 (2H, quint, J= 7.2 Hz, NCH2CH2CH2), 1.91 (2H, t, J= 7.2 Hz, CH2CO), 2.57 (2H, t, J= 11.6 Hz, NCH2CH2CH2), 2.65 (2H, m, N(CHH)2), 3.07 (2H, t, J= 6.8 Hz, NCH2CH2CH2), 3.91 (2H, m, N(CHH)2), 6.39 (1 H, s, NCONH), 6.95 (1 H, t, J= 7.6 Hz, ArH), 7.05 (1 H, t, J= 7.6 Hz, ArH), 7.11 (1 H, s, ArH), 7.31 (1 H, d, J= 8.0 Hz, ArH), 7.47 (1 H, d, J = 8.0 Hz, ArH), 10.30 (1 H, s, NHOH), 10.72 (1 H, bs, IndNH). MF C21 H30N4O3, MW 386.49
Ex 171 4-{1-[3-(S)-Amino-3-(3-chloro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide MF C18H26CIN3O3, MW 367.87 Ex 172 N-Hydroxy-4-[1 -(4-methoxy-benzylthiocarbamoyl)-piperidin-4-yl]- butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.99 (2H, dq, J = 3.6 and 12.9 Hz),
1.11 -1.26 (2H, m), 1.46-1.54 (3H, m), 1.60-1.70 (2H, m), 1.93 (2H, t, J = 7.3
Hz, CH2CO), 2.91 (2H, m, N(CHH)2), 3.81 (3H, s, OCH3), 4.69 (2H, m,
N(CHH)2), 4.77 (2H, s, CH2Ph), 7.86 (2H, d, J=8.6 Hz, ArH), 7.20 (2H, d,
J=8.6 Hz, ArH), 8.03 (1 H, m, NHCON), 8.66 (1 H, bs, OH), 10.31 (1 H, s,
NHOH).
MF C18H27N3O3S, MW 365.49
Ex 173 4_(i -Benzylthiocarbamoyl-piperidin-4-yl)-N-hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.01 (2H, dq, J = 3.4 and 13.0 Hz), 1.14-1.20 (2H, m), 1.42-1.54 (1 H, m), 1.62-1.75 (2H, m), 1.93 (2H, t, J = 7.3 Hz, CH2CO), 2.77 (2H, m, N(CHH)2), 4.65 (2H, m, N(CHH)2), 4.77 (2H, s, CH2Ph), 7.17-7.34 (5H, m, ArH), 8.11 (1 H, m, NHCON), 8.65 (1 H, s, OH), 10.31 (1 H, s, NHOH). MF C17H25N3O2S, MW 335.46
Ex 174 4-{1-[3-(S)-Amino-3-(4-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide MF C18H26FN3O3, MW 351.42
Ex 175 4-{1-[3-(S)-Amino-3-(3-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide MF C18H?fiFN,O,, MW 351.42
Ex 176 4-{1-[3-(S)-Amino-3-(2-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N- hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.82-1.00 (2H, m), 1.14 (2H, m), 1.47 (3H, m), 1.64 (2H, m), 1.91 (2H, m), 2.53 (1 H, m, N(CHH)2), 2.89-3.06 (3H, m, CH2CO, N(CHH)2), 3.78 (1 H, d, J= 12.5 Hz, N(CHH)2), 4.33 (1 H, d, N(CHH)2), 4.81 (1 H, m, NCHCH2), 7.24-7.61 (4H, m, ArH), 8.38 (1 H, s, NH+), 8.64 (1 H, s, OH ), 10.31 (1 H, s, NH). MF C18H26FN3O3, MW 351.42
Ex 177 N-(benzo[d]isoxazol-3-ylmethyl)-4-(4-(hydroxyamino)-4- oxobutyl)piperidine-1-carboxamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.91 (2H, dq, J = 3.2 and 12.4 Hz), 1.09-1.17 (2H, m), 1.28-1.43 (1 H, m) 1.48 (2H, quint, J = 8.0 Hz), 1.53-1.63 (2H, m), 1.91 (2H, t, J = 7.2 Hz, CH2CO), 2.64 (2H, m, N(CHH)2), 3.96 (2H, m, N(CHH)2), 4.62 (2H, s, PhCH2), 7.25 (1 H, s, NCONH), 7.37 (1 H, t, J = 7.2 Hz, ArH), 7.63 (1 H, t, J =7.2 Hz, ArH), 7.68-7.73 (1 H, m, ArH), 7.92 (1 H, d, J = 8.0 Hz, ArH). MF C18H24N4O4, MW 360.41
Ex 178 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- [1,2,3]thiadiazol-4-yl-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.03 (2H, dq, J = 3.6 and 12.5 Hz), 1.17-1.27 (2H, m), 1.36-1.48 (1 H, m), 1.53 (2H, m), 1.62-1.75 (2H, m), 1.94 (2H, t, J= 7.3 Hz, CH2CO), 2.77 (2H, m, N(CHH)2), 4.13 (2H, m, N(CHH)2), 7.65 (2H, d, J=8.8 Hz, ArH), 7.99 (1 H, d, J=8.8 Hz, ArH), 8.70 (1 H, s, NHCON), 9.40 (1 H, s, ThioH), 10.32 (1 H, s, NHOH). MF C18H23N5O3S, MW 389.47
Ex 179 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid [4-(3,5- dimethyl-pyrazol-1-yl)-phenyl]-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.6 and 12.6 Hz), 1.14-1.28 (2H, m), 1.37-1.46 (1 H, m), 1.53 (2H, quin, J = 7.6 Hz), 1.62-1.73 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.16 (3H, s, CH3), 2.23 (3H, s, CH3), 2.76 (2H, m, N(CHH)2), 4.11 (2H, m, N(CHH)2), 6.02 (1 H, s, PyrH), 7.30 (2H, d, J=8.9 Hz, ArH), 7.55 (2H, d, J=8.9 Hz, ArH), 8.60 (1 H, s, NHCON), 10.31 (1 H, s, NHOH). MF C21 H29N5O3, MW 399.4
Ex 180 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid [3-(2- methyl-thiazol-4-yl)-phenyl]-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.5 and 12.3 Hz), 1.14-1.26 (2H, m), 1.38-1.48 (1 H, m), 1.52 (2H, quin, J = 7.4 Hz), 1.61 -1.71 (2H, m), 1.94 (2H, t, J= 7.3 Hz, CH2CO), 2.71 (3H, s, CH3), 2.74 (2H, m, N(CHH)2), 4.12 (2H, m, N(CHH)2), 7.25 (1 H, t, J= 7.9 Hz, ArH), 7.46 (1 H, t, J= 7.4 Hz, ArH), 8.02 (1 H, s, ArH), 8.54 (1 H, s, ThiazH), 8.54 (1 H, s, NHCON), 10.31 (1 H, s, NHOH). MF C20H26N4O3S, MW 402.51
Ex 181 N-(6-aminonaphthalen-2-yl)-4-(4-(hydroxyamino)-4- oxobutyl)piperidine-1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.03 (2H, dq, J = 3.2 and 12.4 Hz), 1.12-1.25 (2H, m), 1.35-1.48 (1 H, m) 1.53 (2H, quint, J = 7.6 Hz), 1.63-1.73 (2H, m), 1.94 (2H, t, J = 7.2 Hz, CH2CO), 2.77 (2H, m, N(CHH)2), 4.14 (2H, m, N(CHH)2), 7.15-7.22 (1 H, m, ArH), 7.39 (1 H, s, ArH), 7.55-7.61 (1 H, m, ArH), 7.71 (2H, t, J = 9.6 Hz, ArH), 7.96 (1 H, s, ArH), 8.61 (1 H, s, NCONH), 10.32 (1 H, s, NHOH). MF C20H26N4O3, MW 370.45
Ex 182 4-(4-(hydroxyamino)-4-oxobutyl)-N-(1 H-indol-5-yl)piperidine-1- carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J= 3.2 and 12.4 Hz), 1.12-1.26 (2H, m), 1.35-1.47 (1 H, m) 1.53 (2H, quint, J= 8.0 Hz), 1.60-1.71 (2H, m), 1.94 (2H, t, J= 7.2 Hz, CH2CO), 2.71 (2H, m, N(CHH)2), 4.10 (2H, m, N(CHH)2), 6.30 (1 H, m, ArH), 7.09 (1 H, dd, J= 2.0 and 8.8 Hz, ArH), 7.21 (1 H, s, ArH), 7.22-7.26 (1 H, m, ArH), 7.56 (1 H, s, ArH), 8.18 (1 H, s, NCONH), 8.66 (1 H, s, OH), 10.32 (1 H, s, NHOH), 10.86 (1 H, bs, IndNH). MF C18H24N4O3, MW 344.41
Ex 183 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (5- methyl-1 -phenyl-1 H-pyrazol-4-yl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.01 (2H, dq, J = 3.7 and 12.6 Hz), 1.17-1.21 (2H, m), 1.35-1.46 (1 H, m), 1.52 (2H, m), 1.59-1.69 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.17 (3H, s, CH3), 2.73 (2H, m, N(CHH)2), 4.06 (2H, m, N(CHH)2), 7.37-7.42 (1 H, m, PyrH), 7.47-7.55 (5H, m, ArH), 8.50 (1 H, s, NHCON), 10.32 (1 H, s, NHOH). MF C20H27N5O3, MW 385.46
Ex 184 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- pyrrol-1 -yl-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.9 and 12.7 Hz), 1.16-1.22 (2H, m), 1.37-1.47 (1 H, m), 1.52 (2H, m), 1.62-1.68 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.74 (2H, m, N(CHH)2), 4.10 (2H, m, N(CHH)2), 6.21 (2H, t, J= 2.1 Hz, PyrH), 7.25 (2H, t, J = 2.1 Hz, PyrH), 7.40 (2H, d, J = 9.0 Hz, ArH), 7.53 (2H, d, J = 9.0 Hz, ArH), 8.50 (1 H, s, OH), 10.32 (1 H, s, NH). MF C20H26N4O3, MW 370.44
Ex 185 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (3- pyrrol-1 -yl-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.9 and 12.8 Hz), 1.16-1.23 (2H, m), 1.38-1.47 (1 H, m), 1.52 (2H, quin, J = 7.4 Hz), 1.63-1.71 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.75 (2H, m, N(CHH)2), 4.11 (2H, m, N(CHH)2), 6.25 (2H, t, J = 2.1 Hz, PyrH), 7.09 (1 H, dd, J = 1.4 and 7.8 Hz, ArH), 7.22 (2H, t, J = 2.1 Hz, PyrH), 7.28 (1 H, t, J = 8.1 Hz, ArH), 7.33- 7.38 (1 H, m, ArH), 7.69 (1 H, t, J=2.0 Hz, ArH), 8.57 (1 H, s, OH), 10.32 (1 H, s, NH).
MF C20H26N4O3, MW 370.44
Ex 186 4-[1-(3-(1)Naphtylamino-propionyl)-piperidin-4-yl]-N-hydroxy- butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.75-1.30 (4H, m), 1.45-1.80 (5H, m), 1.95 (2H, t, J = 7.1 Hz, CH2CO), 2.55 (1 H, t, J =13.0 Hz, CHHNH), 2.76 (2H, t, J = 6.8 Hz, CH2CO), 2.95 ( 1 H, t, J =13.0 Hz, CHHNH), 3.25 (2H, t, J = 6.8 Hz, CH2NH), 3.75 ( 1 H, d, J=13.0 Hz, CHHNH), 4.35 ( 1 H, d, J = 13.0 Hz, CHHNH), 4.70 (2H, s, CH2Ph), 7.55-7.75 (4H, m, ArH), 8.03 (2H, d, J = 8.1 Hz, ArH), 8.24 (1 H, d, J = 8.1 Hz, ArH), 8.60 (1 H, s, NH+), 8.65 (1 H, bs, OH), 10.32 (1 H, s, NHOH) . MF C23H3I N3O3, MW: 397.51
Ex 187 4-(4-(hydroxyamino)-4-oxobutyl)-N-(1 H-indol-3-yl)piperidine-1- carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.04 (2H, dq, J = 3.2 and 12.4 Hz), 1.13-1.26 (2H, m), 1.35-1.47 (1 H, m) 1.53 (2H, quint, J = 7.6 Hz), 1.62-1.72 (2H, m), 1.94 (2H, t, J = 7.2 Hz, CH2CO), 2.74 (2H, m, N(CHH)2), 4.13 (2H, m, N(CHH)2), 6.93 (1 H, t, J = I. Q Hz, ArH), 7.04 (1 H, t, J = 7.6 Hz, ArH), 7.28 (1 H, d, J = 8.0 Hz, ArH), 7.33 (1 H, s, ArH), 7.58 (1 H, d, J = 8.0 Hz, ArH), 8.08 (1 H, t, J = 5.6 Hz, NCONH), 8.65 (1 H, s, OH), 10.32 (1 H, s, NHOH), 10.64 (1 H, bs, IndNH). MF C18H24N4O3, MW 344.41 Ex 188 N-(5-Chloro-benzo[b]thiophen-3-ylmethyl)-4-(4-(hydroxyamino)-4- oxobutyl)piperidine-1-carboxamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.92 (2H, dq, J = 3.2 and 12.0 Hz), 1.10-1.20 (2H, m), 1.28-1.42 (1 H, m) 1.49 (2H, quint, J = 8.0 Hz), 1.53-1.62 (2H, m), 1.91 (2H, t, J = 7.2 Hz, CH2CO), 2.63 (2H, m, N(CHH)2), 3.95 (2H, m, N(CHH)2), 4.43 (2H, s, PhCH2), 7.10 (1 H, t, J = 5.6 Hz, NCONH), 7.39 (1 H, dd, J = 2.0 and 8.4 Hz, ArH), 7.55 (1 H, s, ArH), 7.97-8.04 (2H, d, J = 5.2 Hz, ArH), 10.30 (1 H, s, NHOH). MF C19H24CIN3O3S, MW 409.93
Ex 189 N-(benzo[b]thiophen-5-yl)-4-(4-(hydroxyamino)-4- oxobutyl)piperidine-1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.03 (2H, dq, J = 3.2 and 11.6 Hz), 1.15-1.26 (2H, m), 1.35-1.47 (1 H, m) 1.53 (2H, quint, J = 8.0 Hz), 1.61 -1.71 (2H, m), 1.94 (2H, t, J = 7.2 Hz, CH2CO), 2.75 (2H, m, N(CHH)2), 4.13 (2H, m, N(CHH)2), 7.34 (1 H, d, J = 5.2 Hz, ArH), 7.42 (1 H, dd, J = 2.0 and 8.8 Hz, ArH), 7.67 (1 H, d, J = 5.2 Hz, ArH), 7.81 (1 H, d, J = 8.8 Hz, ArH), 8.02 (1 H, d, J= 2.0 Hz, ArH), 8.52 (1 H, m, NCONH), 8.66 (1 H, s, OH), 10.32 (1 H, s, NHOH). MF C18H23N3O3S, MW 361.46
Ex 190 N-(4-(thiophen-3-yl)benzyl)-4-(4-(hydroxyamino)-4- oxobutyl)piperidine-1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.94 (2H, dq, J = 3.2 and 12.0 Hz), 1.11 -1.21 (2H, m), 1.30-1.43 (1 H, m) 1.50 (2H, quint, J = 8.0 Hz), 1.55-1.64 (2H, m), 1.92 (2H, t, J = 7.2 Hz, CH2CO), 2.64 (2H, m, N(CHH)2), 3.97 (2H, m, N(CHH)2), 4.22 (2H, s, PhCH2), 7.00 (1 H, m, NCONH), 7.26 (2H, d, J= 8.0 Hz, ArH), 7.51 -7.55 (1 H, m, ArH), 7.60-7.66 (3H, m, ArH), 7.79-7.83 (1 H, m, ArH), 8.65 (1 H, s, OH), 10.31 (1 H, s, NHOH). MF C21 H27N3O3S, MW 401.52 Ex 191 4-(4-(hydroxyamino)-4-oxobutyl)-N(3-phenylbenzyl)piperidine-1- carboxamide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.90 (2H, dq, J = 3.6 and 12.4 Hz), 1.10-1.19 (2H, m), 1.31 -1.44 (1 H, m) 1.50 (2H, quint, J = 7.6 Hz), 1.55-1.63 (2H, m), 1.92 (2H, t, J = 7.2 Hz, CH2CO), 2.64 (2H, m, N(CHH)2), 3.98 (2H, m, N(CHH)2), 4.29 (2H, s, PhCH2), 7.04 (1 H, m, NCONH), 7.23 (1 H, d, J = 7.4 Hz, ArH), 7.33-7.42 (2H, m, ArH), 7.43-7.54 (4H, m, ArH), 7.61 (2H, d, J = 7.4 Hz, ArH), 10.31 (1 H, s, NHOH). MF C23H29N3O3, MW 395.49
Ex 192 3-(4-(hydroxyamino)-4-oxobutyl)-N-phenylpiperidine-1 -carboxamide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.95-1.29 (3H, m), 1.29-1.46 (1 H, m) 1.54 (2H, quint, J = 7.6 Hz), 1.58-1.68 (1 H, m), 1.74-1.84 (2H, m), 1.94 (2H, t, J= 7.2 Hz, CH2CO), 2.36-2.46 (1 H, m, NCHH), 2.76 (1 H, m, NCHH), 3.99 (2H, m, N(CHH)2), 6.90 (1 H, t, J= 7.6 Hz, ArH), 7.20 (2H, t, J = 7.6 Hz, ArH), 7.43 (2H, d, J= 7.6 Hz, ArH), 8.41 (1 H, m, NCONH), 8.66 (1 H, s, OH), 10.33 (1 H, s, NHOH). MF C16H23N3O3, MW 305.37
Ex 193 2-(s)-Amino-N-benzyl-4-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1- yl]-4-oxo-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.82-0.94 (2H, m), 1.13-1.31 (3H, m), 1.44-1.57 (2H, m), 1.65-1.70 (2H, m), 1.90-1.95 (2H,t, J = 7.6 Hz), 2.60 (1 H, m), 2.86-2.99 (3H, m), 3.76 (1 H, d, J = 14.7 Hz), 4.09-4.14 (1 H, m, NCHCH2CO), 4.32-4.40 (2H, m, NCH2Ph), 7.24-7.35 (5H, m, ArH), 8.10 (1 H, brs, NH+), 8.69 (1 H, s, OH), 8.80 (1 H, s, NHCH2), 10.30 (1 H, s, NH). MF C20H30N4O4, MW 390.48 Ex 194 2-(R)-Amino-N-benzyl-4-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1- yl]-4-oxo-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ?(ppm) 0.82-0.94 (2H, m), 1.13-1.31 (3H, m), 1.44-1.57 (2H, m), 1.65-1.70 (2H, m), 1.90-1.95 (2H, t, J =7.6 Hz), 2.60 (1 H, m), 2.86-2.99 (3H, m), 3.76 (1 H, d, J = 14.7 Hz), 4.09-4.14 (1 H, m, NCHCH2CO), 4.32-4.40 (2H, m, NCH2Ph), 7.24-7.35 (5H, m, ArH), 8.10 (1 H, brs, NH+), 8.69 (1 H, s, OH), 8.80 (1 H, s, NHCH2), 10.30 (1 H, s, NH). MF C20H30N4O4, MW 390.48
Ex 195 N-(benzo[b]thiophene)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1- carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.02-1.26 (4H, m), 1.39-1.57 (3H, m), 1.66 (2H, d, J = 12..1 Hz), 1.94 (2H, t, J= 7.3 Hz), 2.80 (2H, t, J= 11.9 Hz, N(CHH)2), 4.13 (2H, d, J = 13.2 Hz, N(CHH)2), 7.34-7.41 (2H, m, ArH), 7.53 (1 H, s, ArH), 7.83-7.92 (2H, m, ArH), 8.55 (1 H, m, NHCON), 8.66 (1 H, s, OH), 10.32 (1 H, s, NHOH). MF Ci8H23N3O3S, MW 361.46
Ex 196 4-(4-(hydroxyamino)-4-oxobutyl)-N-((3-methylbenzo[b]thiophen-2- yl)methyl)piperidine-1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.93 (2H, dq, J = 3.2 and 12.0 Hz), 1.10-1.19 (2H, m), 1.27-1.43 (1 H, m) 1.49 (2H, quint, J = 7.6 Hz), 1.54-1.63 (2H, m), 1.92 (2H, t, J = 7.2 Hz, CH2CO), 2.33 (3H, s, CH3), 2.63 (2H, m, N(CHH)2), 3.94 (2H, m, N(CHH)2), 4.44 (2H, s, PhCH2), 7.15 (1 H, t, J = 5.6 Hz, NCONH), 7.29 (1 H, m, ArH), 7.34 (1 H, m, ArH), 7.67 (1 H, d, J = 8.0 Hz, ArH), 7.85 (1 H, d, J = 8.0 Hz, ArH), 10.30 (1 H, s, NHOH). MF C20H27N3O3S, MW 389.51
Ex 197 N-((2,5-dimethylthiazol-4-yl)methyl)-4-(4-(hydroxyamino)-4- oxobutyl)piperidine-1-carboxamide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.90 (2H, dq, J = 3.6 and 12.0 Hz), 1.09-1.18 (2H, m), 1.27-1.39 (1 H, m) 1.48 (2H, quint, J = 7.6 Hz), 1.52-1.61 (2H, m), 1.91 (2H, t, J = 7.2 Hz, CH2CO), 2.35 (3H, s, CH3), 2.46-2.52 (2H, m), 2.50 (3H, s, CH3), 3.92 (2H, m, N(CHH)2), 4.14 (2H, s, PhCH2), 6.84 (1 H, m, NCONH), 10.31 (1 H, s, NHOH). MF C16H26N4O3, MW 354.47
Ex 198 4-(3-Hydroxycarbamoyl-propyl)-pipendine-1-carboxylic acid (5,6,7,8- tetrahydro-naphthalen-1-yl)-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.01 (2H, dq, J = 3.2 and 12.4 Hz), 1.13-1.24 (2H, m), 1.35-1.46 (1 H, m) 1.52 (2H, quint, J = 7.6 Hz), 1.58-1.75 (6H, m), 1.93 (2H, t, J = 7.2 Hz, CH2CO), 2.50-2.59 (2H, m), 2.65-2.79 (4H, m), 4.04 (2H, m, N(CHH)2), 6.84 (1 H, dd, J = 2.4 and 6.4 Hz, ArH), 6.95- 7.02 (2H, m, ArH), 7.78 (1 H, s, OH), 10.32 (1 H, s, NHOH). MF C20H29N3O3, MW 359.46
Ex 199 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid (4- benzyl-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.99 (2H, dq, J = 3.6 and 12.4 Hz), 1.13-1.23 (2H, m), 1.32-1.46 (1 H, m) 1.51 (2H, quint, J = 7.6 Hz), 1.58-1.70 (2H, m), 1.93 (2H, t, J = 7.2 Hz, CH2CO), 2.71 (2H, m, N(CHH)2), 3.84 (2H, m, Ph2CH2), 4.06 (2H, m, N(CHH)2), 7.05 (2H, d, J = 8.4 Hz, ArH), 7.13- 7.22 (3H, m, ArH), 7.23-7.29 (2H, m, ArH), 7.34 (2H, d, J = 8.4 Hz, ArH), 8.34 (1 H, s, NCONH), 8.65 (1 H, s, OH), 10.31 (1 H, s, NHOH). MF C23H29N3O3, MW 395.50
Ex 200 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid (4- benzyloxy-phenyl)-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.99 (2H, dq, J = 3.6 and 12.4 Hz), 1.13-1.23 (2H, m), 1.32-1.46 (1 H, m) 1.52 (2H, quint, J = 7.6 Hz), 1.60-1.70 (2H, m), 1.92 (2H, t, J = 7.6 Hz, CH2CO), 2.70 (2H, m, N(CHH)2), 4.07 (2H, m, N(CHH)2), 5.03 (2H, m, PhCH2O), 6.77 (2H, d, J = 8.8 Hz, ArH), 7.27- 7.47 (7H, m, ArH), 8.26 (1 H, bs, NCONH), 8.65 (1 H, s, OH), 10.32 (1 H, s, NHOH). MF C23H29N3O4, MW 411.49
Ex 201 Benzo[b]thiophene-2-carboxylic acid {3-[4-(3-hydroxycarbamoyl- propyl)-piperidin-1-yl]-3-oxo-propyl}-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.84-1.05 (2H, m), 1.09-1.15 (2H, m), 1.39-1.51 (3H, m), 1.64 (2H, m), 1.91 (2H, t, J = 7.3 Hz), 2.53 (1 H, m, N(CHH)2), 2.58-2.62 (2H, m, dt, J =2.8 and 7.1 Hz, NCHCH2), 2.95 (1 H, t, J = 12.7 Hz, N(CHH)2), 3.37 (2H, m, NCH2CH2) 3.79 (1 H, d, J = 13.2 Hz, N(CHH)2), 4.35 (1 H, d, J= 13.1 Hz, N(CHH)2), 7.40-8.06 (5H, m, ArH), 8.35 (1 H, s, NH+), 8.66 (1 H, s, OH ), 10.30 (1 H, s, NH). MF C21 H19N3O4S, MW 419.54
Ex 202 Benzo[b]thiophene-2-carboxylic acid {4-[4-(3-hydroxycarbamoyl- propyl)-piperidin-1-yl]-4-oxo-butyl}-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.84-1.01 (2H, m), 1.09-1.15 (2H, m), 1.47 (3H, m), 1.64 (2H, t, J= 13.6 Hz), 1.76 (2H, m, COCH2CH2C), 1.91 (2H, t, J= 7.3 Hz), 2.36 (2H, m,COC H2CH2C), 2.96 (1 H, t, J= 12.6 Hz), 3.27 (2H, m), 3.81 (1 H, d, J = 14.1 Hz, N(CHH)2), 4.36 (1 H, d, J = 13.3 Hz, N(CHH)2), 7.45 (2H, m, ArH), 7.92-8.06 (3H, m, ArH), 8.73 (1 H, s, NH+), 10.30 (1 H, s, NH). MF C22H29N3O4S, MW 431.55
Ex 203 Benzo[b]thiophene-2-carboxylic acid {2-(S)-amino-3-[4-(3- hydroxycarbamoyl-propyl)-piperidin-1-yl]-3-oxo-propyl}-amide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.88-0.95 (2H, m), 1.13-1.24 (2H, m), 1.37-1.54 (3H, m), 1.61 -1.76 (2H, m), 1.80-1.96 (2H, m), 2.59-2.66 (1 H, m, N(CHH)2), 2.99-3.11 (1 H, m, N(CHH)2), 3.51 -3.63 (2H, m), 4.03 (1 H, d, J = 13.5 Hz, N(CHH)2), 4.37 (1 H, d, J = 13.2 Hz, N(CHH)2), 4.55 (1 H, m, CHNH2), 7.42-8.09 (5H, m, ArH), 8.26 (1 H, s, NH3 +), 8.61 (1 H, s, OH), 9.03 (11-1, 5, NH+), 10.30 (1 H, d, NH). MF C21 H28N4O4S, MW 432.54
Ex 204 2-(s)-Amino-4-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1-yl]-N- naphthalen-1-ylmethyl-4-oxo-butyramide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 0.82-0.95 (2H, m), 1.13-1.31 (2H, m), 1.41 -1.53 (3H, m), 1.66 (2H, m), 1.90-1.95 (2H, t), 2.52 (1 H, m), 2.87- 2.94 (3H, m), 3.71 (1 H, d, J = 14.0 Hz), 4.10-4.14 (1 H, m, NCHCH2CO), 4.32-4.40 (1 H, t, J = 11.3 Hz), 4.81 (2H, s, NCH2Nap), 7.47-7.57 (4H, m, ArH), 7.86-8.04 (3H, m, ArH), 8.14 (1 H, brs, NH3 +), 8.65 (1 H, s, OH), 8.82 (1 H, s, NHCH2), 10.30 (1 H, s, NH). MF C24H32N4O4, MW 440.53
Ex 205 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid [4-(2- methyl-2H-tetrazol-5-yl)-phenyl]-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.97-1.10 (2H, m), 1.15-1.23 (2H, m), 1.36-1.48 (1 H, m), 1.52 (2H, m), 1.63-1.73 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.76 (2H, m, N(CHH)2), 4.12 (2H, m, N(CHH)2), 4.38 (3H, S1CH3), 7.65 (2H, d, J = 8.8 Hz, ArH), 7.90 (2H, d, J = 8.8 Hz, ArH), 8.71 (1 H, s, OH), 10.32 (1 H, s, NH). MF C18H25N7O3, MW 429.51
Ex 206 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1-carboxylic acid [4-(2- isobutyl-2H-tetrazol-5-yl)-phenyl]-amide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 0.92 (6H, d, J = 6.7 Hz, CH(CH3)2), 1.02 (2H, dq, J = 3.9 and 12.8 Hz), 1.16-1.22 (2H, m), 1.39-1.47 (1 H, m), 1.52 (2H, quin, J = 7.4 Hz), 1.63-1.71 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.31 (1 H, m, CH(CH3)2), 2.76 (2H, m, N(CHH)2), 4.12 (2H, m, N(CHH)2), 4.53 (2H, d, J = 7.1 Hz, CH2CH(CH3)2), 7.65 (2H, d, J = 8.7 Hz, ArH), 7.91 (2H, d, J = 8.7 Hz, ArH), 8.71 (1 H, s, OH), 10.32 (1 H, s, NH). MF C21 H31 N7O3, MW 429.51
Ex 207 4-(3-Hydroxycarbamoyl-piOpyl)-piperidine-1-carboxylic acid [4-(3- methyl-pyrazol-1-yl)-phenyl]-amide
1 H NMR (DMSO-Cl6, 400 MHz): δ (ppm) 1.02 (2H, dq, J = 3.7 and 12.6 Hz), 1.16-1.21 (2H, m), 1.33-1.45 (1 H, m), 1.52 (2H, quint, J = 7.3 Hz), 1.62-1.70 (2H, m), 1.94 (2H, t, J = 7.3 Hz, CH2CO), 2.25 (3H, s, CH3), 2.74 (2H, m, N(CHH)2), 4.11 (2H, m, N(CHH)2), 6.27 (1 H, d, J = 2.3 Hz, PyrH), 7.53 (2H, m, ArH), 7.61 (2H, m, ArH), 8.22 (1 H, d, J = 2.3 Hz, PyrH), 8.52 (1 H, s, OH), 10.32 (1 H, s, NH). MF C20H27N5O3, MW 385.46
Ex 208 4-(3-HydiOxycarbamoyl-propyl)-piperdine-1-carboxylic acid [2-(3- dimethylamino-propyl)-1 H-benzoimidazol-5-yl]-amide 1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.01 (2H, dq, J = 3.2 and 12.8 Hz), 1.11 -1.26 (2H, m), 1.35-1.48 (1 H, m) 1.52 (2H, quint, J = 7.6 Hz), 1.61 -1.74 (2H, m), 1.94 (2H, t, J = 7.6 Hz, CH2CO), 2.17 (2H, quint, J = 7.6 Hz, NCH2CH2CH2Ar), 2.76 (2H, m, N(CHH)2), 2.80 (6H, s, N(CH3J2), 3.02-3.12 (2H, m, NCH2CH2CH2Ar), 3.12-3.21 (2H, m, NCH2CH2CH2Ar), 4.13 (2H, m, N(CHH)2), 7.34-7.52 (1 H, bs, NCONH), 7.52-7.66 (2H, m, ArH), 7.76-8.07 (2H, m, ArH), 8.69 (1 H, bs, OH), 10.34 (1 H, bs, NHOH). MF C22H34N6O3, MW 430.54
Ex 209 4_[i _(i H-Benzoimidazol-2-yl)-piperidin-4-yl]-N-hydroxy-butyramide
1 H NMR (DMSO-d6, 400 MHz): δ (ppm) 1.15-1.28 (4H, m), 1.49-1.58 (3H, m), 1.81 (2H, d, J= 12.3 Hz), 3.26 (2H, t, J= 12.3 Hz, N(CHz)2), 4.01 (2H, d, J= 12.1 Hz, N(CH2J2), 7.22-7.38 (4H, m, ArH), 8.69 (1 H, bs, OH), 10.34 (1 H, bs, NHOH), 12.90 (1 H, brs, H benzimidazol). MF Ci6H22N4O2, MW 302.37
Therapeutic indications
Histone deacetylase inhibitors are a class of potential therapeutic or prophylactic agents for pathological states caused by abnormal gene expression, such as inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocyte leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections, tumors and the like. In particular they are emerging as a new class of drugs with anti-tumor activity. The connection between some tumorous pathologies, such as carcinoma of the mammary, colon and lung, and acetylation levels of nuclear chromatin has been described. Drugs able to modulate chromatin remodelling are able to inhibit tumor proliferation and could provide new instruments for treating tumor pathologies in the not too distant future. Much experimental evidence leads to the belief that the main field of application of this class of drugs could be in combined therapies. The considerable tolerability that has emerged from the first clinical trials leads to the belief that this class of molecules lends itself to combined therapy with traditional drugs such as cytotoxic drugs, or with radiotherapy treatments or with the new generation antitumor agents. In particular, the present invention also provides combinations of compounds with histone deacetylase inhibitory activity of general formula (I) with one or more chemotherapeutic compounds chosen from the group: conventional cytotoxic agents, demethylating agents, cyclin dependent kinase inhibitors, differentiating agents, signal transduction modulators, HSP-90 antagonists, proteasome inhibitors. Preferred compounds are compounds chosen from the following groups: the conventional cytotoxic agents: fludarabine, gemcitabine, decitabine, paclitaxel, carboplatin and Topo l/ll inhibitors to include Etoposide, Irinotecan, Topotecan, T-128 and Anthracyclines such as Doxorubicin, Sabarubicin, Daunorubicin; the demethylating agents (demethylation of DNA): 5-aza-2'-deoxycytidine (5-aza-dC),
5-azacytidine; the cyclin dependent kinase inhibitors: Flavopiridol, olomoucin, roscovitin, purvalanol
B, GW9499, GW5181 , CGP60474, CGP74514, AG12286, AG12275,
Staurosporine, UCN-01 ; the differentiating agents: retinoic acid and derivatives (All Trans Retinoic Acid,
ATRA), 13-cis retinoic acid (CRA), PMA (phorbol myristate acetate); the signal transduction modulators: TRAIL, imatinib mesylate, LY-294002, bortezomib; the HSP-90 antagonists: geldanamycin and its analogues (17-AAG); the proteasome inhibitors: lactacystine, MG132, bortezomib (Velcade™).
Biological activity
The activity of the compounds as histone deacetylase (HDAC) inhibitors was measured using an in vitro acetylation assay. The compounds were then evaluated as inhibitors of proliferation of human tumor cell cultures. The overall data obtained are given in the table.
Deacetylase activity on nuclear extract of HeLa cells (Human cervical cancer cell) The assay (Fluor de Lys™ kit, BioMol) is divided into two steps: in the first step the substrate which comprises an acetylated lysine residue is reacted with the nuclear extract (HeLa) containing the enzymatic activity in the presence and absence of inhibitors. In the second step a fluorogenic reagent is added which highlights the deacetylated residues. A reduction in fluorescence is obtained where there has been inhibition of the deacetylase activity. The result is finally expressed as percent inhibition relative to the control without inhibitor at a concentration of 0.1 μM. Evaluation of cytotoxic activity on culture of human colon carcinoma cells HCT-116 Human colon carcinoma cells HCT-116 were seeded onto 96-well plates in RPMH 640 culture medium with added 10% FBS and 2 mM glutamine. 24 hours after seeding, the compounds at different concentrations are added. All the compounds are diluted in DMSO such that the final concentrations on the cultures is no greater than 0.5%. 72 hours after addition of the compounds, cell viability is measured by means of the dye Alamar Blue. The result is expressed as percent survival of the treated relative to the control, treated with carrier alone.
Table: Biological activity of the new compounds on histone acetylation inhibition and on antiproliferative activity in the human colon carcinoma cell line HCT- 1 16
Example % inhib. HCT-116
0.1μM IC50 (μM)
Ex 7 59 0.3
Ex 8 53 0.7
Ex 15 43 0.84
Ex 22 67 0.94
Ex 34 64 0.33
Ex 35 55 0.71
Ex 36 73 0.83
Ex 39 60 0.81
Ex 45 79 0.89
Ex 52 68 0.5
Ex 73 73 0.84
Ex 79 70 0.77
Ex 82 62 0.53
Ex 83 58 0.67
Ex 90 56 0.45
Ex 93 64 0.5
Ex 101 64 0.51
Ex 102 54 0.79
Ex 103 49 0.20
Ex 105 59 0.95
Ex 106 52 0.71
Ex 109 71 0.068 Ex 110 54 0.26
Ex 111 66 0.55
Ex 112 55 0.31
Ex 113 61 0.27
Ex 114 61 0.34
Ex 115 62 0.9
Ex 122 42 0.42
Ex 126 63 0.4
Ex 137 68 0.15
Ex 139 56 0.4
Ex 144 69 0.24
Ex 146 68 0.06
Ex 149 62 0.13
Ex 150 57 0.18
Ex 151 50 0.1
Ex 154 82 0.53
Ex 157 68 0.6
Ex 158 60 0.9
Ex 159 79 0.2
Ex 160 67 0.2
Ex 161 76 0.03
Ex 164 51 0.6
Ex 165 64 0.7
Ex 168 55 0.09
Ex 170 51 0.2
Ex 171 45 0.4
Ex 175 70 0.6
Ex 178 45 0.3
Ex 179 70 0.5
Ex 181 64 0.47 Ex 186 81 0.36
Ex 188 50 0.21
Ex 190 69 0.48
Ex 192 68 0.6
Ex 193 50 0.9
Ex 195 42 0.4
Ex 198 77 0.4

Claims

1. Compounds of general formula (I):
Figure imgf000086_0001
(I) in which v=0,1 ,2
-B is a bond, or is chosen from the group: -O-, -NR5-, -CO-, -NR5-CO-, -O-CO-, SO2-, -NR5-SO2-, or represents one of the following structures:
Figure imgf000086_0002
in which n=0,1 ,2 in which R5 is a H or a C1 -3 alkyl
-R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl or an acyl derived from one of the following acids: benzoic, phenylacetic, benzothiophene- carboxylic, indole-carboxylic
-R2 represents a H or a C1 -3 alkyl group or R1 and R2 represent jointly with the nitrogen atom, a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine
-R3 represents H or is chosen from the group: -C1 -6 alkyl, -C1 -6 alkylene-W, where
W is chosen from -OR5, -SR5, -CONR7R8, -NR7R8, -OCOR6 -NR5COR6, guanidine, and R7 and R8 independently represent a H or C1 -3 alkyl group or R7 and R8 represent jointly with the nitrogen atom a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and R6 is chosen from the group: hydrogen, C1 -3 alkyl, Ar1 where Ar1 is an aromatic group chosen from phenyl, naphthyl, pyridine, quinoline, indole, benzofuran, benzothiophene and can possibly be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, COOR9, CONR9R10, CH2NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -3 alkyl, -(CH2)q-NR10R11 , pyrrolidine, R10 and R1 1 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3 -R4 is a group chosen from H and C1 -3 alkyl or R4 and R3 represent jointly with the nitrogen atom a heterocycle chosen from pyrrolidine or piperidine
-L1 indicates a group attached to any of the carbon atoms in the heterocyclic ring and is chosen from the group: alkylidene of the type -(CH2)m-, possibly substituted on each C with one or two methyl groups, and in which m can assume the values 1 , 2, 3, 4, 5, or an alkene chosen from -(CH2)e-CH=CH-(CH2)f-, -(CH2)g-CH=CH-(CH2)h- CH=CH-(CH2)I- possibly substituted on each C with one or two methyl groups and in which e, f, g, h and I can independently assume the values 0,1 ,2,3 or 4 -L2 indicates a bond or a group chosen from: : -(CH2)p-, -(CH2)p-CH=CH-, -(CH2)p- T-(CH2)Z-, -(CH2)P-CO-, -(CH2)P-CH=CH-CO-, -CO-T-(CH2)Z- , -(CH2)p-T-CO-, each group being possibly substituted on the Cs with one or two methyl groups and in which p and z can independently assume the values 0,1 ,2,3 or 4 and T is chosen from -O-, -S-, -NR5-
-Ar represents a group derived from the following aromatic systems: phenyl, pyridyl, furyl, pyrimidyl, pyrazyl, piperazyl, triazolyl, tetrazolyl, biphenyl, imidazolyl, naphthyl, quinoline, isoquinoline, diphenyl-methyl, benzofuryl, dihydrobenzofuryl, benzothienyl, indolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, oxazolyl-phenyl, thiodiazolyl- phenyl, pyridyl-phenyl, pyrazolyl-phenyl, thiazolyl-phenyl, furyl-phenyl, thienyl-phenyl, benzyloxy-phenyl, tetrazolyl-phenyl, phenyl-oxazolyl, phenyl-pyrazolyl-, phenyl-thiazolyl, phenyl-thiadiazolyl, phenyl-isothiazolyl, phenyl-oxadiazolyl, phenyl-isoxazolyl, phenyl- imidazolyl, phenyl-triazolyl, phenyl-furyl, phenyl-thiophenyl, phenyl-pyrrolyl, phenyl- pyrrolidyl, indanyl, fluorenyl, benzopyranyl, dihydrobenzopyranyl, benzodioxolyl, phenoxy-phenyl, benzoxazinyl, dihydrobenzoxazinyl in which each group can possibly be substituted with up to three groups independently chosen from C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, -SCF3, COOR9, CONR9R10, -(CH2)q-NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH2)q-NR10R1 1 , pyrrolidine, R10 and R 11 are independently chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3, - or Ar-L2-B can jointly be chosen from the group consisting of:
Figure imgf000088_0001
in which:
- the R12 group represents a H, a C1 -3 alkyl or a C1 -3 acyl
- the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
- the aromatic part can be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, - SCF3, COOR9, CONR9R10, -(CH2)q-NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH2)q-NR10R1 1 , pyrrolidine, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3; the relative prodrug of general formula (IV) and (V)
Figure imgf000089_0001
(IV) (V) in which Rx can be Ac, COEt, CO-nPr, CO-iPr, CO-tBu, benzoyl, pNO2benzoyl, CH3, Et, nPr, iPr, tBu, Benzyl, tetrahydropyranyl, Ry and Rz independently indicate a H or a C1 -3 alkyl group; with the exclusion of products in which:
B is chosen from -NR5-CO- or -NRδ-SQr and at the same time L2 is chosen from -(CH2)p-CO- or -(CH2)P-CH=CH-CO-; possible optical isomers, such as enantiomers and/or diastereoisomers, their mixtures either as racemes or in various ratios thereof, and their inorganic and organic acid salts.
2. Compounds as claimed in claim 1 of general formula (II)
Figure imgf000089_0002
(H) in which v=1
-B is a bond, or is chosen from the group:-CO-, -NR5-CO-, -O-CO-, -SO2-, -NR5- SO2-, or represents one of the following structures:
Figure imgf000090_0001
in which n=0,1 ,2 in which R5 is a H or a C1 -3 alkyl
-R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl or an acyl derived from one of the following acids: benzoic, phenylacetic, benzothiophene- carboxylic, indole-carboxylic
-R2 represents a H or a C1 -3 alkyl group or R1 and R2 represent jointly with the nitrogen atom, a five- or six-membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine
-R3 represents H or is chosen from the group: -C1 -6 alkyl, -C1 -6 alkylene-W, where
W is chosen from -OR5, -SR5, -CONR7R8, -NR7R8, -OCOR6 -NR5COR6, guanidine, and R7 and R8 independently represent a H or a C1 -3 alkyl group or R7 and R8 represent jointly with the nitrogen atom a five- or six- membered heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and R6 is chosen from the group hydrogen, C1 -3 alkyl, Ar1 where Ar1 is an aromatic group chosen from phenyl, naphthyl, pyridine, quinoline, indole, benzofuran, benzothiophene and can possibly be substituted with up to three groups independently chosen from:
C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, COOR9,
CONR9R10, CH2NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -3 alkyl, -(CH2)q-NR10R1 1 , pyrrolidine, R10 and R1 1 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3
-R4 represents a H or a C1 -3 alkyl group or R4 and R3 represent jointly with the nitrogen atom a heterocycle chosen from pyrrolidine or piperidine
-L1 is chosen from the group: alkylidene of the type -(CH2)m-, possibly substituted on each C with one or two methyl groups, and in which m can assume the values 1 , 2, 3 -L2 indicates a bond or a group chosen from: -(CH2)p-, -(CH2)P-CH=CH-, -(CH2)p-T- (CH2)Z-, -(CH2)P-CO-, -(CH2)P-CH=CH-CO-, -CO-T-(CH2)Z-, -(CH2)P-T-CO-, each group being possibly substituted on the Cs with one or two methyl groups and in which p and z can independently assume the values 0,1 ,2,3 or 4 and T is chosen from -O-, -S-, -NR5-
-Ar represents a group derived from the following aromatic systems: phenyl, pyridyl, furyl, pyrimidyl, pyrazyl, piperazyl, triazolyl, tetrazolyl, biphenyl, imidazolyl, naphthyl, quinoline, isoquinoline, diphenyl-methyl, benzofuryl, dihydrobenzofuryl, benzothienyl, indolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, oxazolyl-phenyl, thiodiazolyl- phenyl, pyridyl-phenyl, pyrazolyl-phenyl, thiazolyl-phenyl, furyl-phenyl, thienyl-phenyl, benzyloxy-phenyl, tetrazolyl-phenyl, phenyl-oxazolyl, phenyl-pyrazolyl-, phenyl-thiazolyl, phenyl-thiadiazolyl, phenyl-isothiazolyl, phenyl-oxadiazolyl, phenyl-isoxazolyl, phenyl- imidazolyl, phenyl-triazolyl, phenyl-furyl, phenyl-thiophenyl, phenyl-pyrrolyl, phenyl- pyrrolidyl, indanyl, fluorenyl, benzopyranyl, dihydrobenzopyranyl, benzodioxolyl, phenoxy-phenyl, benzoxazinyl, dihydrobenzoxazinyl in which each group can possibly be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, -SCF3, COOR9, CONR9R10, -(CH2)q-NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH2)q-NR10R11 , pyrrolidine, R10 and 11 are independently chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3, - or Ar-L2-B can jointly be chosen from the group consisting of:
Figure imgf000092_0001
in which:
- the R12 group represents a H, a C1 -3 alkyl or a C1 -3 acyl
- the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
- the aromatic part can be substituted with up to three groups independently chosen from: C1 -3 alkyl, OR9, SR9, NR9R10, N(R9)COR10, NO2, CN, F, Cl, Br, -CF3, - SCF3, COOR9, CONR9R10, -(CH2)q-NR9R10, N(Rg)SO2RI O, CH2OR9, SOH, CH2SO3H, in which R9 is a group chosen from H, C1 -4 alkyl, -(CH2)q-NR10R1 1 , pyrrolidine, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 1 ,2 or 3; the relative prodrugs of general formula (III) and (IV)
Figure imgf000092_0002
(III) (IV) in which Rx can be Ac, COEt, CO-nPr, CO-iPr, CO-tBu, Benzoyl, pNO2Benzoyl, CH3, Et, nPr, iPr, tBu, Benzyl, tetrahydropyranyl Ry and Rz independently indicate a H or a C1 -3 alkyl group; with the exclusion of products in which:
B is chosen from -NR5-CO- or -NRS-SO2- and at the same time L2 is chosen from -(CH2)p-CO- or -(CH2)p-CH=CH-CO-; possible optical isomers, such as enantiomers and/or diastereoisomers, their mixtures, either as racemes or in various ratios thereof, and their inorganic and organic acid salts.
3. Compounds as claimed in claim 2, of general formula (I) in which: v=1
-B is a bond, or is chosen from the group: -CO-, -NR5-CO-, -O-CO-, or represents one of the following structures:
Figure imgf000093_0001
in which n=0,1 in which R5 is a H or a C1 -3 alkyl
-R1 represents a H or is chosen from the group: C1 -3 alkyl, C1 -3 acyl
-R2 represents a H or a C1 -3 alkyl group
-R3 represents H or is a -C1 -6 alkylene-W, where W is chosen from - OR5, -NR7R8 and R7 and R8 independently represent a H or a C1 -3 alkyl group
-R4 represents a H or a C1 -3 alkyl group,
-L1 is chosen from the group: alkylidene of the type -(CH2)m-, possibly substituted on each C with one or two methyl groups, and in which m can assume the values 2, 3
-L2 indicates a bond or a group chosen from: -(CH2)p-, -(CH2)P-CH=CH-, -(CH2)p-T-
(CH2)Z-, -(CH2)P-CO-, -CO-T-(CH2)Z-, -(CH2)p-T-CO-, each group being possibly substituted on the Cs with one or two methyl groups and in which p and z can independently assume the values 0,1 ,2,3, and T is chosen from: -O-, -S-, -NR5-
-Ar represents a group derived from the following aromatic systems: phenyl, pyridyl, furyl, triazolyl, biphenyl, naphthyl, quinoline, isoquinoline, benzofuryl, benzothienyl, indolyl, benzothiazolyl, benzoisoxazolyl, oxazolyl-phenyl, thiodiazolyl-phenyl, pyridyl- phenyl, pyrazolyl-phenyl, thiazolyl-phenyl, furyl-phenyl, thienyl-phenyl, benzyloxy-phenyl, tetrazolyl-phenyl, phenyl-oxazolyl, phenyl-pyrazolyl-, phenyl-thiazolyl, phenyl- thiadiazolyl, phenyl-isothiazolyl, indanyl, fluorenyl, benzodioxolyl, phenoxy-phenyl, in which each group can possibly be substituted with up to two groups independently chosen from: C1 -3 alkyl, OR9, NR9R10, N(R9)COR10, CN, F, Cl, Br, -CF3, -SCF3, - (CH2)q-NR9R10, in which R9 is a group chosen from H, C1 -4 alkyl, R10 and 11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3, or Ar-L2-B can jointly be chosen from the group consisting of
Figure imgf000094_0001
in which:
- the R12 group represents a H, a C1 -3 alkyl
- the Ar2 group is an aromatic chosen from benzyl or an acyl group derived from benzoic, phenylacetic or benzothiophene-carboxylic acids
- the aromatic part can be substituted with up to three groups independently chosen from: a C1 -3 alkyl, OR9, NR9R10, N(R9)COR10, CN, F, Cl, Br, -CF3, -SCF3, -(CH2Jq- NR9R10, in which R9 is a group chosen from H, C1 -4 alkyl, R10 and R11 are independently a group chosen from H and C1 -3 alkyl, q can assume the values 2 or 3; with the exclusion of products in which:
B is chosen from -NR5-CO- and at the same time L2 is chosen from -(CH2)P-CO-.
4. Compounds of general formula (II) as claimed in claim 3, namely: 4-[1 -(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-N-hydroxy-butyramide N-Hydroxy-4-[1 -(4-methyl-naphthalene-2-sulfonyl)-piperidin-4-yl]-butyramide N-Hydroxy-4-[1 -(naphthalene-2-carbonyl)-piperidin-4-yl]- butyramide N-Hydroxy-4-[1 -(naphthalene-1 -carbonyl)-piperidin-4-yl]-butyramide N-Hydroxy-4-[1 -(2-naphthalen-1 -yl-acetyl)-piperidin-4-yl]-butyramide N-Hydroxy-4-[1 -(1 -naphthalen-1 -yl-acetyl)-piperidin-4-yl]-butyramide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid phenylamide N-Hydroxy-4-[1 -(naphthalene-2-sulfonyl)-piperidin-4-yl]-butyramide
N-Hydroxy-4-[1 -(naphthalene-1 -sulfonyl)-piperidin-4-yl]-butyramide
N-{3-[4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carbonyl]-phenyl}-benzamide
4-[1 -(Benzofuran-2-carbonyl)-piperidin-4-yl]-N-hydroxy-butyramide
N-Hydroxy-4-[1 -(6-methoxy-naphthalene-2-carbonyl)-piperidin-4-yl]-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-fluoro-phenyl)-amide
N-Hydroxy-4-[1 -(2-methyl-naphthalene-1 -carbonyl)-piperidin-4-yl]-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-bromo-phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-chloro-phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-chloro-phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-chloro-phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-methoxy-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-methoxy-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid p-tolylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid o-tolylamide
4-[1 -(Benzo[b]thiophene-2-carbonyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-fluoro-phenyl)-amide
4-[1 -(Benzyloxycarbonyl)-piperidin-4-yl]-N-hydroxy-butyramide
N-Hydroxy-4-[1-(3-phenyl-acryloyl)-piperidin-4-yl]-butyramide
N-Hydroxy-4-[1 -(1 -methyl-1 H-indole-3-carbonyl)-piperidin-4-yl]-butyramide
N-Hydroxy-4-[1-(4-phenyl-butyryl)-piperidin-4-yl]-butyramide
N-Hydroxy-4-[1 -(2-1 H-indol-3-yl-acetyl)-piperidin-4-yl]-butyramide
N-Hydroxy-4-{1 -[2-(5-methyl-2-phenyl-oxazol-4-yl)-acetyl]-piperidin-4-yl}-butyramide
N-Hydroxy-4-{1 -[2-(2-phenyl-thiazol-4-yl)-acetyl]-piperidin-4-yl}-butyramide
4-[1 -(2-Benzo[d]isoxazol-3-yl-acetyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 4-chloro-benzylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 1 -naphthylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2-naphthylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2-methoxy-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2-chloro-phenyl)-amide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 3-chloro-benzylamide 4-[1 -(2-(S)-Amino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide 4-[1 -(2-(R)-Amino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2-methoxy-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 3-methoxy-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 4-methoxy-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2-fluoro-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 3-fluoro-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2-chloro-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-dimethylamino- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-amino-phenyl)-amide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2-methyl-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 3-methyl-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 4-methyl-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (pyridin-4-yl methyl- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (naphthalen-1 -ylmethyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (naphthalen-2-ylmethyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (biphenyl-4-ylmethyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 4-phenoxy-benzylamide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid phenethyl-amide 6-{[Benzyl-(2-hydroxy-ethyl)-amino]-methyl}-7-fluoro-benzo[b]thiophene-2-carboxylic acid hydroxyamide
4-{1 -[2-Amino-3-(4-chloro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide 4-{1 -[2-Amino-3-(3-chloro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide MF C18H26CIN3O3, MW: 367.87
4-{1 -[2-(R)-Amino-3-(3,4-dichloro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy- butyramide.
4-{1 -[2-(R)-Amino-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy- butyramide
4-[1 -(2-(R)-Amino-2-methyl-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide.
4-{1 -[2-(R)-Amino-3-(1 H-indol-3-yl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
4-{1 -[2-(S)-Amino-3-(1 H-indol-3-yl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
4-[1 -(2-(R)-Amino-3-benzyloxy-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-{1-[2-(R)-Amino-3-(4-tert-butoxy-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy- butyramide
4-[1 -(2-(R)-Amino-3-benzylsulfanyl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid pyridin-3-ylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (pyridin-3-ylmethyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-amino-phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2-amino-phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 4-dimethylamino- benzylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-fluoro-phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid m-tolylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid benzyl-methyl-amide
N-Hydroxy-4-{1 -[2-(2-1 H-indol-3-yl-acetylamino)-acetyl]-piperidin-4-yl}-butyramide
Benzo[b]thiophene-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1 - yl]-2-oxo-ethyl}-amide
Naphthalene-1 -carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-2- oxo-ethyl}-amide
2-Methyl-naphthalene-1 -carboxylic acid {2-[4-(3-hydroxycarbamoyl-propy l)-piperidin-
1 -yl]-2-oxo-ethyl}-amide
4-[1 -(2-(S)-Amino-4-phenyl-butyryl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-chloro-2-fluoro- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2,4-difluoro-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-chloro-4-methyl- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3,4-difluoro-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3,4-dimethyl-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-chloro-4-fluoro- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2,5-difluoro-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-chloro-2-fluoro- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2,4-dimethoxy-phenyl)- amide
N-Hydroxy-4-[1 -(2-(R)-methylamino-3-phenyl-propionyl)-piperidin-4-yl]-butyramide
4-[1 -(2-(R)-Amino-3-naphthalen-1 -yl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-[1 -(2-(R)-Amino-3-benzo[b]thiophen-3- yl-propionyl)-piperidin-4-yl]-N-hydroxy- butyramide
4-[1 -(2-(R)-Amino-3-m-tolyl-propionyl)- piperidin-4-yl]-N-hydroxy-butyramide
4-{1 -[2-(S)-Amino-3-(4-benzoyl-phenyl)- propionyl]-piperidin-4-yl}-N-hydroxy- butyramide
4-{1 -[2-(R)-Amino-3-(2-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
4-{1 -[2-(R)-Amino-3-(3-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
4-{1 -[2-(R)-Amino-3-(4-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
N-Hydroxy-4-[1 -(2-(R)-hydroxy-3-phenyl- propionyl)-piperidin-4-yl]-butyramide
Benzo[b]thiophene-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1 - yl]-1 -(S)-hydroxymethyl-2-oxo-ethyl}-amide
Benzo[b]thiophene-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1 - yl]-1 -(R)-hydroxymethyl-2-oxo-ethyl}-amide
4-[1 -(2-(S)-Dimethylamino-4-phenyl-buty ryl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 2,4-dichloro- benzylamide
4-[1 -(2-(S)-Amino-4-phenyl-butyryl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (furan-2-ylmethyl)-amide
Benzo[b]thiophene-2-carboxylic acid{4-amino-1 -(R)[4-(3-hydroxycarbamoyl-propyl)- piperidine-1 -carbonyl]-butyl}-amide
4-[1 -(3-(R)-Amino-4-naphthalen-2-yl-butyryl)-piperidin-4-yl]-N-hydroxy-butyramide
4-[1 -(3-(S)-Amino-3-naphthalen-2-yl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
Benzo[b]thiophene-2-carboxylic acid{3-hydroxy-1 -(R)-[4-(3-hydroxycarbamoyl-propyl)- piperidine-1 -carbonyl]-propyl}-amide
4-[1 -(3-(R)-Amino-3-naphthalen-2-yl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-[1 -(3-(S)-Amino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
Benzo[b]thiophene-2-carboxylic acid{3-hydroxy-1 -(S)-[4-(3-hydroxycarbamoyl-propyl)- piperidine-1 -carbonyl]-propyl}-amide
Benzo[b]thiophene-5-carboxylic acid{2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 - yl]-1 -(S)-hydroxymethyl-2-oxo-ethyl}-amide
2-oxo-ethyl}-amideBenzo[b]thiophene-2-carboxylic acid{1 -(R)-aminomethyl-2-[4-(3- hydroxycarbamoyl-propyl)-piperidin-1 -yl]-
4-{1 -[2-(S)-(2-Benzo[b]thiophen-3-yl-acetylamino)-3-hydroxy-propionyl]-piperidin-4-yl}-
N-hydroxy-butyramide
Benzo[b]thiophene-3-carboxylic acid{2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 - yl]-1 -(S)-hydroxymethyl-2-oxo-ethyl}-amide
Benzofuran-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-1 -(S)- hydroxymethyl-2-oxo-ethyl}-amide
N-Hydroxy-4-{1 -[3-hydroxy-2-(S)-(2-naphthalen-1-yl-acetylamino)-propionyl]-piperidin-
4-yl}-butyramide
1 H-lndole-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-1 -(S)- hydroxymethyl-2-oxo-ethyl}-amide
Quinoline-2-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-1 -(S)- hydroxymethyl-2-oxo-ethyl}-amide lsoquinoline-1 -carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-1 -(S)- hydroxymethyl-2-oxo-ethyl}-amide lsoquinoline-3-carboxylic acid {2-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-1 -(S)- hydroxymethyl-2-oxo-ethyl}-amide
Benzo[b]thiophene-2-carboxylic acid{1 -aminomethyl-2-[4-(3-hydroxycarbamoyl- propyl)-piperidin-1 -yl]-2-oxo-ethyl}-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid 4-chloro-2-fluoro- benzylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2-amino-4-methyl- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2-fluoro-6-methoxy- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2-fluoro-5-methyl- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (2-chloro-6-fluoro- phenyl)-amide
4-[1 -(3-(R)-Amino-3-phenyl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-[1 -(3-(S)-Amino-5-phenyl-pentanoyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-butyl-phenyl)-amide
N-Hydroxy-4-(1 -phenylsulfamoyl-piperidin-4-yl)-butyramide
4-[1 -(3-(R)-Amino-5-phenyl-pentanoyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid biphenyl-4-ylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (benzo[1 ,3]dioxol-5- ylmethyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-propoxy-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-propoxy-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-isopropoxy-phenyl)- amide 4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (1 -(R)-phenyl-ethyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (1 -(S)-phenyl-ethyl)- amide
4-[1 -(3-(R)-Amino-3-naphthalen-2-yl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid quinolin-2-ylamide
4-[1 -(3-(R)-Amino-4-naphthalen-2-yl-butyryl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid [4-(2-diethylamino-ethyl)- phenyl]-amide
4-[1 -(3-(S)-Amino-4-benzo[b]thiophen-3-yl-butyryl)-piperidin-4-yl]-N-hydroxy- butyramide
4-[1-(3-(R)-Amino-4-benzo[b]thiophen-3-yl-butyryl)-piperidin-4-yl]-N-hydroxy- butyramide
Benzo[b]thiophene-2-carboxylic acid{1 -dimethylaminomethyl-2-[4-
(3hydroxycarbamoyl-propyl)-piperidin-1 -yl]-2-oxo-ethyl}-amide
4-[1 -(3-(S)-Amino-3-naphthalen-2-yl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid biphenyl-3-ylamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-pyridi n-2-yl-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-oxazol-5-yl-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-pyridin-3-yl-phenyl)- amide
4-[1 -(3-(S)-Amino-4-naphthalen-1 -yl-butyryl)-piperidin-4-yl]-N-hydroxy-butyramide
4-[1 -(3-(R)-Amino-4-naphthalen-1 -yl-butyryl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(4-(hydroxyamino)-4-oxobutyl)-N-((2-phenylthiazol-4-yl)methyl)piperidine-1 - carboxamide
N-(benzo[b]thiophen-3-ylmethyl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 - carboxamide
4-[1 -(3-(S)-Amino-3-naphthalen-1 -yl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-[1 -(3-(R)-Amino-3-naphthalen-1 -yl-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide 4-(4-hydroxyamino)-4-oxobutyl)-N-(1 -methoxynaphthalen-2-yl)piperidine-1 - carboxamide
4-(4-hydroxyamino)-4-oxobutyl)-N-(3-methoxynaphthalen-2-yl)piperidine-1 - carboxamide
4-(4-hydroxyamino)-4-oxobutyl)-N-((5-methyl-2-phenyloxazol-4-yl)methyl)piperidine-1 - carboxamide
N-(2-(1 H-indol-3-yl)ethyl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 -carboxamide
4-[1 -(3-Benzylamino-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3'-fluoro-biphenyl-4-yl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4'-fluoro-biphenyl-4-yl)- amide
4-{1 -[3-(S)-Amino-3-(2-chloro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
4-{1 -[3-(S)-Amino-3-(3-chloro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3'-methoxy-biphenyl-4- yl)-amide
N-(3-(1 H-indol-3-yl)propyl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 -carboxamide
4-{1 -[3-(S)-Amino-3-(3-chloro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
MF C18H26CIN3O3, MF 367.87
N-Hydroxy-4-[1 -(4-methoxy-benzylthiocarbamoyl)-piperidin-4-yl]-butyramide
4-(1 -Benzylthiocarbamoyl-piperidin4-yl)-N-hydroxy-butyramide
4-{1 -[3-(S)-Amino-3-(4-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
4-{1 -[3-(S)-Amino-3-(3-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
4-{1 -[3-(S)-Amino-3-(2-fluoro-phenyl)-propionyl]-piperidin-4-yl}-N-hydroxy-butyramide
N-(benzo[d]isoxazol-3-ylmethyl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 - carboxamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-[1 ,2,3]thiadiazol-4-yl- phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid [4-(3,5-dimethyl-pyrazol-
1 -yl)-phenyl]-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid [3-(2-methyl-thiazol-4-yl)- phenyl]-amide
N-(6-aminonaphthalen-2-yl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 - carboxamide
4-(4-(hydroxyamino)-4-oxobutyl)-N-(1 H-indol-5-yl)piperidine-1 -carboxamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (5-methyl-1 -phenyl-1 H- pyrazol-4-yl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-pyrrol-1 -yl-phenyl)- amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (3-pyrrol-1 -yl-phenyl)- amide
4-[1 -(3-(1)Naphtylamino-propionyl)-piperidin-4-yl]-N-hydroxy-butyramide
4-(4-(hydroxyamino)-4-oxobutyl)-N-(1 H-indol-3-yl)piperidine-1 -carboxamide
N-(5-Chloro-benzo[b]thiophen-3-ylmethyl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-
1 -carboxamide
N-(benzo[b]thiophen-5-yl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 -carboxamide
N-(4-(thiophen-3-yl)benzyl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 -carboxamide
4-(4-(hydroxyamino)-4-oxobutyl)-N(3-phenylbenzyl)piperidine-1 -carboxamide
3-(4-(hydroxyamino)-4-oxobutyl)-N-phenylpiperidine-1 -carboxamide
2-(s)-Amino-N-benzyl-4-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-4-oxo- butyramide
2-(R)-Amino-N-benzyl-4-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-4-oxo- butyramide
N-(benzo[b]thiophene)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 -carboxamide
4-(4-(hydroxyamino)-4-oxobutyl)-N-((3-methylbenzo[b]thiophen-2-yl)methyl)piperidine-
1 -carboxamide
N-((2,5-dimethylthiazol-4-yl)methyl)-4-(4-(hydroxyamino)-4-oxobutyl)piperidine-1 - carboxamide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (5,6,7,8-tetrahydro- naphthalen-1 -yl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-benzyl-phenyl)-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid (4-benzyloxy-phenyl)- amide
Benzo[b]thiophene-2-carboxylic acid {3-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 - yl]-3-oxo-propyl}-amide
Benzo[b]thiophene-2-carboxylic acid {4-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 - yl]-4-oxo-butyl}-amide
Benzo[b]thiophene-2-carboxylic acid {2-(S)-amino-3-[4-(3-hydroxycarbamoyl-propyl)- piperidin-1 -yl]-3-oxo-propyl}-amide
2-(s)-Amino-4-[4-(3-hydroxycarbamoyl-propyl)-piperidin-1 -yl]-N-naphthalen-1 - ylmethyl-4-oxo-butyramide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid [4-(2-methyl-2H-tetrazol-
5-yl)-phenyl]-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid [4-(2-isobutyl-2H- tetrazol-5-yl)-phenyl]-amide
4-(3-Hydroxycarbamoyl-propyl)-piperidine-1 -carboxylic acid [4-(3-methyl-pyrazol-1 - yl)-phenyl]-amide
4-(3-Hydroxycarbamoyl-propyl)-piperdine-1 -carboxylic acid [2-(3-dimethylamino- propyl)-1 H-benzoimidazol-5-yl]-amide
4-[1 -(1 H-Benzoimidazol-2-yl)-piperidin-4-yl]-N-hydroxy-butyramide.
5. Use of compounds claimed in claims 1 -4 for preparing pharmacetical compositions useful as histone deacetylase inhibitors.
6. Use of compounds as claimed in claim 5 for preparing pharmacetical compositions useful for treating inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections and tumorous pathologies.
7. Use of compounds as claimed in claim 6 for preparing pharmaceutical compositions useful for treating tumorous pathologies.
8. Use of compounds claimed in claims 1 -4 in combination with one or more active principles chosen from chemotherapeutic agents, for preparing pharmaceutical compositions useful for treating tumorous pathologies.
9. Use of compounds claimed in claims 1 -4 in combination with radiotherapeutic treatments, for preparing pharmaceutical compositions useful for treating tumorous pathologies.
10. Use of compounds as claimed in claim 8 in combination with one or more compounds chosen from the groups: conventional cytotoxic agents, demethylating agents, cyclin dependent kinase inhibitors, differentiating agents, signal transduction modulators, HSP-90 antagonists, proteasome inhibitors.
1 1. Use of compounds as claimed in claim 10 for preparing a combination with one or more compounds chosen from the conventional cytotoxic agents: Fludarabine, gemcitabine, decitabine, paclitaxel, carboplatin and Topo l/ll inhibitors, to include Etoposide, Irinotecan, Topotecan, T-128 and Anthracyclines such as Doxorubicin, Sabarubicin, Daunorubicin; the demethylating agents: 5-aza-2'-deoxycytidine (5-aza- dC), 5-azacytidine; the cyclin dependent kinase inhibitors: flavopiridol, olomoucin, roscovitin, purvalanol B, GW9499, GW5181 , CGP60474, CGP74514, AG12286, AG12275, Staurosporine, UCN-01 ; the differentiating agents: retinoic acid and derivatives (All Trans Retinoic Acid, ATRA), 13-cis retinoic acid (CRA), PMA (phorbol myristate acetate); the signal transduction modulators: TRAIL, imatinib mesylate, LY- 294002, bortezomib; the HSP-90 antagonists: geldanamycin and its analogues (17- AAG); the proteasome inhibitors: lactacystine, MG132, bortezomib (Velcade™).
12. Pharmaceutical compositions containing as active principle a compound of general formula (I) claimed in claims 1 -4 for treating inflammatory disorders, diabetes, complications of diabetes, homozygotic thalassaemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), transplant rejection, auto-immune diseases, protozoan infections and tumorous pathologies.
PCT/EP2006/060687 2005-03-15 2006-03-14 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them WO2006097460A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2006224624A AU2006224624A1 (en) 2005-03-15 2006-03-14 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
US11/886,160 US20080207694A1 (en) 2005-03-15 2006-03-14 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them
EA200701970A EA012909B1 (en) 2005-03-15 2006-03-14 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
CA002600528A CA2600528A1 (en) 2005-03-15 2006-03-14 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
EP06708749A EP1868997A1 (en) 2005-03-15 2006-03-14 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
JP2008501287A JP2008533091A (en) 2005-03-15 2006-03-14 Hydroxamic acid as histone deacetylase inhibitor and pharmaceutical composition containing the same
MX2007011072A MX2007011072A (en) 2005-03-15 2006-03-14 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them.
AP2007004188A AP2007004188A0 (en) 2005-03-15 2006-03-14 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
BRPI0606290-3A BRPI0606290A2 (en) 2005-03-15 2006-03-14 hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing
IL185882A IL185882A0 (en) 2005-03-15 2007-09-10 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
NO20075281A NO20075281L (en) 2005-03-15 2007-10-15 Hydroxamates such as history deacetylase inhibitors and pharmaceutical formulations containing them

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT000041A ITFI20050041A1 (en) 2005-03-15 2005-03-15 HYDROXAMMED AS INHIBITORS OF ISTONE DEACELITASIS, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM
ITFI2005A000041 2005-03-15
ITFI2005A000239 2005-11-21
IT000239A ITFI20050239A1 (en) 2005-03-15 2005-11-21 HYDROXAMMED AS INHIBITORS OF ISTONE DEACETYLASES AND PHARMACEUTICAL FORMULATIONS THAT COUNT THEM

Publications (2)

Publication Number Publication Date
WO2006097460A1 true WO2006097460A1 (en) 2006-09-21
WO2006097460A8 WO2006097460A8 (en) 2007-11-01

Family

ID=36617217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/060687 WO2006097460A1 (en) 2005-03-15 2006-03-14 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them

Country Status (22)

Country Link
US (1) US20080207694A1 (en)
EP (1) EP1868997A1 (en)
JP (1) JP2008533091A (en)
KR (1) KR20070112240A (en)
CN (1) CN101155780A (en)
AP (1) AP2007004188A0 (en)
AR (1) AR058002A1 (en)
AU (1) AU2006224624A1 (en)
BR (1) BRPI0606290A2 (en)
CA (1) CA2600528A1 (en)
CO (1) CO6321134A2 (en)
CR (1) CR9431A (en)
EA (1) EA012909B1 (en)
IL (1) IL185882A0 (en)
IT (2) ITFI20050041A1 (en)
MA (1) MA29389B1 (en)
MX (1) MX2007011072A (en)
NO (1) NO20075281L (en)
SA (1) SA06270135B1 (en)
TW (1) TW200724529A (en)
WO (1) WO2006097460A1 (en)
ZA (1) ZA200708749B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054727A1 (en) * 2005-11-11 2007-05-18 Cyclacel Limited Combination of roscovitine and a hdca inhibitor to treat prolifeative diseases
WO2007038459A3 (en) * 2005-09-27 2007-07-12 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2009026446A3 (en) * 2007-08-21 2009-09-11 Arqule, Inc. Hdac inhibitors
CN102775368A (en) * 2011-05-10 2012-11-14 中国科学院上海药物研究所 Thiazole compound, and preparation method and application thereof
JP2019505500A (en) * 2015-12-22 2019-02-28 カンセラ・アクチエボラグ Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
WO2019157020A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
WO2023003468A1 (en) * 2021-07-23 2023-01-26 Rijksuniversiteit Groningen Novel inhibitors of histone deacetylase (hdac), and methods, compositions and uses related thereto.

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3398598B1 (en) * 2015-12-31 2022-04-06 Hitgen Inc. Sulfonamide derivative and preparation method and use thereof
CN112325620B (en) * 2020-11-13 2022-04-19 南阳中联水泥有限公司 High-efficient drying equipment of cement manufacture
CN112516142B (en) * 2020-12-11 2021-10-15 北京华氏精恒医药科技有限公司 Pharmaceutical composition with HDAC (Histone deacetylase) inhibitory activity, preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076438A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
US20040072802A1 (en) * 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
WO2005004861A1 (en) * 2003-07-15 2005-01-20 Korea Research Institute Of Bioscience And Biotechnology A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
WO2005040101A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076438A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
US20040072802A1 (en) * 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
WO2005004861A1 (en) * 2003-07-15 2005-01-20 Korea Research Institute Of Bioscience And Biotechnology A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
WO2005040101A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEVRIER, CARINE ET AL: "Simple preparation of N-benzyl-.beta.-aminohydroxamic acids by 1,3-dipolar cycloaddition of nitrones", SYNTHESIS , (8), 1221-1224 CODEN: SYNTBF; ISSN: 0039-7881, 2003, XP002389635 *
UESATO S ET AL: "Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 12, 2002, pages 1347 - 1349, XP002276408, ISSN: 0960-894X *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038459A3 (en) * 2005-09-27 2007-07-12 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2007054727A1 (en) * 2005-11-11 2007-05-18 Cyclacel Limited Combination of roscovitine and a hdca inhibitor to treat prolifeative diseases
WO2009026446A3 (en) * 2007-08-21 2009-09-11 Arqule, Inc. Hdac inhibitors
CN102775368A (en) * 2011-05-10 2012-11-14 中国科学院上海药物研究所 Thiazole compound, and preparation method and application thereof
WO2012152208A1 (en) * 2011-05-10 2012-11-15 中国科学院上海药物研究所 Thiazole compound and preparation method and use thereof
KR101577520B1 (en) 2011-05-10 2015-12-14 상하이 푸이 케미컬 코퍼레이션 리미티드 Thiazole compound and preparation method and use thereof
US9216962B2 (en) 2011-05-10 2015-12-22 Shanghai Puyi Chemical Co., Ltd. Thiazole compounds, methods for preparation and use thereof
CN102775368B (en) * 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 One class thiazole compound and its production and use
JP2019505500A (en) * 2015-12-22 2019-02-28 カンセラ・アクチエボラグ Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
WO2019157020A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
WO2023003468A1 (en) * 2021-07-23 2023-01-26 Rijksuniversiteit Groningen Novel inhibitors of histone deacetylase (hdac), and methods, compositions and uses related thereto.

Also Published As

Publication number Publication date
MX2007011072A (en) 2007-10-08
ITFI20050239A1 (en) 2007-05-22
KR20070112240A (en) 2007-11-22
MA29389B1 (en) 2008-04-01
WO2006097460A8 (en) 2007-11-01
EA200701970A1 (en) 2008-02-28
CN101155780A (en) 2008-04-02
JP2008533091A (en) 2008-08-21
ITFI20050041A1 (en) 2006-09-16
EA012909B1 (en) 2010-02-26
AU2006224624A1 (en) 2006-09-21
ZA200708749B (en) 2009-08-26
EP1868997A1 (en) 2007-12-26
IL185882A0 (en) 2008-01-06
AP2007004188A0 (en) 2007-10-31
BRPI0606290A2 (en) 2009-06-09
US20080207694A1 (en) 2008-08-28
CA2600528A1 (en) 2006-09-21
AR058002A1 (en) 2008-01-23
SA06270135B1 (en) 2009-07-19
CO6321134A2 (en) 2011-09-20
NO20075281L (en) 2007-10-15
CR9431A (en) 2008-07-31
TW200724529A (en) 2007-07-01

Similar Documents

Publication Publication Date Title
US20080207694A1 (en) Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them
EP3330259B1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
EP3328843B1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP1389616B1 (en) 3,4-Dihalobenzylpiperidine derivatives and their medical use
SK172004A3 (en) Aromatic hydroxamic acid derivatives useful as HDAC inhibitors
AU2016299486A1 (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CA2934114A1 (en) Antibacterial agents
JP2006518341A (en) Hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors
KR20000057595A (en) Piperazine compounds as inhibitors of mmp or tnf
MXPA03011336A (en) Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
WO2011127070A2 (en) IRE-1α INHIBITORS
AU2021394226B2 (en) Benzylamine or benzyl alcohol derivative and use thereof
TW202239756A (en) 1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
WO2009013293A1 (en) Substituted cyclohexanecarboxamides useful as bace inhibitors
KR20060130123A (en) Ornithine derivatives as prostaglandin e2 agonists or antagonists
JP2003523337A (en) Thiazepinyl hydroxamic acid derivatives as matrix metalloprotease inhibitors
JP7492033B2 (en) 1,3,4-OXADIAZOLE DERIVATIVE COMPOUND AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
US6610729B1 (en) Hydroxamic acid derivatives and medicinal utilization thereof
EP2265580B1 (en) Novel method for the production of sulphonylpyrroles as hdac inhibitors
RU2810081C1 (en) 1,3,4-oxadiazole derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition containing them
DE60103732T2 (en) PYRIMIDINE DERIVATIVES WITH ANTITUMOR EFFECT
TW202404963A (en) 1,3,4-oxadiazole triazole compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
NZ617505B2 (en) Thiazole compound and preparation method and use thereof
NZ617505A (en) Thiazole compound and preparation method and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: DZP2007000525

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200680006679.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11886160

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/011072

Country of ref document: MX

Ref document number: 185882

Country of ref document: IL

Ref document number: 2600528

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12007502016

Country of ref document: PH

Ref document number: 2008501287

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077022763

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: AP/P/2007/004188

Country of ref document: AP

Ref document number: 2006224624

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: CR2007-009431

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2006708749

Country of ref document: EP

Ref document number: 07107399

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 10323

Country of ref document: GE

Ref document number: 4578/CHENP/2007

Country of ref document: IN

Ref document number: 1200702121

Country of ref document: VN

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200701970

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2006224624

Country of ref document: AU

Date of ref document: 20060314

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006224624

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006708749

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0606290

Country of ref document: BR

Kind code of ref document: A2